#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Brain function, structure and genomic data are linked but show different sensitivity to duration of illness and disease stage in schizophrenia
#Text=The progress of schizophrenia at various stages is an intriguing question, which has been explored to some degree using single-modality brain imaging data, e.g. gray matter (GM) or functional connectivity (FC).
1-1	0-5	Brain	_	
1-2	6-14	function	_	
1-3	14-15	,	_	
1-4	16-25	structure	_	
1-5	26-29	and	_	
1-6	30-37	genomic	_	
1-7	38-42	data	_	
1-8	43-46	are	_	
1-9	47-53	linked	_	
1-10	54-57	but	_	
1-11	58-62	show	_	
1-12	63-72	different	_	
1-13	73-84	sensitivity	_	
1-14	85-87	to	_	
1-15	88-96	duration	_	
1-16	97-99	of	_	
1-17	100-107	illness	_	
1-18	108-111	and	_	
1-19	112-119	disease	_	
1-20	120-125	stage	_	
1-21	126-128	in	_	
1-22	129-142	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
1-23	143-146	The	_	
1-24	147-155	progress	_	
1-25	156-158	of	_	
1-26	159-172	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
1-27	173-175	at	_	
1-28	176-183	various	_	
1-29	184-190	stages	_	
1-30	191-193	is	_	
1-31	194-196	an	_	
1-32	197-207	intriguing	_	
1-33	208-216	question	_	
1-34	216-217	,	_	
1-35	218-223	which	_	
1-36	224-227	has	_	
1-37	228-232	been	_	
1-38	233-241	explored	_	
1-39	242-244	to	_	
1-40	245-249	some	_	
1-41	250-256	degree	_	
1-42	257-262	using	_	
1-43	263-278	single-modality	_	
1-44	279-284	brain	_	
1-45	285-292	imaging	_	
1-46	293-297	data	_	
1-47	297-298	,	_	
1-48	299-302	e.g	_	
1-49	302-303	.	_	
1-50	304-308	gray	_	
1-51	309-315	matter	_	
1-52	316-317	(	_	
1-53	317-319	GM	_	
1-54	319-320	)	_	
1-55	321-323	or	_	
1-56	324-334	functional	_	
1-57	335-347	connectivity	_	
1-58	348-349	(	_	
1-59	349-351	FC	_	
1-60	351-352	)	_	
1-61	352-353	.	_	

#Text=However it remains unclear how those changes from different modalities are correlated with each other and if the sensitivity to duration of illness and disease stages across modalities is different.
2-1	354-361	However	_	
2-2	362-364	it	_	
2-3	365-372	remains	_	
2-4	373-380	unclear	_	
2-5	381-384	how	_	
2-6	385-390	those	_	
2-7	391-398	changes	_	
2-8	399-403	from	_	
2-9	404-413	different	_	
2-10	414-424	modalities	_	
2-11	425-428	are	_	
2-12	429-439	correlated	_	
2-13	440-444	with	_	
2-14	445-449	each	_	
2-15	450-455	other	_	
2-16	456-459	and	_	
2-17	460-462	if	_	
2-18	463-466	the	_	
2-19	467-478	sensitivity	_	
2-20	479-481	to	_	
2-21	482-490	duration	_	
2-22	491-493	of	_	
2-23	494-501	illness	_	
2-24	502-505	and	_	
2-25	506-513	disease	_	
2-26	514-520	stages	_	
2-27	521-527	across	_	
2-28	528-538	modalities	_	
2-29	539-541	is	_	
2-30	542-551	different	_	
2-31	551-552	.	_	

#Text=In this work, we jointly analyzed FC, GM volume and single nucleotide polymorphisms (SNPs) data of 159 individuals including healthy controls (HC), drug-naïve first-episode schizophrenia (FESZ) and chronic schizophrenia patients (CSZ), aiming to evaluate the links among SNP, FC and GM patterns, and their sensitivity to duration of illness and disease stages in schizophrenia.
3-1	553-555	In	_	
3-2	556-560	this	_	
3-3	561-565	work	_	
3-4	565-566	,	_	
3-5	567-569	we	_	
3-6	570-577	jointly	_	
3-7	578-586	analyzed	_	
3-8	587-589	FC	_	
3-9	589-590	,	_	
3-10	591-593	GM	_	
3-11	594-600	volume	_	
3-12	601-604	and	_	
3-13	605-611	single	_	
3-14	612-622	nucleotide	_	
3-15	623-636	polymorphisms	_	
3-16	637-638	(	_	
3-17	638-642	SNPs	_	
3-18	642-643	)	_	
3-19	644-648	data	_	
3-20	649-651	of	_	
3-21	652-655	159	_	
3-22	656-667	individuals	_	
3-23	668-677	including	_	
3-24	678-685	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[1]	
3-25	686-694	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[1]	
3-26	695-696	(	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[1]	
3-27	696-698	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[1]	
3-28	698-699	)	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[1]	
3-29	699-700	,	_	
3-30	701-711	drug-naïve	_	
3-31	712-725	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[2]	
3-32	726-739	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[2]	
3-33	740-741	(	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[2]	
3-34	741-745	FESZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[2]	
3-35	745-746	)	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[2]	
3-36	747-750	and	_	
3-37	751-758	chronic	http://maven.renci.org/NeuroBridge/neurobridge#ChronicSchizophrenia[3]	
3-38	759-772	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#ChronicSchizophrenia[3]	
3-39	773-781	patients	http://maven.renci.org/NeuroBridge/neurobridge#ChronicSchizophrenia[3]	
3-40	782-783	(	http://maven.renci.org/NeuroBridge/neurobridge#ChronicSchizophrenia[3]	
3-41	783-786	CSZ	http://maven.renci.org/NeuroBridge/neurobridge#ChronicSchizophrenia[3]	
3-42	786-787	)	http://maven.renci.org/NeuroBridge/neurobridge#ChronicSchizophrenia[3]	
3-43	787-788	,	http://maven.renci.org/NeuroBridge/neurobridge#ChronicSchizophrenia[3]	
3-44	789-795	aiming	_	
3-45	796-798	to	_	
3-46	799-807	evaluate	_	
3-47	808-811	the	_	
3-48	812-817	links	_	
3-49	818-823	among	_	
3-50	824-827	SNP	_	
3-51	827-828	,	_	
3-52	829-831	FC	_	
3-53	832-835	and	_	
3-54	836-838	GM	_	
3-55	839-847	patterns	_	
3-56	847-848	,	_	
3-57	849-852	and	_	
3-58	853-858	their	_	
3-59	859-870	sensitivity	_	
3-60	871-873	to	_	
3-61	874-882	duration	_	
3-62	883-885	of	_	
3-63	886-893	illness	_	
3-64	894-897	and	_	
3-65	898-905	disease	_	
3-66	906-912	stages	_	
3-67	913-915	in	_	
3-68	916-929	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
3-69	929-930	.	_	

#Text=Our results suggested: 1) both GM and FC highlighted impairments in hippocampal, temporal gyrus and cerebellum in schizophrenia, which were significantly correlated with genes like SATB2, GABBR2, PDE4B, CACNA1C etc. 2) GM and FC presented gradually decrease trend (HC > FESZ>CSZ), while SNP indicated a non-gradual variation trend with un-significant group difference observed between FESZ and CSZ; 3) Group difference between HC and FESZ of FC was more remarkable than GM, and FC presented a stronger negative correlation with duration of illness than GM (p = 0.0006).
4-1	931-934	Our	_	
4-2	935-942	results	_	
4-3	943-952	suggested	_	
4-4	952-953	:	_	
4-5	954-955	1	_	
4-6	955-956	)	_	
4-7	957-961	both	_	
4-8	962-964	GM	_	
4-9	965-968	and	_	
4-10	969-971	FC	_	
4-11	972-983	highlighted	_	
4-12	984-995	impairments	_	
4-13	996-998	in	_	
4-14	999-1010	hippocampal	_	
4-15	1010-1011	,	_	
4-16	1012-1020	temporal	_	
4-17	1021-1026	gyrus	_	
4-18	1027-1030	and	_	
4-19	1031-1041	cerebellum	_	
4-20	1042-1044	in	_	
4-21	1045-1058	schizophrenia	_	
4-22	1058-1059	,	_	
4-23	1060-1065	which	_	
4-24	1066-1070	were	_	
4-25	1071-1084	significantly	_	
4-26	1085-1095	correlated	_	
4-27	1096-1100	with	_	
4-28	1101-1106	genes	_	
4-29	1107-1111	like	_	
4-30	1112-1117	SATB2	_	
4-31	1117-1118	,	_	
4-32	1119-1125	GABBR2	_	
4-33	1125-1126	,	_	
4-34	1127-1132	PDE4B	_	
4-35	1132-1133	,	_	
4-36	1134-1141	CACNA1C	_	
4-37	1142-1145	etc	_	
4-38	1145-1146	.	_	
4-39	1147-1148	2	_	
4-40	1148-1149	)	_	
4-41	1150-1152	GM	_	
4-42	1153-1156	and	_	
4-43	1157-1159	FC	_	
4-44	1160-1169	presented	_	
4-45	1170-1179	gradually	_	
4-46	1180-1188	decrease	_	
4-47	1189-1194	trend	_	
4-48	1195-1196	(	_	
4-49	1196-1198	HC	_	
4-50	1198-1199	 	_	
4-51	1199-1200	>	_	
4-52	1200-1201	 	_	
4-53	1201-1205	FESZ	_	
4-54	1205-1206	>	_	
4-55	1206-1209	CSZ	_	
4-56	1209-1210	)	_	
4-57	1210-1211	,	_	
4-58	1212-1217	while	_	
4-59	1218-1221	SNP	_	
4-60	1222-1231	indicated	_	
4-61	1232-1233	a	_	
4-62	1234-1245	non-gradual	_	
4-63	1246-1255	variation	_	
4-64	1256-1261	trend	_	
4-65	1262-1266	with	_	
4-66	1267-1281	un-significant	_	
4-67	1282-1287	group	_	
4-68	1288-1298	difference	_	
4-69	1299-1307	observed	_	
4-70	1308-1315	between	_	
4-71	1316-1320	FESZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
4-72	1321-1324	and	_	
4-73	1325-1328	CSZ	http://maven.renci.org/NeuroBridge/neurobridge#ChronicSchizophrenia	
4-74	1328-1329	;	_	
4-75	1330-1331	3	_	
4-76	1331-1332	)	_	
4-77	1333-1338	Group	_	
4-78	1339-1349	difference	_	
4-79	1350-1357	between	_	
4-80	1358-1360	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
4-81	1361-1364	and	_	
4-82	1365-1369	FESZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
4-83	1370-1372	of	_	
4-84	1373-1375	FC	_	
4-85	1376-1379	was	_	
4-86	1380-1384	more	_	
4-87	1385-1395	remarkable	_	
4-88	1396-1400	than	_	
4-89	1401-1403	GM	_	
4-90	1403-1404	,	_	
4-91	1405-1408	and	_	
4-92	1409-1411	FC	_	
4-93	1412-1421	presented	_	
4-94	1422-1423	a	_	
4-95	1424-1432	stronger	_	
4-96	1433-1441	negative	_	
4-97	1442-1453	correlation	_	
4-98	1454-1458	with	_	
4-99	1459-1467	duration	_	
4-100	1468-1470	of	_	
4-101	1471-1478	illness	_	
4-102	1479-1483	than	_	
4-103	1484-1486	GM	_	
4-104	1487-1488	(	_	
4-105	1488-1489	p	_	
4-106	1489-1490	 	_	
4-107	1490-1491	=	_	
4-108	1491-1492	 	_	
4-109	1492-1498	0.0006	_	
4-110	1498-1499	)	_	
4-111	1499-1500	.	_	

#Text=Collectively, these results highlight the benefit of leveraging multimodal data and provide additional clues regarding the impact of mental illness at various disease stages.
5-1	1501-1513	Collectively	_	
5-2	1513-1514	,	_	
5-3	1515-1520	these	_	
5-4	1521-1528	results	_	
5-5	1529-1538	highlight	_	
5-6	1539-1542	the	_	
5-7	1543-1550	benefit	_	
5-8	1551-1553	of	_	
5-9	1554-1564	leveraging	_	
5-10	1565-1575	multimodal	_	
5-11	1576-1580	data	_	
5-12	1581-1584	and	_	
5-13	1585-1592	provide	_	
5-14	1593-1603	additional	_	
5-15	1604-1609	clues	_	
5-16	1610-1619	regarding	_	
5-17	1620-1623	the	_	
5-18	1624-1630	impact	_	
5-19	1631-1633	of	_	
5-20	1634-1640	mental	_	
5-21	1641-1648	illness	_	
5-22	1649-1651	at	_	
5-23	1652-1659	various	_	
5-24	1660-1667	disease	_	
5-25	1668-1674	stages	_	
5-26	1674-1675	.	_	

#Text=Highlights
#Text=Investigation of linked SNP, GM and FC pattern through parallel ICA method;
#Text=SNP indicated a non-gradual variation trend, highlighted genes like GABBR2 etc.;
#Text=GM and FC exhibited greater deficits at late disease stages (HC > FESZ>CSZ);
#Text=FC presented a stronger negative correlation with duration of illness than GM.
6-1	1676-1686	Highlights	_	
6-2	1687-1700	Investigation	_	
6-3	1701-1703	of	_	
6-4	1704-1710	linked	_	
6-5	1711-1714	SNP	_	
6-6	1714-1715	,	_	
6-7	1716-1718	GM	_	
6-8	1719-1722	and	_	
6-9	1723-1725	FC	_	
6-10	1726-1733	pattern	_	
6-11	1734-1741	through	_	
6-12	1742-1750	parallel	_	
6-13	1751-1754	ICA	_	
6-14	1755-1761	method	_	
6-15	1761-1762	;	_	
6-16	1763-1766	SNP	_	
6-17	1767-1776	indicated	_	
6-18	1777-1778	a	_	
6-19	1779-1790	non-gradual	_	
6-20	1791-1800	variation	_	
6-21	1801-1806	trend	_	
6-22	1806-1807	,	_	
6-23	1808-1819	highlighted	_	
6-24	1820-1825	genes	_	
6-25	1826-1830	like	_	
6-26	1831-1837	GABBR2	_	
6-27	1838-1841	etc	_	
6-28	1841-1842	.	_	
6-29	1842-1843	;	_	
6-30	1844-1846	GM	_	
6-31	1847-1850	and	_	
6-32	1851-1853	FC	_	
6-33	1854-1863	exhibited	_	
6-34	1864-1871	greater	_	
6-35	1872-1880	deficits	_	
6-36	1881-1883	at	_	
6-37	1884-1888	late	_	
6-38	1889-1896	disease	_	
6-39	1897-1903	stages	_	
6-40	1904-1905	(	_	
6-41	1905-1907	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
6-42	1907-1908	 	_	
6-43	1908-1909	>	_	
6-44	1909-1910	 	_	
6-45	1910-1914	FESZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
6-46	1914-1915	>	_	
6-47	1915-1918	CSZ	http://maven.renci.org/NeuroBridge/neurobridge#ChronicSchizophrenia	
6-48	1918-1919	)	_	
6-49	1919-1920	;	_	
6-50	1921-1923	FC	_	
6-51	1924-1933	presented	_	
6-52	1934-1935	a	_	
6-53	1936-1944	stronger	_	
6-54	1945-1953	negative	_	
6-55	1954-1965	correlation	_	
6-56	1966-1970	with	_	
6-57	1971-1979	duration	_	
6-58	1980-1982	of	_	
6-59	1983-1990	illness	_	
6-60	1991-1995	than	_	
6-61	1996-1998	GM	_	
6-62	1998-1999	.	_	

#Text=Introduction
#Text=Schizophrenia (SZ) is a severe mental illness with high heritability, as well as structural and functional brain impairments.
7-1	2000-2012	Introduction	_	
7-2	2013-2026	Schizophrenia	_	
7-3	2027-2028	(	_	
7-4	2028-2030	SZ	_	
7-5	2030-2031	)	_	
7-6	2032-2034	is	_	
7-7	2035-2036	a	_	
7-8	2037-2043	severe	_	
7-9	2044-2050	mental	_	
7-10	2051-2058	illness	_	
7-11	2059-2063	with	_	
7-12	2064-2068	high	_	
7-13	2069-2081	heritability	_	
7-14	2081-2082	,	_	
7-15	2083-2085	as	_	
7-16	2086-2090	well	_	
7-17	2091-2093	as	_	
7-18	2094-2104	structural	_	
7-19	2105-2108	and	_	
7-20	2109-2119	functional	_	
7-21	2120-2125	brain	_	
7-22	2126-2137	impairments	_	
7-23	2137-2138	.	_	

#Text=Genome wide association studies (GWAS) from Psychiatric Genomics Consortium (PGC) have announced landmark findings, which highlighted a list of susceptible loci.
8-1	2139-2145	Genome	_	
8-2	2146-2150	wide	_	
8-3	2151-2162	association	_	
8-4	2163-2170	studies	_	
8-5	2171-2172	(	_	
8-6	2172-2176	GWAS	_	
8-7	2176-2177	)	_	
8-8	2178-2182	from	_	
8-9	2183-2194	Psychiatric	_	
8-10	2195-2203	Genomics	_	
8-11	2204-2214	Consortium	_	
8-12	2215-2216	(	_	
8-13	2216-2219	PGC	_	
8-14	2219-2220	)	_	
8-15	2221-2225	have	_	
8-16	2226-2235	announced	_	
8-17	2236-2244	landmark	_	
8-18	2245-2253	findings	_	
8-19	2253-2254	,	_	
8-20	2255-2260	which	_	
8-21	2261-2272	highlighted	_	
8-22	2273-2274	a	_	
8-23	2275-2279	list	_	
8-24	2280-2282	of	_	
8-25	2283-2294	susceptible	_	
8-26	2295-2299	loci	_	
8-27	2299-2300	.	_	

#Text=The disease-related abnormalities in brain regions were also demonstrated by many previous studies.
9-1	2301-2304	The	_	
9-2	2305-2320	disease-related	_	
9-3	2321-2334	abnormalities	_	
9-4	2335-2337	in	_	
9-5	2338-2343	brain	_	
9-6	2344-2351	regions	_	
9-7	2352-2356	were	_	
9-8	2357-2361	also	_	
9-9	2362-2374	demonstrated	_	
9-10	2375-2377	by	_	
9-11	2378-2382	many	_	
9-12	2383-2391	previous	_	
9-13	2392-2399	studies	_	
9-14	2399-2400	.	_	

#Text=For instance, gray matter (GM) volumes of the temporal and prefrontal gyrus were largely reported to be impaired.
10-1	2401-2404	For	_	
10-2	2405-2413	instance	_	
10-3	2413-2414	,	_	
10-4	2415-2419	gray	_	
10-5	2420-2426	matter	_	
10-6	2427-2428	(	_	
10-7	2428-2430	GM	_	
10-8	2430-2431	)	_	
10-9	2432-2439	volumes	_	
10-10	2440-2442	of	_	
10-11	2443-2446	the	_	
10-12	2447-2455	temporal	_	
10-13	2456-2459	and	_	
10-14	2460-2470	prefrontal	_	
10-15	2471-2476	gyrus	_	
10-16	2477-2481	were	_	
10-17	2482-2489	largely	_	
10-18	2490-2498	reported	_	
10-19	2499-2501	to	_	
10-20	2502-2504	be	_	
10-21	2505-2513	impaired	_	
10-22	2513-2514	.	_	

#Text=Functional connectivity (FC) computed from functional magnetic resonance imaging (MRI) data, which measures interregional temporal correlations of blood oxygenation level-dependent (BOLD) signal fluctuations, has been reported disabilities involving a number of brain regions, including the frontal lobe, sensory-motor areas, limbic structures and temporal gyrus.
11-1	2515-2525	Functional	_	
11-2	2526-2538	connectivity	_	
11-3	2539-2540	(	_	
11-4	2540-2542	FC	_	
11-5	2542-2543	)	_	
11-6	2544-2552	computed	_	
11-7	2553-2557	from	_	
11-8	2558-2568	functional	_	
11-9	2569-2577	magnetic	_	
11-10	2578-2587	resonance	_	
11-11	2588-2595	imaging	_	
11-12	2596-2597	(	_	
11-13	2597-2600	MRI	_	
11-14	2600-2601	)	_	
11-15	2602-2606	data	_	
11-16	2606-2607	,	_	
11-17	2608-2613	which	_	
11-18	2614-2622	measures	_	
11-19	2623-2636	interregional	_	
11-20	2637-2645	temporal	_	
11-21	2646-2658	correlations	_	
11-22	2659-2661	of	_	
11-23	2662-2667	blood	_	
11-24	2668-2679	oxygenation	_	
11-25	2680-2695	level-dependent	_	
11-26	2696-2697	(	_	
11-27	2697-2701	BOLD	_	
11-28	2701-2702	)	_	
11-29	2703-2709	signal	_	
11-30	2710-2722	fluctuations	_	
11-31	2722-2723	,	_	
11-32	2724-2727	has	_	
11-33	2728-2732	been	_	
11-34	2733-2741	reported	_	
11-35	2742-2754	disabilities	_	
11-36	2755-2764	involving	_	
11-37	2765-2766	a	_	
11-38	2767-2773	number	_	
11-39	2774-2776	of	_	
11-40	2777-2782	brain	_	
11-41	2783-2790	regions	_	
11-42	2790-2791	,	_	
11-43	2792-2801	including	_	
11-44	2802-2805	the	_	
11-45	2806-2813	frontal	_	
11-46	2814-2818	lobe	_	
11-47	2818-2819	,	_	
11-48	2820-2833	sensory-motor	_	
11-49	2834-2839	areas	_	
11-50	2839-2840	,	_	
11-51	2841-2847	limbic	_	
11-52	2848-2858	structures	_	
11-53	2859-2862	and	_	
11-54	2863-2871	temporal	_	
11-55	2872-2877	gyrus	_	
11-56	2877-2878	.	_	

#Text=As different modalities may be related to each other constituting complementary observations of the same phenomenon, many multimodal methods have been developed and applied into analysis of mental disease.
12-1	2879-2881	As	_	
12-2	2882-2891	different	_	
12-3	2892-2902	modalities	_	
12-4	2903-2906	may	_	
12-5	2907-2909	be	_	
12-6	2910-2917	related	_	
12-7	2918-2920	to	_	
12-8	2921-2925	each	_	
12-9	2926-2931	other	_	
12-10	2932-2944	constituting	_	
12-11	2945-2958	complementary	_	
12-12	2959-2971	observations	_	
12-13	2972-2974	of	_	
12-14	2975-2978	the	_	
12-15	2979-2983	same	_	
12-16	2984-2994	phenomenon	_	
12-17	2994-2995	,	_	
12-18	2996-3000	many	_	
12-19	3001-3011	multimodal	_	
12-20	3012-3019	methods	_	
12-21	3020-3024	have	_	
12-22	3025-3029	been	_	
12-23	3030-3039	developed	_	
12-24	3040-3043	and	_	
12-25	3044-3051	applied	_	
12-26	3052-3056	into	_	
12-27	3057-3065	analysis	_	
12-28	3066-3068	of	_	
12-29	3069-3075	mental	_	
12-30	3076-3083	disease	_	
12-31	3083-3084	.	_	

#Text=For example, Sui et al. developed a multimodal canonical correlation analysis plus joint independent component analysis (mCCA+jICA) method to reveal that GM density abnormalities in default model network (DMN) were related to white-matter impairments in anterior thalamic radiation in schizophrenia.
13-1	3085-3088	For	_	
13-2	3089-3096	example	_	
13-3	3096-3097	,	_	
13-4	3098-3101	Sui	_	
13-5	3102-3104	et	_	
13-6	3105-3107	al	_	
13-7	3107-3108	.	_	
13-8	3109-3118	developed	_	
13-9	3119-3120	a	_	
13-10	3121-3131	multimodal	_	
13-11	3132-3141	canonical	_	
13-12	3142-3153	correlation	_	
13-13	3154-3162	analysis	_	
13-14	3163-3167	plus	_	
13-15	3168-3173	joint	_	
13-16	3174-3185	independent	_	
13-17	3186-3195	component	_	
13-18	3196-3204	analysis	_	
13-19	3205-3206	(	_	
13-20	3206-3210	mCCA	_	
13-21	3210-3211	+	_	
13-22	3211-3215	jICA	_	
13-23	3215-3216	)	_	
13-24	3217-3223	method	_	
13-25	3224-3226	to	_	
13-26	3227-3233	reveal	_	
13-27	3234-3238	that	_	
13-28	3239-3241	GM	_	
13-29	3242-3249	density	_	
13-30	3250-3263	abnormalities	_	
13-31	3264-3266	in	_	
13-32	3267-3274	default	_	
13-33	3275-3280	model	_	
13-34	3281-3288	network	_	
13-35	3289-3290	(	_	
13-36	3290-3293	DMN	_	
13-37	3293-3294	)	_	
13-38	3295-3299	were	_	
13-39	3300-3307	related	_	
13-40	3308-3310	to	_	
13-41	3311-3323	white-matter	_	
13-42	3324-3335	impairments	_	
13-43	3336-3338	in	_	
13-44	3339-3347	anterior	_	
13-45	3348-3356	thalamic	_	
13-46	3357-3366	radiation	_	
13-47	3367-3369	in	_	
13-48	3370-3383	schizophrenia	_	
13-49	3383-3384	.	_	

#Text=Chen et al. used a parallel independent component analysis (para-ICA) method to reveal that higher activation in precentral and postcentral gyri was observed in SZ with higher loadings of the linked SNP component.
14-1	3385-3389	Chen	_	
14-2	3390-3392	et	_	
14-3	3393-3395	al	_	
14-4	3395-3396	.	_	
14-5	3397-3401	used	_	
14-6	3402-3403	a	_	
14-7	3404-3412	parallel	_	
14-8	3413-3424	independent	_	
14-9	3425-3434	component	_	
14-10	3435-3443	analysis	_	
14-11	3444-3445	(	_	
14-12	3445-3453	para-ICA	_	
14-13	3453-3454	)	_	
14-14	3455-3461	method	_	
14-15	3462-3464	to	_	
14-16	3465-3471	reveal	_	
14-17	3472-3476	that	_	
14-18	3477-3483	higher	_	
14-19	3484-3494	activation	_	
14-20	3495-3497	in	_	
14-21	3498-3508	precentral	_	
14-22	3509-3512	and	_	
14-23	3513-3524	postcentral	_	
14-24	3525-3529	gyri	_	
14-25	3530-3533	was	_	
14-26	3534-3542	observed	_	
14-27	3543-3545	in	_	
14-28	3546-3548	SZ	_	
14-29	3549-3553	with	_	
14-30	3554-3560	higher	_	
14-31	3561-3569	loadings	_	
14-32	3570-3572	of	_	
14-33	3573-3576	the	_	
14-34	3577-3583	linked	_	
14-35	3584-3587	SNP	_	
14-36	3588-3597	component	_	
14-37	3597-3598	.	_	

#Text=Nervertheless, there are few studies combining structural, functional and genomic data to analyze schizophrenia.
15-1	3599-3612	Nervertheless	_	
15-2	3612-3613	,	_	
15-3	3614-3619	there	_	
15-4	3620-3623	are	_	
15-5	3624-3627	few	_	
15-6	3628-3635	studies	_	
15-7	3636-3645	combining	_	
15-8	3646-3656	structural	_	
15-9	3656-3657	,	_	
15-10	3658-3668	functional	_	
15-11	3669-3672	and	_	
15-12	3673-3680	genomic	_	
15-13	3681-3685	data	_	
15-14	3686-3688	to	_	
15-15	3689-3696	analyze	_	
15-16	3697-3710	schizophrenia	_	
15-17	3710-3711	.	_	

#Text=Moreover, it's still not clear whether there are progressive changes in each modality and the time at which for changes in different modalities are first evident.
16-1	3712-3720	Moreover	_	
16-2	3720-3721	,	_	
16-3	3722-3726	it's	_	
16-4	3727-3732	still	_	
16-5	3733-3736	not	_	
16-6	3737-3742	clear	_	
16-7	3743-3750	whether	_	
16-8	3751-3756	there	_	
16-9	3757-3760	are	_	
16-10	3761-3772	progressive	_	
16-11	3773-3780	changes	_	
16-12	3781-3783	in	_	
16-13	3784-3788	each	_	
16-14	3789-3797	modality	_	
16-15	3798-3801	and	_	
16-16	3802-3805	the	_	
16-17	3806-3810	time	_	
16-18	3811-3813	at	_	
16-19	3814-3819	which	_	
16-20	3820-3823	for	_	
16-21	3824-3831	changes	_	
16-22	3832-3834	in	_	
16-23	3835-3844	different	_	
16-24	3845-3855	modalities	_	
16-25	3856-3859	are	_	
16-26	3860-3865	first	_	
16-27	3866-3873	evident	_	
16-28	3873-3874	.	_	

#Text=Previous studies have explored the progressive changes primarily based on single modality.
17-1	3875-3883	Previous	_	
17-2	3884-3891	studies	_	
17-3	3892-3896	have	_	
17-4	3897-3905	explored	_	
17-5	3906-3909	the	_	
17-6	3910-3921	progressive	_	
17-7	3922-3929	changes	_	
17-8	3930-3939	primarily	_	
17-9	3940-3945	based	_	
17-10	3946-3948	on	_	
17-11	3949-3955	single	_	
17-12	3956-3964	modality	_	
17-13	3964-3965	.	_	

#Text=For example, the progressive decreases of GM volumes were pronounced mainy in the temporal and prefrontal gyrus, while increase in the lateral ventricle.
18-1	3966-3969	For	_	
18-2	3970-3977	example	_	
18-3	3977-3978	,	_	
18-4	3979-3982	the	_	
18-5	3983-3994	progressive	_	
18-6	3995-4004	decreases	_	
18-7	4005-4007	of	_	
18-8	4008-4010	GM	_	
18-9	4011-4018	volumes	_	
18-10	4019-4023	were	_	
18-11	4024-4034	pronounced	_	
18-12	4035-4040	mainy	_	
18-13	4041-4043	in	_	
18-14	4044-4047	the	_	
18-15	4048-4056	temporal	_	
18-16	4057-4060	and	_	
18-17	4061-4071	prefrontal	_	
18-18	4072-4077	gyrus	_	
18-19	4077-4078	,	_	
18-20	4079-4084	while	_	
18-21	4085-4093	increase	_	
18-22	4094-4096	in	_	
18-23	4097-4100	the	_	
18-24	4101-4108	lateral	_	
18-25	4109-4118	ventricle	_	
18-26	4118-4119	.	_	

#Text=Another recent study consisting of 39 medication naïve, first-episode schizophrenia and 31 matched controls revealed that first-episode patients presented reduced global efficiency and decreased regional nodal efficiency in hippocampal and precuneus.
19-1	4120-4127	Another	_	
19-2	4128-4134	recent	_	
19-3	4135-4140	study	_	
19-4	4141-4151	consisting	_	
19-5	4152-4154	of	_	
19-6	4155-4157	39	_	
19-7	4158-4168	medication	_	
19-8	4169-4174	naïve	_	
19-9	4174-4175	,	_	
19-10	4176-4189	first-episode	_	
19-11	4190-4203	schizophrenia	_	
19-12	4204-4207	and	_	
19-13	4208-4210	31	_	
19-14	4211-4218	matched	_	
19-15	4219-4227	controls	_	
19-16	4228-4236	revealed	_	
19-17	4237-4241	that	_	
19-18	4242-4255	first-episode	_	
19-19	4256-4264	patients	_	
19-20	4265-4274	presented	_	
19-21	4275-4282	reduced	_	
19-22	4283-4289	global	_	
19-23	4290-4300	efficiency	_	
19-24	4301-4304	and	_	
19-25	4305-4314	decreased	_	
19-26	4315-4323	regional	_	
19-27	4324-4329	nodal	_	
19-28	4330-4340	efficiency	_	
19-29	4341-4343	in	_	
19-30	4344-4355	hippocampal	_	
19-31	4356-4359	and	_	
19-32	4360-4369	precuneus	_	
19-33	4369-4370	.	_	

#Text=Li et al. demonstrated that 90% of the FC changes during the first-episode stage of SZ were centered on the inferior frontal gyrus, while more thalamus-related connectivity were extended to show FC differences in chronic SZ patients.
20-1	4371-4373	Li	_	
20-2	4374-4376	et	_	
20-3	4377-4379	al	_	
20-4	4379-4380	.	_	
20-5	4381-4393	demonstrated	_	
20-6	4394-4398	that	_	
20-7	4399-4402	90%	_	
20-8	4403-4405	of	_	
20-9	4406-4409	the	_	
20-10	4410-4412	FC	_	
20-11	4413-4420	changes	_	
20-12	4421-4427	during	_	
20-13	4428-4431	the	_	
20-14	4432-4445	first-episode	_	
20-15	4446-4451	stage	_	
20-16	4452-4454	of	_	
20-17	4455-4457	SZ	_	
20-18	4458-4462	were	_	
20-19	4463-4471	centered	_	
20-20	4472-4474	on	_	
20-21	4475-4478	the	_	
20-22	4479-4487	inferior	_	
20-23	4488-4495	frontal	_	
20-24	4496-4501	gyrus	_	
20-25	4501-4502	,	_	
20-26	4503-4508	while	_	
20-27	4509-4513	more	_	
20-28	4514-4530	thalamus-related	_	
20-29	4531-4543	connectivity	_	
20-30	4544-4548	were	_	
20-31	4549-4557	extended	_	
20-32	4558-4560	to	_	
20-33	4561-4565	show	_	
20-34	4566-4568	FC	_	
20-35	4569-4580	differences	_	
20-36	4581-4583	in	_	
20-37	4584-4591	chronic	_	
20-38	4592-4594	SZ	_	
20-39	4595-4603	patients	_	
20-40	4603-4604	.	_	

#Text=However, the direct comparison of progressive impairments among different modalities are not largely explored.
21-1	4605-4612	However	_	
21-2	4612-4613	,	_	
21-3	4614-4617	the	_	
21-4	4618-4624	direct	_	
21-5	4625-4635	comparison	_	
21-6	4636-4638	of	_	
21-7	4639-4650	progressive	_	
21-8	4651-4662	impairments	_	
21-9	4663-4668	among	_	
21-10	4669-4678	different	_	
21-11	4679-4689	modalities	_	
21-12	4690-4693	are	_	
21-13	4694-4697	not	_	
21-14	4698-4705	largely	_	
21-15	4706-4714	explored	_	
21-16	4714-4715	.	_	

#Text=Based on the linked SNP-FC-GM pattern identified from the multimodal fusion method, we can further compare the modality-specific sensitivity to the disease progression.
22-1	4716-4721	Based	_	
22-2	4722-4724	on	_	
22-3	4725-4728	the	_	
22-4	4729-4735	linked	_	
22-5	4736-4745	SNP-FC-GM	_	
22-6	4746-4753	pattern	_	
22-7	4754-4764	identified	_	
22-8	4765-4769	from	_	
22-9	4770-4773	the	_	
22-10	4774-4784	multimodal	_	
22-11	4785-4791	fusion	_	
22-12	4792-4798	method	_	
22-13	4798-4799	,	_	
22-14	4800-4802	we	_	
22-15	4803-4806	can	_	
22-16	4807-4814	further	_	
22-17	4815-4822	compare	_	
22-18	4823-4826	the	_	
22-19	4827-4844	modality-specific	_	
22-20	4845-4856	sensitivity	_	
22-21	4857-4859	to	_	
22-22	4860-4863	the	_	
22-23	4864-4871	disease	_	
22-24	4872-4883	progression	_	
22-25	4883-4884	.	_	

#Text=Overall, in this study, we performed a multimodal analysis of first-episode SZ patients (FESZ), chronic SZ patients (CSZ) and healthy controls (HC) with three features, i.e., GM volume, FC and single nucleotide polymorphisms (SNP), aiming to evaluate the links among the three modalities, and their association with duration of illness (DOI) and disease stages.
23-1	4885-4892	Overall	_	
23-2	4892-4893	,	_	
23-3	4894-4896	in	_	
23-4	4897-4901	this	_	
23-5	4902-4907	study	_	
23-6	4907-4908	,	_	
23-7	4909-4911	we	_	
23-8	4912-4921	performed	_	
23-9	4922-4923	a	_	
23-10	4924-4934	multimodal	_	
23-11	4935-4943	analysis	_	
23-12	4944-4946	of	_	
23-13	4947-4960	first-episode	_	
23-14	4961-4963	SZ	_	
23-15	4964-4972	patients	_	
23-16	4973-4974	(	_	
23-17	4974-4978	FESZ	_	
23-18	4978-4979	)	_	
23-19	4979-4980	,	_	
23-20	4981-4988	chronic	_	
23-21	4989-4991	SZ	_	
23-22	4992-5000	patients	_	
23-23	5001-5002	(	_	
23-24	5002-5005	CSZ	_	
23-25	5005-5006	)	_	
23-26	5007-5010	and	_	
23-27	5011-5018	healthy	_	
23-28	5019-5027	controls	_	
23-29	5028-5029	(	_	
23-30	5029-5031	HC	_	
23-31	5031-5032	)	_	
23-32	5033-5037	with	_	
23-33	5038-5043	three	_	
23-34	5044-5052	features	_	
23-35	5052-5053	,	_	
23-36	5054-5057	i.e	_	
23-37	5057-5058	.	_	
23-38	5058-5059	,	_	
23-39	5060-5062	GM	_	
23-40	5063-5069	volume	_	
23-41	5069-5070	,	_	
23-42	5071-5073	FC	_	
23-43	5074-5077	and	_	
23-44	5078-5084	single	_	
23-45	5085-5095	nucleotide	_	
23-46	5096-5109	polymorphisms	_	
23-47	5110-5111	(	_	
23-48	5111-5114	SNP	_	
23-49	5114-5115	)	_	
23-50	5115-5116	,	_	
23-51	5117-5123	aiming	_	
23-52	5124-5126	to	_	
23-53	5127-5135	evaluate	_	
23-54	5136-5139	the	_	
23-55	5140-5145	links	_	
23-56	5146-5151	among	_	
23-57	5152-5155	the	_	
23-58	5156-5161	three	_	
23-59	5162-5172	modalities	_	
23-60	5172-5173	,	_	
23-61	5174-5177	and	_	
23-62	5178-5183	their	_	
23-63	5184-5195	association	_	
23-64	5196-5200	with	_	
23-65	5201-5209	duration	_	
23-66	5210-5212	of	_	
23-67	5213-5220	illness	_	
23-68	5221-5222	(	_	
23-69	5222-5225	DOI	_	
23-70	5225-5226	)	_	
23-71	5227-5230	and	_	
23-72	5231-5238	disease	_	
23-73	5239-5245	stages	_	
23-74	5245-5246	.	_	

#Text=Note that we preselected SNPs from PGC's SCZ2 database based on the p-value, while these SNPs are not functionally homogeneous.
24-1	5247-5251	Note	_	
24-2	5252-5256	that	_	
24-3	5257-5259	we	_	
24-4	5260-5271	preselected	_	
24-5	5272-5276	SNPs	_	
24-6	5277-5281	from	_	
24-7	5282-5287	PGC's	_	
24-8	5288-5292	SCZ2	_	
24-9	5293-5301	database	_	
24-10	5302-5307	based	_	
24-11	5308-5310	on	_	
24-12	5311-5314	the	_	
24-13	5315-5322	p-value	_	
24-14	5322-5323	,	_	
24-15	5324-5329	while	_	
24-16	5330-5335	these	_	
24-17	5336-5340	SNPs	_	
24-18	5341-5344	are	_	
24-19	5345-5348	not	_	
24-20	5349-5361	functionally	_	
24-21	5362-5373	homogeneous	_	
24-22	5373-5374	.	_	

#Text=Since our recent study has proved that no reliable SNP-imaging association was noted in the polygenic risk score (PGRS) analyses when calculating PGRS on SNPs with high heterogeneity.
25-1	5375-5380	Since	_	
25-2	5381-5384	our	_	
25-3	5385-5391	recent	_	
25-4	5392-5397	study	_	
25-5	5398-5401	has	_	
25-6	5402-5408	proved	_	
25-7	5409-5413	that	_	
25-8	5414-5416	no	_	
25-9	5417-5425	reliable	_	
25-10	5426-5437	SNP-imaging	_	
25-11	5438-5449	association	_	
25-12	5450-5453	was	_	
25-13	5454-5459	noted	_	
25-14	5460-5462	in	_	
25-15	5463-5466	the	_	
25-16	5467-5476	polygenic	_	
25-17	5477-5481	risk	_	
25-18	5482-5487	score	_	
25-19	5488-5489	(	_	
25-20	5489-5493	PGRS	_	
25-21	5493-5494	)	_	
25-22	5495-5503	analyses	_	
25-23	5504-5508	when	_	
25-24	5509-5520	calculating	_	
25-25	5521-5525	PGRS	_	
25-26	5526-5528	on	_	
25-27	5529-5533	SNPs	_	
25-28	5534-5538	with	_	
25-29	5539-5543	high	_	
25-30	5544-5557	heterogeneity	_	
25-31	5557-5558	.	_	

#Text=The multimodal data-driven method would slove this by computing subgroups of all SNPs first and then inverstigate the associated structural and functional brain impairments based on the subgroups.
26-1	5559-5562	The	_	
26-2	5563-5573	multimodal	_	
26-3	5574-5585	data-driven	_	
26-4	5586-5592	method	_	
26-5	5593-5598	would	_	
26-6	5599-5604	slove	_	
26-7	5605-5609	this	_	
26-8	5610-5612	by	_	
26-9	5613-5622	computing	_	
26-10	5623-5632	subgroups	_	
26-11	5633-5635	of	_	
26-12	5636-5639	all	_	
26-13	5640-5644	SNPs	_	
26-14	5645-5650	first	_	
26-15	5651-5654	and	_	
26-16	5655-5659	then	_	
26-17	5660-5672	inverstigate	_	
26-18	5673-5676	the	_	
26-19	5677-5687	associated	_	
26-20	5688-5698	structural	_	
26-21	5699-5702	and	_	
26-22	5703-5713	functional	_	
26-23	5714-5719	brain	_	
26-24	5720-5731	impairments	_	
26-25	5732-5737	based	_	
26-26	5738-5740	on	_	
26-27	5741-5744	the	_	
26-28	5745-5754	subgroups	_	
26-29	5754-5755	.	_	

#Text=These subgroup SNPs are more likely to converge within brain regions.
27-1	5756-5761	These	_	
27-2	5762-5770	subgroup	_	
27-3	5771-5775	SNPs	_	
27-4	5776-5779	are	_	
27-5	5780-5784	more	_	
27-6	5785-5791	likely	_	
27-7	5792-5794	to	_	
27-8	5795-5803	converge	_	
27-9	5804-5810	within	_	
27-10	5811-5816	brain	_	
27-11	5817-5824	regions	_	
27-12	5824-5825	.	_	

#Text=We hypothesized that a significant correlated SNP-FC-GM pattern would be revealed, as well as significant group differences among HC, FESZ and CSZ in each modality.
28-1	5826-5828	We	_	
28-2	5829-5841	hypothesized	_	
28-3	5842-5846	that	_	
28-4	5847-5848	a	_	
28-5	5849-5860	significant	_	
28-6	5861-5871	correlated	_	
28-7	5872-5881	SNP-FC-GM	_	
28-8	5882-5889	pattern	_	
28-9	5890-5895	would	_	
28-10	5896-5898	be	_	
28-11	5899-5907	revealed	_	
28-12	5907-5908	,	_	
28-13	5909-5911	as	_	
28-14	5912-5916	well	_	
28-15	5917-5919	as	_	
28-16	5920-5931	significant	_	
28-17	5932-5937	group	_	
28-18	5938-5949	differences	_	
28-19	5950-5955	among	_	
28-20	5956-5958	HC	_	
28-21	5958-5959	,	_	
28-22	5960-5964	FESZ	_	
28-23	5965-5968	and	_	
28-24	5969-5972	CSZ	_	
28-25	5973-5975	in	_	
28-26	5976-5980	each	_	
28-27	5981-5989	modality	_	
28-28	5989-5990	.	_	

#Text=More importantly, different sensitivity to DOI and disease stages (i.e., the order of feature impairment) would be revealed for different modalities, which may provide us additional clues regarding the impact of mental illness at various disease stages.
29-1	5991-5995	More	_	
29-2	5996-6007	importantly	_	
29-3	6007-6008	,	_	
29-4	6009-6018	different	_	
29-5	6019-6030	sensitivity	_	
29-6	6031-6033	to	_	
29-7	6034-6037	DOI	_	
29-8	6038-6041	and	_	
29-9	6042-6049	disease	_	
29-10	6050-6056	stages	_	
29-11	6057-6058	(	_	
29-12	6058-6061	i.e	_	
29-13	6061-6062	.	_	
29-14	6062-6063	,	_	
29-15	6064-6067	the	_	
29-16	6068-6073	order	_	
29-17	6074-6076	of	_	
29-18	6077-6084	feature	_	
29-19	6085-6095	impairment	_	
29-20	6095-6096	)	_	
29-21	6097-6102	would	_	
29-22	6103-6105	be	_	
29-23	6106-6114	revealed	_	
29-24	6115-6118	for	_	
29-25	6119-6128	different	_	
29-26	6129-6139	modalities	_	
29-27	6139-6140	,	_	
29-28	6141-6146	which	_	
29-29	6147-6150	may	_	
29-30	6151-6158	provide	_	
29-31	6159-6161	us	_	
29-32	6162-6172	additional	_	
29-33	6173-6178	clues	_	
29-34	6179-6188	regarding	_	
29-35	6189-6192	the	_	
29-36	6193-6199	impact	_	
29-37	6200-6202	of	_	
29-38	6203-6209	mental	_	
29-39	6210-6217	illness	_	
29-40	6218-6220	at	_	
29-41	6221-6228	various	_	
29-42	6229-6236	disease	_	
29-43	6237-6243	stages	_	
29-44	6243-6244	.	_	

#Text=Materials and methods
#Text=Participants
#Text=Demographic characteristics of the subjects in the present study.
30-1	6245-6254	Materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[4]	
30-2	6255-6258	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[4]	
30-3	6259-6266	methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[4]	
30-4	6267-6279	Participants	_	
30-5	6280-6291	Demographic	_	
30-6	6292-6307	characteristics	_	
30-7	6308-6310	of	_	
30-8	6311-6314	the	_	
30-9	6315-6323	subjects	_	
30-10	6324-6326	in	_	
30-11	6327-6330	the	_	
30-12	6331-6338	present	_	
30-13	6339-6344	study	_	
30-14	6344-6345	.	_	

#Text=Table 1\t \t
#Text=Demographics\t\tHC\tFESZ\tCSZ\tp\t \tNumber\t\t87\t20\t52\t\t \tGender\tM/F\t47/40\t10/10\t30/22\t0.83\t \tAge (y)\tMean ± SD\t39.91 ± 14.84\t33.60 ± 10.80\t46.12 ± 11.38\t0.0011\t \tEducation\tMean ± SD\t12.67 ± 4.28\t10.65 ± 4.65\t10.75 ± 2.69\t0.0091\t \tDuration of Illness (y)\tMean ± SD\tNA\t0.96 ± 0.85\t20.63 ± 9.84\t\t \tChlorpromazine Equivalent\tMean ± SD\tNA\tDrug-naïve\t17.26 ± 9.44\t\t \tPANSS positive\tMean ± SD\tNA\t27.8 ± 4.64\t19.62 ± 3.82\t9.20E-08\t \tPANSS negative\tMean ± SD\tNA\t19.65 ± 4.78\t24.40 ± 3.52\t3.87E-04\t \tPANSS general\tMean ± SD\tNA\t46.45 ± 7.49\t41.77 ± 5.11\t0.016\t \t
#Text=Note: Chlorpromazine equivalent = Chlorpromazine total (standardized current dose of antipsychotic medication).
31-1	6346-6351	Table	_	
31-2	6352-6353	1	_	
31-3	6357-6369	Demographics	_	
31-4	6371-6373	HC	_	
31-5	6374-6378	FESZ	_	
31-6	6379-6382	CSZ	_	
31-7	6383-6384	p	_	
31-8	6387-6393	Number	_	
31-9	6395-6397	87	_	
31-10	6398-6400	20	_	
31-11	6401-6403	52	_	
31-12	6407-6413	Gender	_	
31-13	6414-6415	M	_	
31-14	6415-6416	/	_	
31-15	6416-6417	F	_	
31-16	6418-6420	47	_	
31-17	6420-6421	/	_	
31-18	6421-6423	40	_	
31-19	6424-6426	10	_	
31-20	6426-6427	/	_	
31-21	6427-6429	10	_	
31-22	6430-6432	30	_	
31-23	6432-6433	/	_	
31-24	6433-6435	22	_	
31-25	6436-6440	0.83	_	
31-26	6443-6446	Age	_	
31-27	6447-6448	(	_	
31-28	6448-6449	y	_	
31-29	6449-6450	)	_	
31-30	6451-6455	Mean	_	
31-31	6455-6456	 	_	
31-32	6456-6457	±	_	
31-33	6457-6458	 	_	
31-34	6458-6460	SD	_	
31-35	6461-6466	39.91	_	
31-36	6466-6467	 	_	
31-37	6467-6468	±	_	
31-38	6468-6469	 	_	
31-39	6469-6474	14.84	_	
31-40	6475-6480	33.60	_	
31-41	6480-6481	 	_	
31-42	6481-6482	±	_	
31-43	6482-6483	 	_	
31-44	6483-6488	10.80	_	
31-45	6489-6494	46.12	_	
31-46	6494-6495	 	_	
31-47	6495-6496	±	_	
31-48	6496-6497	 	_	
31-49	6497-6502	11.38	_	
31-50	6503-6509	0.0011	_	
31-51	6512-6521	Education	_	
31-52	6522-6526	Mean	_	
31-53	6526-6527	 	_	
31-54	6527-6528	±	_	
31-55	6528-6529	 	_	
31-56	6529-6531	SD	_	
31-57	6532-6537	12.67	_	
31-58	6537-6538	 	_	
31-59	6538-6539	±	_	
31-60	6539-6540	 	_	
31-61	6540-6544	4.28	_	
31-62	6545-6550	10.65	_	
31-63	6550-6551	 	_	
31-64	6551-6552	±	_	
31-65	6552-6553	 	_	
31-66	6553-6557	4.65	_	
31-67	6558-6563	10.75	_	
31-68	6563-6564	 	_	
31-69	6564-6565	±	_	
31-70	6565-6566	 	_	
31-71	6566-6570	2.69	_	
31-72	6571-6577	0.0091	_	
31-73	6580-6588	Duration	_	
31-74	6589-6591	of	_	
31-75	6592-6599	Illness	_	
31-76	6600-6601	(	_	
31-77	6601-6602	y	_	
31-78	6602-6603	)	_	
31-79	6604-6608	Mean	_	
31-80	6608-6609	 	_	
31-81	6609-6610	±	_	
31-82	6610-6611	 	_	
31-83	6611-6613	SD	_	
31-84	6614-6616	NA	_	
31-85	6617-6621	0.96	_	
31-86	6621-6622	 	_	
31-87	6622-6623	±	_	
31-88	6623-6624	 	_	
31-89	6624-6628	0.85	_	
31-90	6629-6634	20.63	_	
31-91	6634-6635	 	_	
31-92	6635-6636	±	_	
31-93	6636-6637	 	_	
31-94	6637-6641	9.84	_	
31-95	6645-6659	Chlorpromazine	_	
31-96	6660-6670	Equivalent	_	
31-97	6671-6675	Mean	_	
31-98	6675-6676	 	_	
31-99	6676-6677	±	_	
31-100	6677-6678	 	_	
31-101	6678-6680	SD	_	
31-102	6681-6683	NA	_	
31-103	6684-6694	Drug-naïve	_	
31-104	6695-6700	17.26	_	
31-105	6700-6701	 	_	
31-106	6701-6702	±	_	
31-107	6702-6703	 	_	
31-108	6703-6707	9.44	_	
31-109	6711-6716	PANSS	_	
31-110	6717-6725	positive	_	
31-111	6726-6730	Mean	_	
31-112	6730-6731	 	_	
31-113	6731-6732	±	_	
31-114	6732-6733	 	_	
31-115	6733-6735	SD	_	
31-116	6736-6738	NA	_	
31-117	6739-6743	27.8	_	
31-118	6743-6744	 	_	
31-119	6744-6745	±	_	
31-120	6745-6746	 	_	
31-121	6746-6750	4.64	_	
31-122	6751-6756	19.62	_	
31-123	6756-6757	 	_	
31-124	6757-6758	±	_	
31-125	6758-6759	 	_	
31-126	6759-6763	3.82	_	
31-127	6764-6769	9.20E	_	
31-128	6769-6770	-	_	
31-129	6770-6772	08	_	
31-130	6775-6780	PANSS	_	
31-131	6781-6789	negative	_	
31-132	6790-6794	Mean	_	
31-133	6794-6795	 	_	
31-134	6795-6796	±	_	
31-135	6796-6797	 	_	
31-136	6797-6799	SD	_	
31-137	6800-6802	NA	_	
31-138	6803-6808	19.65	_	
31-139	6808-6809	 	_	
31-140	6809-6810	±	_	
31-141	6810-6811	 	_	
31-142	6811-6815	4.78	_	
31-143	6816-6821	24.40	_	
31-144	6821-6822	 	_	
31-145	6822-6823	±	_	
31-146	6823-6824	 	_	
31-147	6824-6828	3.52	_	
31-148	6829-6834	3.87E	_	
31-149	6834-6835	-	_	
31-150	6835-6837	04	_	
31-151	6840-6845	PANSS	_	
31-152	6846-6853	general	_	
31-153	6854-6858	Mean	_	
31-154	6858-6859	 	_	
31-155	6859-6860	±	_	
31-156	6860-6861	 	_	
31-157	6861-6863	SD	_	
31-158	6864-6866	NA	_	
31-159	6867-6872	46.45	_	
31-160	6872-6873	 	_	
31-161	6873-6874	±	_	
31-162	6874-6875	 	_	
31-163	6875-6879	7.49	_	
31-164	6880-6885	41.77	_	
31-165	6885-6886	 	_	
31-166	6886-6887	±	_	
31-167	6887-6888	 	_	
31-168	6888-6892	5.11	_	
31-169	6893-6898	0.016	_	
31-170	6902-6906	Note	_	
31-171	6906-6907	:	_	
31-172	6908-6922	Chlorpromazine	_	
31-173	6923-6933	equivalent	_	
31-174	6933-6934	 	_	
31-175	6934-6935	=	_	
31-176	6935-6936	 	_	
31-177	6936-6950	Chlorpromazine	_	
31-178	6951-6956	total	_	
31-179	6957-6958	(	_	
31-180	6958-6970	standardized	_	
31-181	6971-6978	current	_	
31-182	6979-6983	dose	_	
31-183	6984-6986	of	_	
31-184	6987-7000	antipsychotic	_	
31-185	7001-7011	medication	_	
31-186	7011-7012	)	_	
31-187	7012-7013	.	_	

#Text=P values represent the results of chi-square test for gender, analysis of variance (ANOVA) test for age and education, two sample t-test for PANSS scores.
32-1	7014-7015	P	_	
32-2	7016-7022	values	_	
32-3	7023-7032	represent	_	
32-4	7033-7036	the	_	
32-5	7037-7044	results	_	
32-6	7045-7047	of	_	
32-7	7048-7058	chi-square	_	
32-8	7059-7063	test	_	
32-9	7064-7067	for	_	
32-10	7068-7074	gender	_	
32-11	7074-7075	,	_	
32-12	7076-7084	analysis	_	
32-13	7085-7087	of	_	
32-14	7088-7096	variance	_	
32-15	7097-7098	(	_	
32-16	7098-7103	ANOVA	_	
32-17	7103-7104	)	_	
32-18	7105-7109	test	_	
32-19	7110-7113	for	_	
32-20	7114-7117	age	_	
32-21	7118-7121	and	_	
32-22	7122-7131	education	_	
32-23	7131-7132	,	_	
32-24	7133-7136	two	_	
32-25	7137-7143	sample	_	
32-26	7144-7150	t-test	_	
32-27	7151-7154	for	_	
32-28	7155-7160	PANSS	_	
32-29	7161-7167	scores	_	
32-30	7167-7168	.	_	

#Text=HC: healthy control subjects; FESZ: first-episode schizophrenia; CSZ: chronic schizophrenia; F: female; M: male; NA: not applicable.
#Text=159 subjects were recruited from Wuxi Mental Health Center, consisting of eighty-seven HC, twenty drug-naïve FESZs and fifty-two CSZs.
33-1	7169-7171	HC	_	
33-2	7171-7172	:	_	
33-3	7173-7180	healthy	_	
33-4	7181-7188	control	_	
33-5	7189-7197	subjects	_	
33-6	7197-7198	;	_	
33-7	7199-7203	FESZ	_	
33-8	7203-7204	:	_	
33-9	7205-7218	first-episode	_	
33-10	7219-7232	schizophrenia	_	
33-11	7232-7233	;	_	
33-12	7234-7237	CSZ	_	
33-13	7237-7238	:	_	
33-14	7239-7246	chronic	_	
33-15	7247-7260	schizophrenia	_	
33-16	7260-7261	;	_	
33-17	7262-7263	F	_	
33-18	7263-7264	:	_	
33-19	7265-7271	female	_	
33-20	7271-7272	;	_	
33-21	7273-7274	M	_	
33-22	7274-7275	:	_	
33-23	7276-7280	male	_	
33-24	7280-7281	;	_	
33-25	7282-7284	NA	_	
33-26	7284-7285	:	_	
33-27	7286-7289	not	_	
33-28	7290-7300	applicable	_	
33-29	7300-7301	.	_	
33-30	7302-7305	159	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-31	7306-7314	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-32	7315-7319	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-33	7320-7329	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-34	7330-7334	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-35	7335-7339	Wuxi	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-36	7340-7346	Mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-37	7347-7353	Health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-38	7354-7360	Center	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-39	7360-7361	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-40	7362-7372	consisting	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-41	7373-7375	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-42	7376-7388	eighty-seven	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-43	7389-7391	HC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[6]	
33-44	7391-7392	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-45	7393-7399	twenty	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-46	7400-7410	drug-naïve	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-47	7411-7416	FESZs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[7]	
33-48	7417-7420	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-49	7421-7430	fifty-two	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-50	7431-7435	CSZs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#ChronicSchizophrenia[8]	
33-51	7435-7436	.	_	

#Text=Table 1 describes the demographic information of the data.
34-1	7437-7442	Table	_	
34-2	7443-7444	1	_	
34-3	7445-7454	describes	_	
34-4	7455-7458	the	_	
34-5	7459-7470	demographic	_	
34-6	7471-7482	information	_	
34-7	7483-7485	of	_	
34-8	7486-7489	the	_	
34-9	7490-7494	data	_	
34-10	7494-7495	.	_	

#Text=Patients who have DOI ≤ 2 years were definded as FESZ patients (0.96 ± 0.85), others were identified as chronic patients (20.63 ± 9.84).
35-1	7496-7504	Patients	_	
35-2	7505-7508	who	_	
35-3	7509-7513	have	_	
35-4	7514-7517	DOI	_	
35-5	7518-7519	≤	_	
35-6	7520-7521	2	_	
35-7	7521-7522	 	_	
35-8	7522-7527	years	_	
35-9	7528-7532	were	_	
35-10	7533-7541	definded	_	
35-11	7542-7544	as	_	
35-12	7545-7549	FESZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
35-13	7550-7558	patients	_	
35-14	7559-7560	(	_	
35-15	7560-7564	0.96	_	
35-16	7564-7565	 	_	
35-17	7565-7566	±	_	
35-18	7566-7567	 	_	
35-19	7567-7571	0.85	_	
35-20	7571-7572	)	_	
35-21	7572-7573	,	_	
35-22	7574-7580	others	_	
35-23	7581-7585	were	_	
35-24	7586-7596	identified	_	
35-25	7597-7599	as	_	
35-26	7600-7607	chronic	_	
35-27	7608-7616	patients	_	
35-28	7617-7618	(	_	
35-29	7618-7623	20.63	_	
35-30	7623-7624	 	_	
35-31	7624-7625	±	_	
35-32	7625-7626	 	_	
35-33	7626-7630	9.84	_	
35-34	7630-7631	)	_	
35-35	7631-7632	.	_	

#Text=Subjects were excluded if they had any current or past neurological illness, substance abuse or head injury resulting in loss of consciousness.
36-1	7633-7641	Subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-2	7642-7646	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-3	7647-7655	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-4	7656-7658	if	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-5	7659-7663	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-6	7664-7667	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-7	7668-7671	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-8	7672-7679	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-9	7680-7682	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-10	7683-7687	past	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-11	7688-7700	neurological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-12	7701-7708	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-13	7708-7709	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-14	7710-7719	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-15	7720-7725	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-16	7726-7728	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-17	7729-7733	head	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-18	7734-7740	injury	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-19	7741-7750	resulting	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-20	7751-7753	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-21	7754-7758	loss	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-22	7759-7761	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-23	7762-7775	consciousness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-24	7775-7776	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	

#Text=All the patients were diagnosed according to the DSM-IV diagnostic criteria by at least two qualified psychiatrists.
37-1	7777-7780	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
37-2	7781-7784	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
37-3	7785-7793	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
37-4	7794-7798	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
37-5	7799-7808	diagnosed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
37-6	7809-7818	according	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
37-7	7819-7821	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
37-8	7822-7825	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
37-9	7826-7832	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
37-10	7833-7843	diagnostic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
37-11	7844-7852	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
37-12	7853-7855	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
37-13	7856-7858	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
37-14	7859-7864	least	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
37-15	7865-7868	two	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
37-16	7869-7878	qualified	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
37-17	7879-7892	psychiatrists	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
37-18	7892-7893	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	

#Text=Data collection
#Text=All subjects were scanned by structural MRI and resting-state functional MRI on a 3.0-Tesla Magnetom TIM Trio (Siemens Medical System) at the Department of Medical Imaging, Wuxi People's Hospital, Nanjing Medical University.
38-1	7894-7898	Data	_	
38-2	7899-7909	collection	_	
38-3	7910-7913	All	_	
38-4	7914-7922	subjects	_	
38-5	7923-7927	were	_	
38-6	7928-7935	scanned	_	
38-7	7936-7938	by	_	
38-8	7939-7949	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[11]	
38-9	7950-7953	MRI	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[11]	
38-10	7954-7957	and	_	
38-11	7958-7971	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[12]	
38-12	7972-7982	functional	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[12]	
38-13	7983-7986	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[12]	
38-14	7987-7989	on	_	
38-15	7990-7991	a	_	
38-16	7992-7995	3.0	_	
38-17	7995-7996	-	_	
38-18	7996-8001	Tesla	_	
38-19	8002-8010	Magnetom	_	
38-20	8011-8014	TIM	_	
38-21	8015-8019	Trio	_	
38-22	8020-8021	(	_	
38-23	8021-8028	Siemens	_	
38-24	8029-8036	Medical	_	
38-25	8037-8043	System	_	
38-26	8043-8044	)	_	
38-27	8045-8047	at	_	
38-28	8048-8051	the	_	
38-29	8052-8062	Department	_	
38-30	8063-8065	of	_	
38-31	8066-8073	Medical	_	
38-32	8074-8081	Imaging	_	
38-33	8081-8082	,	_	
38-34	8083-8087	Wuxi	_	
38-35	8088-8096	People's	_	
38-36	8097-8105	Hospital	_	
38-37	8105-8106	,	_	
38-38	8107-8114	Nanjing	_	
38-39	8115-8122	Medical	_	
38-40	8123-8133	University	_	
38-41	8133-8134	.	_	

#Text=Foam pads were used to reduce head motion and scanner noise.
39-1	8135-8139	Foam	_	
39-2	8140-8144	pads	_	
39-3	8145-8149	were	_	
39-4	8150-8154	used	_	
39-5	8155-8157	to	_	
39-6	8158-8164	reduce	_	
39-7	8165-8169	head	_	
39-8	8170-8176	motion	_	
39-9	8177-8180	and	_	
39-10	8181-8188	scanner	_	
39-11	8189-8194	noise	_	
39-12	8194-8195	.	_	

#Text=Prior to the scan, the subjects were instructed to keep their eyes closed, relax but not fall asleep, and move as little as possible during data acquisition. fMRI: Resting-state scans were acquired using a single-shot gradient-echo echo-planar-imaging sequence as with the following parameters: TR = 2000 ms, TE = 30 ms, flip angle = 90°, matrix size = 64 × 64, FOV = 220 × 220 mm2, 33 axial slices, slice thickness = 4 mm, acquisition voxel size = 3.4 × 3.4 × 4 mm3, resulting in 240 volumes. sMRI: Three-dimensional T1-weighted images were acquired by employing a 3D-MPRAGE sequence as with the following parameters: time repetition (TR) = 2530 ms, time echo (TE) = 3.44 ms, flip angle = 7°, matrix size = 256 × 256, field of view (FOV) = 256 × 256 mm2, 192 sagittal slices, slice thickness = 1 mm, acquisition voxel size = 1 × 1 × 1 mm3, total acquisition time = 649 s.
40-1	8196-8201	Prior	_	
40-2	8202-8204	to	_	
40-3	8205-8208	the	_	
40-4	8209-8213	scan	_	
40-5	8213-8214	,	_	
40-6	8215-8218	the	_	
40-7	8219-8227	subjects	_	
40-8	8228-8232	were	_	
40-9	8233-8243	instructed	_	
40-10	8244-8246	to	_	
40-11	8247-8251	keep	_	
40-12	8252-8257	their	_	
40-13	8258-8262	eyes	_	
40-14	8263-8269	closed	_	
40-15	8269-8270	,	_	
40-16	8271-8276	relax	_	
40-17	8277-8280	but	_	
40-18	8281-8284	not	_	
40-19	8285-8289	fall	_	
40-20	8290-8296	asleep	_	
40-21	8296-8297	,	_	
40-22	8298-8301	and	_	
40-23	8302-8306	move	_	
40-24	8307-8309	as	_	
40-25	8310-8316	little	_	
40-26	8317-8319	as	_	
40-27	8320-8328	possible	_	
40-28	8329-8335	during	_	
40-29	8336-8340	data	_	
40-30	8341-8352	acquisition	_	
40-31	8352-8353	.	_	
40-32	8354-8358	fMRI	_	
40-33	8358-8359	:	_	
40-34	8360-8373	Resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[13]	
40-35	8374-8379	scans	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[13]	
40-36	8380-8384	were	_	
40-37	8385-8393	acquired	_	
40-38	8394-8399	using	_	
40-39	8400-8401	a	_	
40-40	8402-8413	single-shot	_	
40-41	8414-8427	gradient-echo	_	
40-42	8428-8447	echo-planar-imaging	_	
40-43	8448-8456	sequence	_	
40-44	8457-8459	as	_	
40-45	8460-8464	with	_	
40-46	8465-8468	the	_	
40-47	8469-8478	following	_	
40-48	8479-8489	parameters	_	
40-49	8489-8490	:	_	
40-50	8491-8493	TR	_	
40-51	8493-8494	 	_	
40-52	8494-8495	=	_	
40-53	8495-8496	 	_	
40-54	8496-8500	2000	_	
40-55	8500-8501	 	_	
40-56	8501-8503	ms	_	
40-57	8503-8504	,	_	
40-58	8505-8507	TE	_	
40-59	8507-8508	 	_	
40-60	8508-8509	=	_	
40-61	8509-8510	 	_	
40-62	8510-8512	30	_	
40-63	8512-8513	 	_	
40-64	8513-8515	ms	_	
40-65	8515-8516	,	_	
40-66	8517-8521	flip	_	
40-67	8522-8527	angle	_	
40-68	8527-8528	 	_	
40-69	8528-8529	=	_	
40-70	8529-8530	 	_	
40-71	8530-8532	90	_	
40-72	8532-8533	°	_	
40-73	8533-8534	,	_	
40-74	8535-8541	matrix	_	
40-75	8542-8546	size	_	
40-76	8546-8547	 	_	
40-77	8547-8548	=	_	
40-78	8548-8549	 	_	
40-79	8549-8551	64	_	
40-80	8551-8552	 	_	
40-81	8552-8553	×	_	
40-82	8553-8554	 	_	
40-83	8554-8556	64	_	
40-84	8556-8557	,	_	
40-85	8558-8561	FOV	_	
40-86	8561-8562	 	_	
40-87	8562-8563	=	_	
40-88	8563-8564	 	_	
40-89	8564-8567	220	_	
40-90	8567-8568	 	_	
40-91	8568-8569	×	_	
40-92	8569-8570	 	_	
40-93	8570-8573	220	_	
40-94	8573-8574	 	_	
40-95	8574-8577	mm2	_	
40-96	8577-8578	,	_	
40-97	8579-8581	33	_	
40-98	8582-8587	axial	_	
40-99	8588-8594	slices	_	
40-100	8594-8595	,	_	
40-101	8596-8601	slice	_	
40-102	8602-8611	thickness	_	
40-103	8611-8612	 	_	
40-104	8612-8613	=	_	
40-105	8613-8614	 	_	
40-106	8614-8615	4	_	
40-107	8615-8616	 	_	
40-108	8616-8618	mm	_	
40-109	8618-8619	,	_	
40-110	8620-8631	acquisition	_	
40-111	8632-8637	voxel	_	
40-112	8638-8642	size	_	
40-113	8642-8643	 	_	
40-114	8643-8644	=	_	
40-115	8644-8645	 	_	
40-116	8645-8648	3.4	_	
40-117	8648-8649	 	_	
40-118	8649-8650	×	_	
40-119	8650-8651	 	_	
40-120	8651-8654	3.4	_	
40-121	8654-8655	 	_	
40-122	8655-8656	×	_	
40-123	8656-8657	 	_	
40-124	8657-8658	4	_	
40-125	8658-8659	 	_	
40-126	8659-8662	mm3	_	
40-127	8662-8663	,	_	
40-128	8664-8673	resulting	_	
40-129	8674-8676	in	_	
40-130	8677-8680	240	_	
40-131	8681-8688	volumes	_	
40-132	8688-8689	.	_	
40-133	8690-8694	sMRI	_	
40-134	8694-8695	:	_	
40-135	8696-8713	Three-dimensional	_	
40-136	8714-8716	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[14]	
40-137	8716-8717	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[14]	
40-138	8717-8725	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[14]	
40-139	8726-8732	images	_	
40-140	8733-8737	were	_	
40-141	8738-8746	acquired	_	
40-142	8747-8749	by	_	
40-143	8750-8759	employing	_	
40-144	8760-8761	a	_	
40-145	8762-8771	3D-MPRAGE	_	
40-146	8772-8780	sequence	_	
40-147	8781-8783	as	_	
40-148	8784-8788	with	_	
40-149	8789-8792	the	_	
40-150	8793-8802	following	_	
40-151	8803-8813	parameters	_	
40-152	8813-8814	:	_	
40-153	8815-8819	time	_	
40-154	8820-8830	repetition	_	
40-155	8831-8832	(	_	
40-156	8832-8834	TR	_	
40-157	8834-8835	)	_	
40-158	8835-8836	 	_	
40-159	8836-8837	=	_	
40-160	8837-8838	 	_	
40-161	8838-8842	2530	_	
40-162	8842-8843	 	_	
40-163	8843-8845	ms	_	
40-164	8845-8846	,	_	
40-165	8847-8851	time	_	
40-166	8852-8856	echo	_	
40-167	8857-8858	(	_	
40-168	8858-8860	TE	_	
40-169	8860-8861	)	_	
40-170	8861-8862	 	_	
40-171	8862-8863	=	_	
40-172	8863-8864	 	_	
40-173	8864-8868	3.44	_	
40-174	8868-8869	 	_	
40-175	8869-8871	ms	_	
40-176	8871-8872	,	_	
40-177	8873-8877	flip	_	
40-178	8878-8883	angle	_	
40-179	8883-8884	 	_	
40-180	8884-8885	=	_	
40-181	8885-8886	 	_	
40-182	8886-8887	7	_	
40-183	8887-8888	°	_	
40-184	8888-8889	,	_	
40-185	8890-8896	matrix	_	
40-186	8897-8901	size	_	
40-187	8901-8902	 	_	
40-188	8902-8903	=	_	
40-189	8903-8904	 	_	
40-190	8904-8907	256	_	
40-191	8907-8908	 	_	
40-192	8908-8909	×	_	
40-193	8909-8910	 	_	
40-194	8910-8913	256	_	
40-195	8913-8914	,	_	
40-196	8915-8920	field	_	
40-197	8921-8923	of	_	
40-198	8924-8928	view	_	
40-199	8929-8930	(	_	
40-200	8930-8933	FOV	_	
40-201	8933-8934	)	_	
40-202	8934-8935	 	_	
40-203	8935-8936	=	_	
40-204	8936-8937	 	_	
40-205	8937-8940	256	_	
40-206	8940-8941	 	_	
40-207	8941-8942	×	_	
40-208	8942-8943	 	_	
40-209	8943-8946	256	_	
40-210	8946-8947	 	_	
40-211	8947-8950	mm2	_	
40-212	8950-8951	,	_	
40-213	8952-8955	192	_	
40-214	8956-8964	sagittal	_	
40-215	8965-8971	slices	_	
40-216	8971-8972	,	_	
40-217	8973-8978	slice	_	
40-218	8979-8988	thickness	_	
40-219	8988-8989	 	_	
40-220	8989-8990	=	_	
40-221	8990-8991	 	_	
40-222	8991-8992	1	_	
40-223	8992-8993	 	_	
40-224	8993-8995	mm	_	
40-225	8995-8996	,	_	
40-226	8997-9008	acquisition	_	
40-227	9009-9014	voxel	_	
40-228	9015-9019	size	_	
40-229	9019-9020	 	_	
40-230	9020-9021	=	_	
40-231	9021-9022	 	_	
40-232	9022-9023	1	_	
40-233	9023-9024	 	_	
40-234	9024-9025	×	_	
40-235	9025-9026	 	_	
40-236	9026-9027	1	_	
40-237	9027-9028	 	_	
40-238	9028-9029	×	_	
40-239	9029-9030	 	_	
40-240	9030-9031	1	_	
40-241	9031-9032	 	_	
40-242	9032-9035	mm3	_	
40-243	9035-9036	,	_	
40-244	9037-9042	total	_	
40-245	9043-9054	acquisition	_	
40-246	9055-9059	time	_	
40-247	9059-9060	 	_	
40-248	9060-9061	=	_	
40-249	9061-9062	 	_	
40-250	9062-9065	649	_	
40-251	9065-9066	 	_	
40-252	9066-9067	s	_	
40-253	9067-9068	.	_	

#Text=All participants provided blood samples for genetic analysis.
41-1	9069-9072	All	_	
41-2	9073-9085	participants	_	
41-3	9086-9094	provided	_	
41-4	9095-9100	blood	_	
41-5	9101-9108	samples	_	
41-6	9109-9112	for	_	
41-7	9113-9120	genetic	_	
41-8	9121-9129	analysis	_	
41-9	9129-9130	.	_	

#Text=Genomic deoxyribonucleic acid (DNA) was extracted according to the standard protocol by protease K digestion, phenol-chloroform extraction and ethanol precipitation.
42-1	9131-9138	Genomic	_	
42-2	9139-9155	deoxyribonucleic	_	
42-3	9156-9160	acid	_	
42-4	9161-9162	(	_	
42-5	9162-9165	DNA	_	
42-6	9165-9166	)	_	
42-7	9167-9170	was	_	
42-8	9171-9180	extracted	_	
42-9	9181-9190	according	_	
42-10	9191-9193	to	_	
42-11	9194-9197	the	_	
42-12	9198-9206	standard	_	
42-13	9207-9215	protocol	_	
42-14	9216-9218	by	_	
42-15	9219-9227	protease	_	
42-16	9228-9229	K	_	
42-17	9230-9239	digestion	_	
42-18	9239-9240	,	_	
42-19	9241-9258	phenol-chloroform	_	
42-20	9259-9269	extraction	_	
42-21	9270-9273	and	_	
42-22	9274-9281	ethanol	_	
42-23	9282-9295	precipitation	_	
42-24	9295-9296	.	_	

#Text=Afterwards, whole-genome genotyping was conducted on 571,054 loci using Illumina human PsychArray-24.
43-1	9297-9307	Afterwards	_	
43-2	9307-9308	,	_	
43-3	9309-9321	whole-genome	_	
43-4	9322-9332	genotyping	_	
43-5	9333-9336	was	_	
43-6	9337-9346	conducted	_	
43-7	9347-9349	on	_	
43-8	9350-9357	571,054	_	
43-9	9358-9362	loci	_	
43-10	9363-9368	using	_	
43-11	9369-9377	Illumina	_	
43-12	9378-9383	human	_	
43-13	9384-9394	PsychArray	_	
43-14	9394-9395	-	_	
43-15	9395-9397	24	_	
43-16	9397-9398	.	_	

#Text=Data preprocessing
#Text=The structural MRI data and functional MRI data were preprocessed using the SPM8 (www.fil.ion.ucl.ac.uk/spm/software/spm8) voxel based morphometry module and the Brant software (http://brant.brainnetome.org/en/latest/,), respectively (see supplementary file for more details).
44-1	9399-9403	Data	_	
44-2	9404-9417	preprocessing	_	
44-3	9418-9421	The	_	
44-4	9422-9432	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[15]	
44-5	9433-9436	MRI	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[15]	
44-6	9437-9441	data	_	
44-7	9442-9445	and	_	
44-8	9446-9456	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[16]	
44-9	9457-9460	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[16]	
44-10	9461-9465	data	_	
44-11	9466-9470	were	_	
44-12	9471-9483	preprocessed	_	
44-13	9484-9489	using	_	
44-14	9490-9493	the	_	
44-15	9494-9498	SPM8	_	
44-16	9499-9500	(	_	
44-17	9500-9521	www.fil.ion.ucl.ac.uk	_	
44-18	9521-9522	/	_	
44-19	9522-9525	spm	_	
44-20	9525-9526	/	_	
44-21	9526-9534	software	_	
44-22	9534-9535	/	_	
44-23	9535-9539	spm8	_	
44-24	9539-9540	)	_	
44-25	9541-9546	voxel	_	
44-26	9547-9552	based	_	
44-27	9553-9564	morphometry	_	
44-28	9565-9571	module	_	
44-29	9572-9575	and	_	
44-30	9576-9579	the	_	
44-31	9580-9585	Brant	_	
44-32	9586-9594	software	_	
44-33	9595-9596	(	_	
44-34	9596-9600	http	_	
44-35	9600-9601	:	_	
44-36	9601-9602	/	_	
44-37	9602-9603	/	_	
44-38	9603-9624	brant.brainnetome.org	_	
44-39	9624-9625	/	_	
44-40	9625-9627	en	_	
44-41	9627-9628	/	_	
44-42	9628-9634	latest	_	
44-43	9634-9635	/	_	
44-44	9635-9636	,	_	
44-45	9636-9637	)	_	
44-46	9637-9638	,	_	
44-47	9639-9651	respectively	_	
44-48	9652-9653	(	_	
44-49	9653-9656	see	_	
44-50	9657-9670	supplementary	_	
44-51	9671-9675	file	_	
44-52	9676-9679	for	_	
44-53	9680-9684	more	_	
44-54	9685-9692	details	_	
44-55	9692-9693	)	_	
44-56	9693-9694	.	_	

#Text=A mask for the preprocessed structural data was then generated to include voxels with a mean value larger than 0.2 across all the subjects.
45-1	9695-9696	A	_	
45-2	9697-9701	mask	_	
45-3	9702-9705	for	_	
45-4	9706-9709	the	_	
45-5	9710-9722	preprocessed	_	
45-6	9723-9733	structural	_	
45-7	9734-9738	data	_	
45-8	9739-9742	was	_	
45-9	9743-9747	then	_	
45-10	9748-9757	generated	_	
45-11	9758-9760	to	_	
45-12	9761-9768	include	_	
45-13	9769-9775	voxels	_	
45-14	9776-9780	with	_	
45-15	9781-9782	a	_	
45-16	9783-9787	mean	_	
45-17	9788-9793	value	_	
45-18	9794-9800	larger	_	
45-19	9801-9805	than	_	
45-20	9806-9809	0.2	_	
45-21	9810-9816	across	_	
45-22	9817-9820	all	_	
45-23	9821-9824	the	_	
45-24	9825-9833	subjects	_	
45-25	9833-9834	.	_	

#Text=Based on the 116 × 116 automatic anatomical labelling (AAL) atlas, FC network was constructed upon computing pearson correlation of averaged BOLD signals between all pairs of regions, resulting in 6786 edges.
46-1	9835-9840	Based	_	
46-2	9841-9843	on	_	
46-3	9844-9847	the	_	
46-4	9848-9851	116	_	
46-5	9851-9852	 	_	
46-6	9852-9853	×	_	
46-7	9853-9854	 	_	
46-8	9854-9857	116	_	
46-9	9858-9867	automatic	_	
46-10	9868-9878	anatomical	_	
46-11	9879-9888	labelling	_	
46-12	9889-9890	(	_	
46-13	9890-9893	AAL	_	
46-14	9893-9894	)	_	
46-15	9895-9900	atlas	_	
46-16	9900-9901	,	_	
46-17	9902-9904	FC	_	
46-18	9905-9912	network	_	
46-19	9913-9916	was	_	
46-20	9917-9928	constructed	_	
46-21	9929-9933	upon	_	
46-22	9934-9943	computing	_	
46-23	9944-9951	pearson	_	
46-24	9952-9963	correlation	_	
46-25	9964-9966	of	_	
46-26	9967-9975	averaged	_	
46-27	9976-9980	BOLD	_	
46-28	9981-9988	signals	_	
46-29	9989-9996	between	_	
46-30	9997-10000	all	_	
46-31	10001-10006	pairs	_	
46-32	10007-10009	of	_	
46-33	10010-10017	regions	_	
46-34	10017-10018	,	_	
46-35	10019-10028	resulting	_	
46-36	10029-10031	in	_	
46-37	10032-10036	6786	_	
46-38	10037-10042	edges	_	
46-39	10042-10043	.	_	

#Text=The genetic data were preprocessed using PLINK following the quality control procedures in and further overlaped with PGC's SCZ2 database (p < 0.01), resulting in 4937 SNPs (see supplementary file).
47-1	10044-10047	The	_	
47-2	10048-10055	genetic	_	
47-3	10056-10060	data	_	
47-4	10061-10065	were	_	
47-5	10066-10078	preprocessed	_	
47-6	10079-10084	using	_	
47-7	10085-10090	PLINK	_	
47-8	10091-10100	following	_	
47-9	10101-10104	the	_	
47-10	10105-10112	quality	_	
47-11	10113-10120	control	_	
47-12	10121-10131	procedures	_	
47-13	10132-10134	in	_	
47-14	10135-10138	and	_	
47-15	10139-10146	further	_	
47-16	10147-10156	overlaped	_	
47-17	10157-10161	with	_	
47-18	10162-10167	PGC's	_	
47-19	10168-10172	SCZ2	_	
47-20	10173-10181	database	_	
47-21	10182-10183	(	_	
47-22	10183-10184	p	_	
47-23	10184-10185	 	_	
47-24	10185-10186	<	_	
47-25	10186-10187	 	_	
47-26	10187-10191	0.01	_	
47-27	10191-10192	)	_	
47-28	10192-10193	,	_	
47-29	10194-10203	resulting	_	
47-30	10204-10206	in	_	
47-31	10207-10211	4937	_	
47-32	10212-10216	SNPs	_	
47-33	10217-10218	(	_	
47-34	10218-10221	see	_	
47-35	10222-10235	supplementary	_	
47-36	10236-10240	file	_	
47-37	10240-10241	)	_	
47-38	10241-10242	.	_	

#Text=Discrete numbers were assigned to the categorical genotypes: 0 for no minor allele, 1 for one minor allele, and 2 for two minor alleles.
48-1	10243-10251	Discrete	_	
48-2	10252-10259	numbers	_	
48-3	10260-10264	were	_	
48-4	10265-10273	assigned	_	
48-5	10274-10276	to	_	
48-6	10277-10280	the	_	
48-7	10281-10292	categorical	_	
48-8	10293-10302	genotypes	_	
48-9	10302-10303	:	_	
48-10	10304-10305	0	_	
48-11	10306-10309	for	_	
48-12	10310-10312	no	_	
48-13	10313-10318	minor	_	
48-14	10319-10325	allele	_	
48-15	10325-10326	,	_	
48-16	10327-10328	1	_	
48-17	10329-10332	for	_	
48-18	10333-10336	one	_	
48-19	10337-10342	minor	_	
48-20	10343-10349	allele	_	
48-21	10349-10350	,	_	
48-22	10351-10354	and	_	
48-23	10355-10356	2	_	
48-24	10357-10360	for	_	
48-25	10361-10364	two	_	
48-26	10365-10370	minor	_	
48-27	10371-10378	alleles	_	
48-28	10378-10379	.	_	

#Text=Accordingly, the three feature matrices included: FC (subjects by voxels: 159 × 6786), GM (subjects by voxels: 159 × 77,122) and SNPs (subjects by alleles:159 × 4937).
49-1	10380-10391	Accordingly	_	
49-2	10391-10392	,	_	
49-3	10393-10396	the	_	
49-4	10397-10402	three	_	
49-5	10403-10410	feature	_	
49-6	10411-10419	matrices	_	
49-7	10420-10428	included	_	
49-8	10428-10429	:	_	
49-9	10430-10432	FC	_	
49-10	10433-10434	(	_	
49-11	10434-10442	subjects	_	
49-12	10443-10445	by	_	
49-13	10446-10452	voxels	_	
49-14	10452-10453	:	_	
49-15	10454-10457	159	_	
49-16	10457-10458	 	_	
49-17	10458-10459	×	_	
49-18	10459-10460	 	_	
49-19	10460-10464	6786	_	
49-20	10464-10465	)	_	
49-21	10465-10466	,	_	
49-22	10467-10469	GM	_	
49-23	10470-10471	(	_	
49-24	10471-10479	subjects	_	
49-25	10480-10482	by	_	
49-26	10483-10489	voxels	_	
49-27	10489-10490	:	_	
49-28	10491-10494	159	_	
49-29	10494-10495	 	_	
49-30	10495-10496	×	_	
49-31	10496-10497	 	_	
49-32	10497-10503	77,122	_	
49-33	10503-10504	)	_	
49-34	10505-10508	and	_	
49-35	10509-10513	SNPs	_	
49-36	10514-10515	(	_	
49-37	10515-10523	subjects	_	
49-38	10524-10526	by	_	
49-39	10527-10534	alleles	_	
49-40	10534-10535	:	_	
49-41	10535-10538	159	_	
49-42	10538-10539	 	_	
49-43	10539-10540	×	_	
49-44	10540-10541	 	_	
49-45	10541-10545	4937	_	
49-46	10545-10546	)	_	
49-47	10546-10547	.	_	

#Text=The feature matrices were then normalized to ensure that all modalities had the same average sum-of-squares (computed across all subjects and all voxels/SNPs for each modality).
50-1	10548-10551	The	_	
50-2	10552-10559	feature	_	
50-3	10560-10568	matrices	_	
50-4	10569-10573	were	_	
50-5	10574-10578	then	_	
50-6	10579-10589	normalized	_	
50-7	10590-10592	to	_	
50-8	10593-10599	ensure	_	
50-9	10600-10604	that	_	
50-10	10605-10608	all	_	
50-11	10609-10619	modalities	_	
50-12	10620-10623	had	_	
50-13	10624-10627	the	_	
50-14	10628-10632	same	_	
50-15	10633-10640	average	_	
50-16	10641-10655	sum-of-squares	_	
50-17	10656-10657	(	_	
50-18	10657-10665	computed	_	
50-19	10666-10672	across	_	
50-20	10673-10676	all	_	
50-21	10677-10685	subjects	_	
50-22	10686-10689	and	_	
50-23	10690-10693	all	_	
50-24	10694-10700	voxels	_	
50-25	10700-10701	/	_	
50-26	10701-10705	SNPs	_	
50-27	10706-10709	for	_	
50-28	10710-10714	each	_	
50-29	10715-10723	modality	_	
50-30	10723-10724	)	_	
50-31	10724-10725	.	_	

#Text=Medication information (chlorpromazine equivalent) was regressed out for the chronic patients prior to additional analyses.
51-1	10726-10736	Medication	_	
51-2	10737-10748	information	_	
51-3	10749-10750	(	_	
51-4	10750-10764	chlorpromazine	_	
51-5	10765-10775	equivalent	_	
51-6	10775-10776	)	_	
51-7	10777-10780	was	_	
51-8	10781-10790	regressed	_	
51-9	10791-10794	out	_	
51-10	10795-10798	for	_	
51-11	10799-10802	the	_	
51-12	10803-10810	chronic	_	
51-13	10811-10819	patients	_	
51-14	10820-10825	prior	_	
51-15	10826-10828	to	_	
51-16	10829-10839	additional	_	
51-17	10840-10848	analyses	_	
51-18	10848-10849	.	_	

#Text=Data analysis
#Text=Three-way para-ICA
#Text=Analysis pipeline of the study.
52-1	10850-10854	Data	_	
52-2	10855-10863	analysis	_	
52-3	10864-10873	Three-way	_	
52-4	10874-10882	para-ICA	_	
52-5	10883-10891	Analysis	_	
52-6	10892-10900	pipeline	_	
52-7	10901-10903	of	_	
52-8	10904-10907	the	_	
52-9	10908-10913	study	_	
52-10	10913-10914	.	_	

#Text=We firstly applied three-way para-ICA on the healthy controls (HC), first-episode schizophrenia (FESZ) and chronic schizophrenia (CSZ) subjects with three modalities [Single nucleotide polymorphism (SNP), functional connectivity (FC) and gray matter (GM)] to identify a linked SNP-FC-GM pattern.
53-1	10915-10917	We	_	
53-2	10918-10925	firstly	_	
53-3	10926-10933	applied	_	
53-4	10934-10943	three-way	_	
53-5	10944-10952	para-ICA	_	
53-6	10953-10955	on	_	
53-7	10956-10959	the	_	
53-8	10960-10967	healthy	_	
53-9	10968-10976	controls	_	
53-10	10977-10978	(	_	
53-11	10978-10980	HC	_	
53-12	10980-10981	)	_	
53-13	10981-10982	,	_	
53-14	10983-10996	first-episode	_	
53-15	10997-11010	schizophrenia	_	
53-16	11011-11012	(	_	
53-17	11012-11016	FESZ	_	
53-18	11016-11017	)	_	
53-19	11018-11021	and	_	
53-20	11022-11029	chronic	_	
53-21	11030-11043	schizophrenia	_	
53-22	11044-11045	(	_	
53-23	11045-11048	CSZ	_	
53-24	11048-11049	)	_	
53-25	11050-11058	subjects	_	
53-26	11059-11063	with	_	
53-27	11064-11069	three	_	
53-28	11070-11080	modalities	_	
53-29	11081-11082	[	_	
53-30	11082-11088	Single	_	
53-31	11089-11099	nucleotide	_	
53-32	11100-11112	polymorphism	_	
53-33	11113-11114	(	_	
53-34	11114-11117	SNP	_	
53-35	11117-11118	)	_	
53-36	11118-11119	,	_	
53-37	11120-11130	functional	_	
53-38	11131-11143	connectivity	_	
53-39	11144-11145	(	_	
53-40	11145-11147	FC	_	
53-41	11147-11148	)	_	
53-42	11149-11152	and	_	
53-43	11153-11157	gray	_	
53-44	11158-11164	matter	_	
53-45	11165-11166	(	_	
53-46	11166-11168	GM	_	
53-47	11168-11169	)	_	
53-48	11169-11170	]	_	
53-49	11171-11173	to	_	
53-50	11174-11182	identify	_	
53-51	11183-11184	a	_	
53-52	11185-11191	linked	_	
53-53	11192-11201	SNP-FC-GM	_	
53-54	11202-11209	pattern	_	
53-55	11209-11210	.	_	

#Text=Afterwards, ANOVA analysis and two sample t-test were used to measure the group difference across groups for the linked SNP-FC-GM pattern.
54-1	11211-11221	Afterwards	_	
54-2	11221-11222	,	_	
54-3	11223-11228	ANOVA	_	
54-4	11229-11237	analysis	_	
54-5	11238-11241	and	_	
54-6	11242-11245	two	_	
54-7	11246-11252	sample	_	
54-8	11253-11259	t-test	_	
54-9	11260-11264	were	_	
54-10	11265-11269	used	_	
54-11	11270-11272	to	_	
54-12	11273-11280	measure	_	
54-13	11281-11284	the	_	
54-14	11285-11290	group	_	
54-15	11291-11301	difference	_	
54-16	11302-11308	across	_	
54-17	11309-11315	groups	_	
54-18	11316-11319	for	_	
54-19	11320-11323	the	_	
54-20	11324-11330	linked	_	
54-21	11331-11340	SNP-FC-GM	_	
54-22	11341-11348	pattern	_	
54-23	11348-11349	.	_	

#Text=We further plotted the relationship between the identified imaging modalities and duration of illness (DOI), and used the slopes to compare sensitivity for FC and GM.
55-1	11350-11352	We	_	
55-2	11353-11360	further	_	
55-3	11361-11368	plotted	_	
55-4	11369-11372	the	_	
55-5	11373-11385	relationship	_	
55-6	11386-11393	between	_	
55-7	11394-11397	the	_	
55-8	11398-11408	identified	_	
55-9	11409-11416	imaging	_	
55-10	11417-11427	modalities	_	
55-11	11428-11431	and	_	
55-12	11432-11440	duration	_	
55-13	11441-11443	of	_	
55-14	11444-11451	illness	_	
55-15	11452-11453	(	_	
55-16	11453-11456	DOI	_	
55-17	11456-11457	)	_	
55-18	11457-11458	,	_	
55-19	11459-11462	and	_	
55-20	11463-11467	used	_	
55-21	11468-11471	the	_	
55-22	11472-11478	slopes	_	
55-23	11479-11481	to	_	
55-24	11482-11489	compare	_	
55-25	11490-11501	sensitivity	_	
55-26	11502-11505	for	_	
55-27	11506-11508	FC	_	
55-28	11509-11512	and	_	
55-29	11513-11515	GM	_	
55-30	11515-11516	.	_	

#Text=Fig. 1
#Text=We firstly applied three-way para-ICA to identify a linked SNP-FC-GM pattern as shown in Fig. 1.
56-1	11517-11520	Fig	_	
56-2	11520-11521	.	_	
56-3	11522-11523	1	_	
56-4	11524-11526	We	_	
56-5	11527-11534	firstly	_	
56-6	11535-11542	applied	_	
56-7	11543-11552	three-way	_	
56-8	11553-11561	para-ICA	_	
56-9	11562-11564	to	_	
56-10	11565-11573	identify	_	
56-11	11574-11575	a	_	
56-12	11576-11582	linked	_	
56-13	11583-11592	SNP-FC-GM	_	
56-14	11593-11600	pattern	_	
56-15	11601-11603	as	_	
56-16	11604-11609	shown	_	
56-17	11610-11612	in	_	
56-18	11613-11616	Fig	_	
56-19	11616-11617	.	_	
56-20	11618-11619	1	_	
56-21	11619-11620	.	_	

#Text=Three-way para-ICA is a multivariate association analysis method that estimates maximally independent components within each modality using Infomax ICA separately and maximizes the sum of pair-wise correlations between modalities (Method details are provided in the supplementary file).
57-1	11621-11630	Three-way	_	
57-2	11631-11639	para-ICA	_	
57-3	11640-11642	is	_	
57-4	11643-11644	a	_	
57-5	11645-11657	multivariate	_	
57-6	11658-11669	association	_	
57-7	11670-11678	analysis	_	
57-8	11679-11685	method	_	
57-9	11686-11690	that	_	
57-10	11691-11700	estimates	_	
57-11	11701-11710	maximally	_	
57-12	11711-11722	independent	_	
57-13	11723-11733	components	_	
57-14	11734-11740	within	_	
57-15	11741-11745	each	_	
57-16	11746-11754	modality	_	
57-17	11755-11760	using	_	
57-18	11761-11768	Infomax	_	
57-19	11769-11772	ICA	_	
57-20	11773-11783	separately	_	
57-21	11784-11787	and	_	
57-22	11788-11797	maximizes	_	
57-23	11798-11801	the	_	
57-24	11802-11805	sum	_	
57-25	11806-11808	of	_	
57-26	11809-11818	pair-wise	_	
57-27	11819-11831	correlations	_	
57-28	11832-11839	between	_	
57-29	11840-11850	modalities	_	
57-30	11851-11852	(	_	
57-31	11852-11858	Method	_	
57-32	11859-11866	details	_	
57-33	11867-11870	are	_	
57-34	11871-11879	provided	_	
57-35	11880-11882	in	_	
57-36	11883-11886	the	_	
57-37	11887-11900	supplementary	_	
57-38	11901-11905	file	_	
57-39	11905-11906	)	_	
57-40	11906-11907	.	_	

#Text=The code is open through the Fusion ICA Toolbox (FIT, http://mialab.mrn.org/software/fit).
58-1	11908-11911	The	_	
58-2	11912-11916	code	_	
58-3	11917-11919	is	_	
58-4	11920-11924	open	_	
58-5	11925-11932	through	_	
58-6	11933-11936	the	_	
58-7	11937-11943	Fusion	_	
58-8	11944-11947	ICA	_	
58-9	11948-11955	Toolbox	_	
58-10	11956-11957	(	_	
58-11	11957-11960	FIT	_	
58-12	11960-11961	,	_	
58-13	11962-11966	http	_	
58-14	11966-11967	:	_	
58-15	11967-11968	/	_	
58-16	11968-11969	/	_	
58-17	11969-11983	mialab.mrn.org	_	
58-18	11983-11984	/	_	
58-19	11984-11992	software	_	
58-20	11992-11993	/	_	
58-21	11993-11996	fit	_	
58-22	11996-11997	)	_	
58-23	11997-11998	.	_	

#Text=The number of components was measured to be 14 for FC and GM modalitites through a modified minimum description length (MDL) criterion, an efficient method as discussed in previous ICA associated studies.
59-1	11999-12002	The	_	
59-2	12003-12009	number	_	
59-3	12010-12012	of	_	
59-4	12013-12023	components	_	
59-5	12024-12027	was	_	
59-6	12028-12036	measured	_	
59-7	12037-12039	to	_	
59-8	12040-12042	be	_	
59-9	12043-12045	14	_	
59-10	12046-12049	for	_	
59-11	12050-12052	FC	_	
59-12	12053-12056	and	_	
59-13	12057-12059	GM	_	
59-14	12060-12071	modalitites	_	
59-15	12072-12079	through	_	
59-16	12080-12081	a	_	
59-17	12082-12090	modified	_	
59-18	12091-12098	minimum	_	
59-19	12099-12110	description	_	
59-20	12111-12117	length	_	
59-21	12118-12119	(	_	
59-22	12119-12122	MDL	_	
59-23	12122-12123	)	_	
59-24	12124-12133	criterion	_	
59-25	12133-12134	,	_	
59-26	12135-12137	an	_	
59-27	12138-12147	efficient	_	
59-28	12148-12154	method	_	
59-29	12155-12157	as	_	
59-30	12158-12167	discussed	_	
59-31	12168-12170	in	_	
59-32	12171-12179	previous	_	
59-33	12180-12183	ICA	_	
59-34	12184-12194	associated	_	
59-35	12195-12202	studies	_	
59-36	12202-12203	.	_	

#Text=A consistency-based method was used to identify number of components for the SNP modality, which ran ICA decompositions across a range of numbers of components and determined the comoponent number with the most reliable results (in our case the final model order was estimated to be 6).
60-1	12204-12205	A	_	
60-2	12206-12223	consistency-based	_	
60-3	12224-12230	method	_	
60-4	12231-12234	was	_	
60-5	12235-12239	used	_	
60-6	12240-12242	to	_	
60-7	12243-12251	identify	_	
60-8	12252-12258	number	_	
60-9	12259-12261	of	_	
60-10	12262-12272	components	_	
60-11	12273-12276	for	_	
60-12	12277-12280	the	_	
60-13	12281-12284	SNP	_	
60-14	12285-12293	modality	_	
60-15	12293-12294	,	_	
60-16	12295-12300	which	_	
60-17	12301-12304	ran	_	
60-18	12305-12308	ICA	_	
60-19	12309-12323	decompositions	_	
60-20	12324-12330	across	_	
60-21	12331-12332	a	_	
60-22	12333-12338	range	_	
60-23	12339-12341	of	_	
60-24	12342-12349	numbers	_	
60-25	12350-12352	of	_	
60-26	12353-12363	components	_	
60-27	12364-12367	and	_	
60-28	12368-12378	determined	_	
60-29	12379-12382	the	_	
60-30	12383-12393	comoponent	_	
60-31	12394-12400	number	_	
60-32	12401-12405	with	_	
60-33	12406-12409	the	_	
60-34	12410-12414	most	_	
60-35	12415-12423	reliable	_	
60-36	12424-12431	results	_	
60-37	12432-12433	(	_	
60-38	12433-12435	in	_	
60-39	12436-12439	our	_	
60-40	12440-12444	case	_	
60-41	12445-12448	the	_	
60-42	12449-12454	final	_	
60-43	12455-12460	model	_	
60-44	12461-12466	order	_	
60-45	12467-12470	was	_	
60-46	12471-12480	estimated	_	
60-47	12481-12483	to	_	
60-48	12484-12486	be	_	
60-49	12487-12488	6	_	
60-50	12488-12489	)	_	
60-51	12489-12490	.	_	

#Text=Correlation and group difference analysis
#Text=Cross correlations among the loading parameters of the three modalities were assessed, and the significant levels were adjusted using Bonferroni correction for multiple comparison.
61-1	12491-12502	Correlation	_	
61-2	12503-12506	and	_	
61-3	12507-12512	group	_	
61-4	12513-12523	difference	_	
61-5	12524-12532	analysis	_	
61-6	12533-12538	Cross	_	
61-7	12539-12551	correlations	_	
61-8	12552-12557	among	_	
61-9	12558-12561	the	_	
61-10	12562-12569	loading	_	
61-11	12570-12580	parameters	_	
61-12	12581-12583	of	_	
61-13	12584-12587	the	_	
61-14	12588-12593	three	_	
61-15	12594-12604	modalities	_	
61-16	12605-12609	were	_	
61-17	12610-12618	assessed	_	
61-18	12618-12619	,	_	
61-19	12620-12623	and	_	
61-20	12624-12627	the	_	
61-21	12628-12639	significant	_	
61-22	12640-12646	levels	_	
61-23	12647-12651	were	_	
61-24	12652-12660	adjusted	_	
61-25	12661-12666	using	_	
61-26	12667-12677	Bonferroni	_	
61-27	12678-12688	correction	_	
61-28	12689-12692	for	_	
61-29	12693-12701	multiple	_	
61-30	12702-12712	comparison	_	
61-31	12712-12713	.	_	

#Text=To measure the consistency of the identified joint pattern across participants, we applied a ten-fold cross validation method to replicate the associations.
62-1	12714-12716	To	_	
62-2	12717-12724	measure	_	
62-3	12725-12728	the	_	
62-4	12729-12740	consistency	_	
62-5	12741-12743	of	_	
62-6	12744-12747	the	_	
62-7	12748-12758	identified	_	
62-8	12759-12764	joint	_	
62-9	12765-12772	pattern	_	
62-10	12773-12779	across	_	
62-11	12780-12792	participants	_	
62-12	12792-12793	,	_	
62-13	12794-12796	we	_	
62-14	12797-12804	applied	_	
62-15	12805-12806	a	_	
62-16	12807-12815	ten-fold	_	
62-17	12816-12821	cross	_	
62-18	12822-12832	validation	_	
62-19	12833-12839	method	_	
62-20	12840-12842	to	_	
62-21	12843-12852	replicate	_	
62-22	12853-12856	the	_	
62-23	12857-12869	associations	_	
62-24	12869-12870	.	_	

#Text=Moreover, in order to evaluate the stability of the linked SNP-FC-GM pattern, we conducted 1000 permutation tests to investigate the possibility of overfitting.
63-1	12871-12879	Moreover	_	
63-2	12879-12880	,	_	
63-3	12881-12883	in	_	
63-4	12884-12889	order	_	
63-5	12890-12892	to	_	
63-6	12893-12901	evaluate	_	
63-7	12902-12905	the	_	
63-8	12906-12915	stability	_	
63-9	12916-12918	of	_	
63-10	12919-12922	the	_	
63-11	12923-12929	linked	_	
63-12	12930-12939	SNP-FC-GM	_	
63-13	12940-12947	pattern	_	
63-14	12947-12948	,	_	
63-15	12949-12951	we	_	
63-16	12952-12961	conducted	_	
63-17	12962-12966	1000	_	
63-18	12967-12978	permutation	_	
63-19	12979-12984	tests	_	
63-20	12985-12987	to	_	
63-21	12988-12999	investigate	_	
63-22	13000-13003	the	_	
63-23	13004-13015	possibility	_	
63-24	13016-13018	of	_	
63-25	13019-13030	overfitting	_	
63-26	13030-13031	.	_	

#Text=Particularly, we randomly permuted subjects of all the three modalities and ran three-way para-ICA again on the permuted subjects.
64-1	13032-13044	Particularly	_	
64-2	13044-13045	,	_	
64-3	13046-13048	we	_	
64-4	13049-13057	randomly	_	
64-5	13058-13066	permuted	_	
64-6	13067-13075	subjects	_	
64-7	13076-13078	of	_	
64-8	13079-13082	all	_	
64-9	13083-13086	the	_	
64-10	13087-13092	three	_	
64-11	13093-13103	modalities	_	
64-12	13104-13107	and	_	
64-13	13108-13111	ran	_	
64-14	13112-13121	three-way	_	
64-15	13122-13130	para-ICA	_	
64-16	13131-13136	again	_	
64-17	13137-13139	on	_	
64-18	13140-13143	the	_	
64-19	13144-13152	permuted	_	
64-20	13153-13161	subjects	_	
64-21	13161-13162	.	_	

#Text=Then we extracted the top correlated SNP-FC-GM pair in each of the 1000 permutation tests and calculated the tail probability to evaluate the significance level of the identified SNP-FC-GM association.
65-1	13163-13167	Then	_	
65-2	13168-13170	we	_	
65-3	13171-13180	extracted	_	
65-4	13181-13184	the	_	
65-5	13185-13188	top	_	
65-6	13189-13199	correlated	_	
65-7	13200-13209	SNP-FC-GM	_	
65-8	13210-13214	pair	_	
65-9	13215-13217	in	_	
65-10	13218-13222	each	_	
65-11	13223-13225	of	_	
65-12	13226-13229	the	_	
65-13	13230-13234	1000	_	
65-14	13235-13246	permutation	_	
65-15	13247-13252	tests	_	
65-16	13253-13256	and	_	
65-17	13257-13267	calculated	_	
65-18	13268-13271	the	_	
65-19	13272-13276	tail	_	
65-20	13277-13288	probability	_	
65-21	13289-13291	to	_	
65-22	13292-13300	evaluate	_	
65-23	13301-13304	the	_	
65-24	13305-13317	significance	_	
65-25	13318-13323	level	_	
65-26	13324-13326	of	_	
65-27	13327-13330	the	_	
65-28	13331-13341	identified	_	
65-29	13342-13351	SNP-FC-GM	_	
65-30	13352-13363	association	_	
65-31	13363-13364	.	_	

#Text=Finally, the sptial maps of the SNP-FC-SNP pattern were transformed to Z scores and the top contributing brain regions, FC and SNPs were selected and plotted.
66-1	13365-13372	Finally	_	
66-2	13372-13373	,	_	
66-3	13374-13377	the	_	
66-4	13378-13384	sptial	_	
66-5	13385-13389	maps	_	
66-6	13390-13392	of	_	
66-7	13393-13396	the	_	
66-8	13397-13407	SNP-FC-SNP	_	
66-9	13408-13415	pattern	_	
66-10	13416-13420	were	_	
66-11	13421-13432	transformed	_	
66-12	13433-13435	to	_	
66-13	13436-13437	Z	_	
66-14	13438-13444	scores	_	
66-15	13445-13448	and	_	
66-16	13449-13452	the	_	
66-17	13453-13456	top	_	
66-18	13457-13469	contributing	_	
66-19	13470-13475	brain	_	
66-20	13476-13483	regions	_	
66-21	13483-13484	,	_	
66-22	13485-13487	FC	_	
66-23	13488-13491	and	_	
66-24	13492-13496	SNPs	_	
66-25	13497-13501	were	_	
66-26	13502-13510	selected	_	
66-27	13511-13514	and	_	
66-28	13515-13522	plotted	_	
66-29	13522-13523	.	_	

#Text=Sensitivity to disease stages and DOI
#Text=To investigate the different sensitivities to diease stages and DOI, we applied analysis of variance (ANOVA) analysis and two sample t-test to measure the group difference across different disease stages within each modality for the linked SNP-FC-GM pattern (Fig. 1).
67-1	13524-13535	Sensitivity	_	
67-2	13536-13538	to	_	
67-3	13539-13546	disease	_	
67-4	13547-13553	stages	_	
67-5	13554-13557	and	_	
67-6	13558-13561	DOI	_	
67-7	13562-13564	To	_	
67-8	13565-13576	investigate	_	
67-9	13577-13580	the	_	
67-10	13581-13590	different	_	
67-11	13591-13604	sensitivities	_	
67-12	13605-13607	to	_	
67-13	13608-13614	diease	_	
67-14	13615-13621	stages	_	
67-15	13622-13625	and	_	
67-16	13626-13629	DOI	_	
67-17	13629-13630	,	_	
67-18	13631-13633	we	_	
67-19	13634-13641	applied	_	
67-20	13642-13650	analysis	_	
67-21	13651-13653	of	_	
67-22	13654-13662	variance	_	
67-23	13663-13664	(	_	
67-24	13664-13669	ANOVA	_	
67-25	13669-13670	)	_	
67-26	13671-13679	analysis	_	
67-27	13680-13683	and	_	
67-28	13684-13687	two	_	
67-29	13688-13694	sample	_	
67-30	13695-13701	t-test	_	
67-31	13702-13704	to	_	
67-32	13705-13712	measure	_	
67-33	13713-13716	the	_	
67-34	13717-13722	group	_	
67-35	13723-13733	difference	_	
67-36	13734-13740	across	_	
67-37	13741-13750	different	_	
67-38	13751-13758	disease	_	
67-39	13759-13765	stages	_	
67-40	13766-13772	within	_	
67-41	13773-13777	each	_	
67-42	13778-13786	modality	_	
67-43	13787-13790	for	_	
67-44	13791-13794	the	_	
67-45	13795-13801	linked	_	
67-46	13802-13811	SNP-FC-GM	_	
67-47	13812-13819	pattern	_	
67-48	13820-13821	(	_	
67-49	13821-13824	Fig	_	
67-50	13824-13825	.	_	
67-51	13826-13827	1	_	
67-52	13827-13828	)	_	
67-53	13828-13829	.	_	

#Text=Then we calculated the relationship between the identified imaging modalities and DOI, and used Z value to compare the difference between slopes of the two modalities.
68-1	13830-13834	Then	_	
68-2	13835-13837	we	_	
68-3	13838-13848	calculated	_	
68-4	13849-13852	the	_	
68-5	13853-13865	relationship	_	
68-6	13866-13873	between	_	
68-7	13874-13877	the	_	
68-8	13878-13888	identified	_	
68-9	13889-13896	imaging	_	
68-10	13897-13907	modalities	_	
68-11	13908-13911	and	_	
68-12	13912-13915	DOI	_	
68-13	13915-13916	,	_	
68-14	13917-13920	and	_	
68-15	13921-13925	used	_	
68-16	13926-13927	Z	_	
68-17	13928-13933	value	_	
68-18	13934-13936	to	_	
68-19	13937-13944	compare	_	
68-20	13945-13948	the	_	
68-21	13949-13959	difference	_	
68-22	13960-13967	between	_	
68-23	13968-13974	slopes	_	
68-24	13975-13977	of	_	
68-25	13978-13981	the	_	
68-26	13982-13985	two	_	
68-27	13986-13996	modalities	_	
68-28	13996-13997	.	_	

#Text=Specifically, we first applied generalized linear regression (GLM) model to identify a regression line for the relationship between imaging modalitites and DOI.
69-1	13998-14010	Specifically	_	
69-2	14010-14011	,	_	
69-3	14012-14014	we	_	
69-4	14015-14020	first	_	
69-5	14021-14028	applied	_	
69-6	14029-14040	generalized	_	
69-7	14041-14047	linear	_	
69-8	14048-14058	regression	_	
69-9	14059-14060	(	_	
69-10	14060-14063	GLM	_	
69-11	14063-14064	)	_	
69-12	14065-14070	model	_	
69-13	14071-14073	to	_	
69-14	14074-14082	identify	_	
69-15	14083-14084	a	_	
69-16	14085-14095	regression	_	
69-17	14096-14100	line	_	
69-18	14101-14104	for	_	
69-19	14105-14108	the	_	
69-20	14109-14121	relationship	_	
69-21	14122-14129	between	_	
69-22	14130-14137	imaging	_	
69-23	14138-14149	modalitites	_	
69-24	14150-14153	and	_	
69-25	14154-14157	DOI	_	
69-26	14157-14158	.	_	

#Text=Then the slope of the regression line was the corresponding beta value of the loading parameter of each modality (kGM for the GM modality and kFC for the FC modality).
70-1	14159-14163	Then	_	
70-2	14164-14167	the	_	
70-3	14168-14173	slope	_	
70-4	14174-14176	of	_	
70-5	14177-14180	the	_	
70-6	14181-14191	regression	_	
70-7	14192-14196	line	_	
70-8	14197-14200	was	_	
70-9	14201-14204	the	_	
70-10	14205-14218	corresponding	_	
70-11	14219-14223	beta	_	
70-12	14224-14229	value	_	
70-13	14230-14232	of	_	
70-14	14233-14236	the	_	
70-15	14237-14244	loading	_	
70-16	14245-14254	parameter	_	
70-17	14255-14257	of	_	
70-18	14258-14262	each	_	
70-19	14263-14271	modality	_	
70-20	14272-14273	(	_	
70-21	14273-14276	kGM	_	
70-22	14277-14280	for	_	
70-23	14281-14284	the	_	
70-24	14285-14287	GM	_	
70-25	14288-14296	modality	_	
70-26	14297-14300	and	_	
70-27	14301-14304	kFC	_	
70-28	14305-14308	for	_	
70-29	14309-14312	the	_	
70-30	14313-14315	FC	_	
70-31	14316-14324	modality	_	
70-32	14324-14325	)	_	
70-33	14325-14326	.	_	

#Text=Z value was computed as the difference between the two slopes divided by the standard error of the difference between the slopes.
71-1	14327-14328	Z	_	
71-2	14329-14334	value	_	
71-3	14335-14338	was	_	
71-4	14339-14347	computed	_	
71-5	14348-14350	as	_	
71-6	14351-14354	the	_	
71-7	14355-14365	difference	_	
71-8	14366-14373	between	_	
71-9	14374-14377	the	_	
71-10	14378-14381	two	_	
71-11	14382-14388	slopes	_	
71-12	14389-14396	divided	_	
71-13	14397-14399	by	_	
71-14	14400-14403	the	_	
71-15	14404-14412	standard	_	
71-16	14413-14418	error	_	
71-17	14419-14421	of	_	
71-18	14422-14425	the	_	
71-19	14426-14436	difference	_	
71-20	14437-14444	between	_	
71-21	14445-14448	the	_	
71-22	14449-14455	slopes	_	
71-23	14455-14456	.	_	

#Text=As the GLM model gave us the standard error of each slope (stand_kGM for the GM modality and stand_kFC for the FC modality), then the standard error of the difference between the two slopes can be computed as .
72-1	14457-14459	As	_	
72-2	14460-14463	the	_	
72-3	14464-14467	GLM	_	
72-4	14468-14473	model	_	
72-5	14474-14478	gave	_	
72-6	14479-14481	us	_	
72-7	14482-14485	the	_	
72-8	14486-14494	standard	_	
72-9	14495-14500	error	_	
72-10	14501-14503	of	_	
72-11	14504-14508	each	_	
72-12	14509-14514	slope	_	
72-13	14515-14516	(	_	
72-14	14516-14525	stand_kGM	_	
72-15	14526-14529	for	_	
72-16	14530-14533	the	_	
72-17	14534-14536	GM	_	
72-18	14537-14545	modality	_	
72-19	14546-14549	and	_	
72-20	14550-14559	stand_kFC	_	
72-21	14560-14563	for	_	
72-22	14564-14567	the	_	
72-23	14568-14570	FC	_	
72-24	14571-14579	modality	_	
72-25	14579-14580	)	_	
72-26	14580-14581	,	_	
72-27	14582-14586	then	_	
72-28	14587-14590	the	_	
72-29	14591-14599	standard	_	
72-30	14600-14605	error	_	
72-31	14606-14608	of	_	
72-32	14609-14612	the	_	
72-33	14613-14623	difference	_	
72-34	14624-14631	between	_	
72-35	14632-14635	the	_	
72-36	14636-14639	two	_	
72-37	14640-14646	slopes	_	
72-38	14647-14650	can	_	
72-39	14651-14653	be	_	
72-40	14654-14662	computed	_	
72-41	14663-14665	as	_	
72-42	14666-14667	.	_	

#Text=Then we calculated the Z value as Eq. (1):
#Text=Afterwards, we computed the two-tailed p-value corresponding to the Z value to evaluate the significance of the two slopes.
73-1	14668-14672	Then	_	
73-2	14673-14675	we	_	
73-3	14676-14686	calculated	_	
73-4	14687-14690	the	_	
73-5	14691-14692	Z	_	
73-6	14693-14698	value	_	
73-7	14699-14701	as	_	
73-8	14702-14704	Eq	_	
73-9	14704-14705	.	_	
73-10	14706-14707	(	_	
73-11	14707-14708	1	_	
73-12	14708-14709	)	_	
73-13	14709-14710	:	_	
73-14	14711-14721	Afterwards	_	
73-15	14721-14722	,	_	
73-16	14723-14725	we	_	
73-17	14726-14734	computed	_	
73-18	14735-14738	the	_	
73-19	14739-14749	two-tailed	_	
73-20	14750-14757	p-value	_	
73-21	14758-14771	corresponding	_	
73-22	14772-14774	to	_	
73-23	14775-14778	the	_	
73-24	14779-14780	Z	_	
73-25	14781-14786	value	_	
73-26	14787-14789	to	_	
73-27	14790-14798	evaluate	_	
73-28	14799-14802	the	_	
73-29	14803-14815	significance	_	
73-30	14816-14818	of	_	
73-31	14819-14822	the	_	
73-32	14823-14826	two	_	
73-33	14827-14833	slopes	_	
73-34	14833-14834	.	_	

#Text=Genetic pathway analysis
#Text=After converting the spatial map of the SNP component to Z scores, the high-ranking SNPs (|Z| > 2) were annotated to genes.
74-1	14835-14842	Genetic	_	
74-2	14843-14850	pathway	_	
74-3	14851-14859	analysis	_	
74-4	14860-14865	After	_	
74-5	14866-14876	converting	_	
74-6	14877-14880	the	_	
74-7	14881-14888	spatial	_	
74-8	14889-14892	map	_	
74-9	14893-14895	of	_	
74-10	14896-14899	the	_	
74-11	14900-14903	SNP	_	
74-12	14904-14913	component	_	
74-13	14914-14916	to	_	
74-14	14917-14918	Z	_	
74-15	14919-14925	scores	_	
74-16	14925-14926	,	_	
74-17	14927-14930	the	_	
74-18	14931-14943	high-ranking	_	
74-19	14944-14948	SNPs	_	
74-20	14949-14950	(	_	
74-21	14950-14951	|	_	
74-22	14951-14952	Z	_	
74-23	14952-14953	|	_	
74-24	14953-14954	 	_	
74-25	14954-14955	>	_	
74-26	14955-14956	 	_	
74-27	14956-14957	2	_	
74-28	14957-14958	)	_	
74-29	14959-14963	were	_	
74-30	14964-14973	annotated	_	
74-31	14974-14976	to	_	
74-32	14977-14982	genes	_	
74-33	14982-14983	.	_	

#Text=To further interpret the relationship between the SNP component and schizophrenia, we fed these top contributing genes to the WebGestalt software for Gene Ontology (GO) analysis, which used a hypergenometrix test to detect overrepresentation of the genes among the whole genome in a GO category.
75-1	14984-14986	To	_	
75-2	14987-14994	further	_	
75-3	14995-15004	interpret	_	
75-4	15005-15008	the	_	
75-5	15009-15021	relationship	_	
75-6	15022-15029	between	_	
75-7	15030-15033	the	_	
75-8	15034-15037	SNP	_	
75-9	15038-15047	component	_	
75-10	15048-15051	and	_	
75-11	15052-15065	schizophrenia	_	
75-12	15065-15066	,	_	
75-13	15067-15069	we	_	
75-14	15070-15073	fed	_	
75-15	15074-15079	these	_	
75-16	15080-15083	top	_	
75-17	15084-15096	contributing	_	
75-18	15097-15102	genes	_	
75-19	15103-15105	to	_	
75-20	15106-15109	the	_	
75-21	15110-15120	WebGestalt	_	
75-22	15121-15129	software	_	
75-23	15130-15133	for	_	
75-24	15134-15138	Gene	_	
75-25	15139-15147	Ontology	_	
75-26	15148-15149	(	_	
75-27	15149-15151	GO	_	
75-28	15151-15152	)	_	
75-29	15153-15161	analysis	_	
75-30	15161-15162	,	_	
75-31	15163-15168	which	_	
75-32	15169-15173	used	_	
75-33	15174-15175	a	_	
75-34	15176-15191	hypergenometrix	_	
75-35	15192-15196	test	_	
75-36	15197-15199	to	_	
75-37	15200-15206	detect	_	
75-38	15207-15225	overrepresentation	_	
75-39	15226-15228	of	_	
75-40	15229-15232	the	_	
75-41	15233-15238	genes	_	
75-42	15239-15244	among	_	
75-43	15245-15248	the	_	
75-44	15249-15254	whole	_	
75-45	15255-15261	genome	_	
75-46	15262-15264	in	_	
75-47	15265-15266	a	_	
75-48	15267-15269	GO	_	
75-49	15270-15278	category	_	
75-50	15278-15279	.	_	

#Text=Results
#Text=SNP-FC-GM multivariate linkage
#Text=The pairwise correlation plots of the identified SNP-FC-GM component.
76-1	15280-15287	Results	_	
76-2	15288-15297	SNP-FC-GM	_	
76-3	15298-15310	multivariate	_	
76-4	15311-15318	linkage	_	
76-5	15319-15322	The	_	
76-6	15323-15331	pairwise	_	
76-7	15332-15343	correlation	_	
76-8	15344-15349	plots	_	
76-9	15350-15352	of	_	
76-10	15353-15356	the	_	
76-11	15357-15367	identified	_	
76-12	15368-15377	SNP-FC-GM	_	
76-13	15378-15387	component	_	
76-14	15387-15388	.	_	

#Text=(A) The correlation among FC, GM and SNP modalities before regressing out any variables.
77-1	15389-15390	(	_	
77-2	15390-15391	A	_	
77-3	15391-15392	)	_	
77-4	15393-15396	The	_	
77-5	15397-15408	correlation	_	
77-6	15409-15414	among	_	
77-7	15415-15417	FC	_	
77-8	15417-15418	,	_	
77-9	15419-15421	GM	_	
77-10	15422-15425	and	_	
77-11	15426-15429	SNP	_	
77-12	15430-15440	modalities	_	
77-13	15441-15447	before	_	
77-14	15448-15458	regressing	_	
77-15	15459-15462	out	_	
77-16	15463-15466	any	_	
77-17	15467-15476	variables	_	
77-18	15476-15477	.	_	

#Text=(B) The correlation among FC, GM and SNP modalities after regressing out age, gender, education and diagnosis.
78-1	15478-15479	(	_	
78-2	15479-15480	B	_	
78-3	15480-15481	)	_	
78-4	15482-15485	The	_	
78-5	15486-15497	correlation	_	
78-6	15498-15503	among	_	
78-7	15504-15506	FC	_	
78-8	15506-15507	,	_	
78-9	15508-15510	GM	_	
78-10	15511-15514	and	_	
78-11	15515-15518	SNP	_	
78-12	15519-15529	modalities	_	
78-13	15530-15535	after	_	
78-14	15536-15546	regressing	_	
78-15	15547-15550	out	_	
78-16	15551-15554	age	_	
78-17	15554-15555	,	_	
78-18	15556-15562	gender	_	
78-19	15562-15563	,	_	
78-20	15564-15573	education	_	
78-21	15574-15577	and	_	
78-22	15578-15587	diagnosis	_	
78-23	15587-15588	.	_	

#Text=Note: The blue dots represent the healthy controls(HC).
79-1	15589-15593	Note	_	
79-2	15593-15594	:	_	
79-3	15595-15598	The	_	
79-4	15599-15603	blue	_	
79-5	15604-15608	dots	_	
79-6	15609-15618	represent	_	
79-7	15619-15622	the	_	
79-8	15623-15630	healthy	_	
79-9	15631-15639	controls	_	
79-10	15639-15640	(	_	
79-11	15640-15642	HC	_	
79-12	15642-15643	)	_	
79-13	15643-15644	.	_	

#Text=The red dots represent the chronic schizophrenia patients (CSZ).
80-1	15645-15648	The	_	
80-2	15649-15652	red	_	
80-3	15653-15657	dots	_	
80-4	15658-15667	represent	_	
80-5	15668-15671	the	_	
80-6	15672-15679	chronic	_	
80-7	15680-15693	schizophrenia	_	
80-8	15694-15702	patients	_	
80-9	15703-15704	(	_	
80-10	15704-15707	CSZ	_	
80-11	15707-15708	)	_	
80-12	15708-15709	.	_	

#Text=The green dots represent the first-episode schizophrenia patients(FESZ).
81-1	15710-15713	The	_	
81-2	15714-15719	green	_	
81-3	15720-15724	dots	_	
81-4	15725-15734	represent	_	
81-5	15735-15738	the	_	
81-6	15739-15752	first-episode	_	
81-7	15753-15766	schizophrenia	_	
81-8	15767-15775	patients	_	
81-9	15775-15776	(	_	
81-10	15776-15780	FESZ	_	
81-11	15780-15781	)	_	
81-12	15781-15782	.	_	

#Text=Fig. 2
#Text=The strongest connected SNP-FC-GM triplet from the three-way para-ICA was identified, which presented significant pair-wise correlations (FC-GM: r = 0.58, p < 10−12; SNP-FC: r = 0.31, p = 8.83 × 10−5; SNP-GM: r = 0.32, p = 3.39 × 10−5, passing the Bonferroni correction) as shown in Fig. 2A.
82-1	15783-15786	Fig	_	
82-2	15786-15787	.	_	
82-3	15788-15789	2	_	
82-4	15790-15793	The	_	
82-5	15794-15803	strongest	_	
82-6	15804-15813	connected	_	
82-7	15814-15823	SNP-FC-GM	_	
82-8	15824-15831	triplet	_	
82-9	15832-15836	from	_	
82-10	15837-15840	the	_	
82-11	15841-15850	three-way	_	
82-12	15851-15859	para-ICA	_	
82-13	15860-15863	was	_	
82-14	15864-15874	identified	_	
82-15	15874-15875	,	_	
82-16	15876-15881	which	_	
82-17	15882-15891	presented	_	
82-18	15892-15903	significant	_	
82-19	15904-15913	pair-wise	_	
82-20	15914-15926	correlations	_	
82-21	15927-15928	(	_	
82-22	15928-15933	FC-GM	_	
82-23	15933-15934	:	_	
82-24	15935-15936	r	_	
82-25	15936-15937	 	_	
82-26	15937-15938	=	_	
82-27	15938-15939	 	_	
82-28	15939-15943	0.58	_	
82-29	15943-15944	,	_	
82-30	15945-15946	p	_	
82-31	15946-15947	 	_	
82-32	15947-15948	<	_	
82-33	15948-15949	 	_	
82-34	15949-15951	10	_	
82-35	15951-15952	−	_	
82-36	15952-15954	12	_	
82-37	15954-15955	;	_	
82-38	15956-15962	SNP-FC	_	
82-39	15962-15963	:	_	
82-40	15964-15965	r	_	
82-41	15965-15966	 	_	
82-42	15966-15967	=	_	
82-43	15967-15968	 	_	
82-44	15968-15972	0.31	_	
82-45	15972-15973	,	_	
82-46	15974-15975	p	_	
82-47	15975-15976	 	_	
82-48	15976-15977	=	_	
82-49	15977-15978	 	_	
82-50	15978-15982	8.83	_	
82-51	15982-15983	 	_	
82-52	15983-15984	×	_	
82-53	15984-15985	 	_	
82-54	15985-15987	10	_	
82-55	15987-15988	−	_	
82-56	15988-15989	5	_	
82-57	15989-15990	;	_	
82-58	15991-15997	SNP-GM	_	
82-59	15997-15998	:	_	
82-60	15999-16000	r	_	
82-61	16000-16001	 	_	
82-62	16001-16002	=	_	
82-63	16002-16003	 	_	
82-64	16003-16007	0.32	_	
82-65	16007-16008	,	_	
82-66	16009-16010	p	_	
82-67	16010-16011	 	_	
82-68	16011-16012	=	_	
82-69	16012-16013	 	_	
82-70	16013-16017	3.39	_	
82-71	16017-16018	 	_	
82-72	16018-16019	×	_	
82-73	16019-16020	 	_	
82-74	16020-16022	10	_	
82-75	16022-16023	−	_	
82-76	16023-16024	5	_	
82-77	16024-16025	,	_	
82-78	16026-16033	passing	_	
82-79	16034-16037	the	_	
82-80	16038-16048	Bonferroni	_	
82-81	16049-16059	correction	_	
82-82	16059-16060	)	_	
82-83	16061-16063	as	_	
82-84	16064-16069	shown	_	
82-85	16070-16072	in	_	
82-86	16073-16076	Fig	_	
82-87	16076-16077	.	_	
82-88	16078-16080	2A	_	
82-89	16080-16081	.	_	

#Text=Ten-fold analysis revealed that the correlations were stable with averge correlation of 0.58 ± 0.08(FC-GM), 0.28±0.04(SNP-FC), 0.27±0.06(SNP-GM).
83-1	16082-16090	Ten-fold	_	
83-2	16091-16099	analysis	_	
83-3	16100-16108	revealed	_	
83-4	16109-16113	that	_	
83-5	16114-16117	the	_	
83-6	16118-16130	correlations	_	
83-7	16131-16135	were	_	
83-8	16136-16142	stable	_	
83-9	16143-16147	with	_	
83-10	16148-16154	averge	_	
83-11	16155-16166	correlation	_	
83-12	16167-16169	of	_	
83-13	16170-16174	0.58	_	
83-14	16174-16175	 	_	
83-15	16175-16176	±	_	
83-16	16176-16177	 	_	
83-17	16177-16181	0.08	_	
83-18	16181-16182	(	_	
83-19	16182-16187	FC-GM	_	
83-20	16187-16188	)	_	
83-21	16188-16189	,	_	
83-22	16190-16194	0.28	_	
83-23	16194-16195	±	_	
83-24	16195-16199	0.04	_	
83-25	16199-16200	(	_	
83-26	16200-16206	SNP-FC	_	
83-27	16206-16207	)	_	
83-28	16207-16208	,	_	
83-29	16209-16213	0.27	_	
83-30	16213-16214	±	_	
83-31	16214-16218	0.06	_	
83-32	16218-16219	(	_	
83-33	16219-16225	SNP-GM	_	
83-34	16225-16226	)	_	
83-35	16226-16227	.	_	

#Text=Permutation tests further indicated the significance of the links with empirical p-values of 0.001(FC-GM), 0.03(SNP-FC), 0.01(SNP-GM).
84-1	16228-16239	Permutation	_	
84-2	16240-16245	tests	_	
84-3	16246-16253	further	_	
84-4	16254-16263	indicated	_	
84-5	16264-16267	the	_	
84-6	16268-16280	significance	_	
84-7	16281-16283	of	_	
84-8	16284-16287	the	_	
84-9	16288-16293	links	_	
84-10	16294-16298	with	_	
84-11	16299-16308	empirical	_	
84-12	16309-16317	p-values	_	
84-13	16318-16320	of	_	
84-14	16321-16326	0.001	_	
84-15	16326-16327	(	_	
84-16	16327-16332	FC-GM	_	
84-17	16332-16333	)	_	
84-18	16333-16334	,	_	
84-19	16335-16339	0.03	_	
84-20	16339-16340	(	_	
84-21	16340-16346	SNP-FC	_	
84-22	16346-16347	)	_	
84-23	16347-16348	,	_	
84-24	16349-16353	0.01	_	
84-25	16353-16354	(	_	
84-26	16354-16360	SNP-GM	_	
84-27	16360-16361	)	_	
84-28	16361-16362	.	_	

#Text=Partial correlations of the linked SNP-FC-GM pattern were still significant when controlling for diagnosis, age, education and gender (SNP-FC: r = 0.21, p = 0.0074; SNP-GM: r = 0.27, p = 6.27 × 10−4, FC-GM: r = 0.19, p = 0.015) as shown in Fig. 2B, passing Bonferroni correction.
85-1	16363-16370	Partial	_	
85-2	16371-16383	correlations	_	
85-3	16384-16386	of	_	
85-4	16387-16390	the	_	
85-5	16391-16397	linked	_	
85-6	16398-16407	SNP-FC-GM	_	
85-7	16408-16415	pattern	_	
85-8	16416-16420	were	_	
85-9	16421-16426	still	_	
85-10	16427-16438	significant	_	
85-11	16439-16443	when	_	
85-12	16444-16455	controlling	_	
85-13	16456-16459	for	_	
85-14	16460-16469	diagnosis	_	
85-15	16469-16470	,	_	
85-16	16471-16474	age	_	
85-17	16474-16475	,	_	
85-18	16476-16485	education	_	
85-19	16486-16489	and	_	
85-20	16490-16496	gender	_	
85-21	16497-16498	(	_	
85-22	16498-16504	SNP-FC	_	
85-23	16504-16505	:	_	
85-24	16506-16507	r	_	
85-25	16507-16508	 	_	
85-26	16508-16509	=	_	
85-27	16509-16510	 	_	
85-28	16510-16514	0.21	_	
85-29	16514-16515	,	_	
85-30	16516-16517	p	_	
85-31	16517-16518	 	_	
85-32	16518-16519	=	_	
85-33	16519-16520	 	_	
85-34	16520-16526	0.0074	_	
85-35	16526-16527	;	_	
85-36	16528-16534	SNP-GM	_	
85-37	16534-16535	:	_	
85-38	16536-16537	r	_	
85-39	16537-16538	 	_	
85-40	16538-16539	=	_	
85-41	16539-16540	 	_	
85-42	16540-16544	0.27	_	
85-43	16544-16545	,	_	
85-44	16546-16547	p	_	
85-45	16547-16548	 	_	
85-46	16548-16549	=	_	
85-47	16549-16550	 	_	
85-48	16550-16554	6.27	_	
85-49	16554-16555	 	_	
85-50	16555-16556	×	_	
85-51	16556-16557	 	_	
85-52	16557-16559	10	_	
85-53	16559-16560	−	_	
85-54	16560-16561	4	_	
85-55	16561-16562	,	_	
85-56	16563-16568	FC-GM	_	
85-57	16568-16569	:	_	
85-58	16570-16571	r	_	
85-59	16571-16572	 	_	
85-60	16572-16573	=	_	
85-61	16573-16574	 	_	
85-62	16574-16578	0.19	_	
85-63	16578-16579	,	_	
85-64	16580-16581	p	_	
85-65	16581-16582	 	_	
85-66	16582-16583	=	_	
85-67	16583-16584	 	_	
85-68	16584-16589	0.015	_	
85-69	16589-16590	)	_	
85-70	16591-16593	as	_	
85-71	16594-16599	shown	_	
85-72	16600-16602	in	_	
85-73	16603-16606	Fig	_	
85-74	16606-16607	.	_	
85-75	16608-16610	2B	_	
85-76	16610-16611	,	_	
85-77	16612-16619	passing	_	
85-78	16620-16630	Bonferroni	_	
85-79	16631-16641	correction	_	
85-80	16641-16642	.	_	

#Text=The positive correlations of SNP-FC and SNP-GM indicated that higher allele counts for the positively contributing SNPs were associated with an increase of both FC and GM; higher allele counts for the negatively contributing SNPs were associated with a decrease of both FC and GM.
86-1	16643-16646	The	_	
86-2	16647-16655	positive	_	
86-3	16656-16668	correlations	_	
86-4	16669-16671	of	_	
86-5	16672-16678	SNP-FC	_	
86-6	16679-16682	and	_	
86-7	16683-16689	SNP-GM	_	
86-8	16690-16699	indicated	_	
86-9	16700-16704	that	_	
86-10	16705-16711	higher	_	
86-11	16712-16718	allele	_	
86-12	16719-16725	counts	_	
86-13	16726-16729	for	_	
86-14	16730-16733	the	_	
86-15	16734-16744	positively	_	
86-16	16745-16757	contributing	_	
86-17	16758-16762	SNPs	_	
86-18	16763-16767	were	_	
86-19	16768-16778	associated	_	
86-20	16779-16783	with	_	
86-21	16784-16786	an	_	
86-22	16787-16795	increase	_	
86-23	16796-16798	of	_	
86-24	16799-16803	both	_	
86-25	16804-16806	FC	_	
86-26	16807-16810	and	_	
86-27	16811-16813	GM	_	
86-28	16813-16814	;	_	
86-29	16815-16821	higher	_	
86-30	16822-16828	allele	_	
86-31	16829-16835	counts	_	
86-32	16836-16839	for	_	
86-33	16840-16843	the	_	
86-34	16844-16854	negatively	_	
86-35	16855-16867	contributing	_	
86-36	16868-16872	SNPs	_	
86-37	16873-16877	were	_	
86-38	16878-16888	associated	_	
86-39	16889-16893	with	_	
86-40	16894-16895	a	_	
86-41	16896-16904	decrease	_	
86-42	16905-16907	of	_	
86-43	16908-16912	both	_	
86-44	16913-16915	FC	_	
86-45	16916-16919	and	_	
86-46	16920-16922	GM	_	
86-47	16922-16923	.	_	

#Text=The positive correlations between FC and GM revealed that FC decrease was related with GM volume reduction.
87-1	16924-16927	The	_	
87-2	16928-16936	positive	_	
87-3	16937-16949	correlations	_	
87-4	16950-16957	between	_	
87-5	16958-16960	FC	_	
87-6	16961-16964	and	_	
87-7	16965-16967	GM	_	
87-8	16968-16976	revealed	_	
87-9	16977-16981	that	_	
87-10	16982-16984	FC	_	
87-11	16985-16993	decrease	_	
87-12	16994-16997	was	_	
87-13	16998-17005	related	_	
87-14	17006-17010	with	_	
87-15	17011-17013	GM	_	
87-16	17014-17020	volume	_	
87-17	17021-17030	reduction	_	
87-18	17030-17031	.	_	

#Text=Different sensitivity to disease stages and DOI
#Text=Different sensitivity to disease stages and DOI.
88-1	17032-17041	Different	_	
88-2	17042-17053	sensitivity	_	
88-3	17054-17056	to	_	
88-4	17057-17064	disease	_	
88-5	17065-17071	stages	_	
88-6	17072-17075	and	_	
88-7	17076-17079	DOI	_	
88-8	17080-17089	Different	_	
88-9	17090-17101	sensitivity	_	
88-10	17102-17104	to	_	
88-11	17105-17112	disease	_	
88-12	17113-17119	stages	_	
88-13	17120-17123	and	_	
88-14	17124-17127	DOI	_	
88-15	17127-17128	.	_	

#Text=(A) ANOVA and two-sample t-tests within each modality.
89-1	17129-17130	(	_	
89-2	17130-17131	A	_	
89-3	17131-17132	)	_	
89-4	17133-17138	ANOVA	_	
89-5	17139-17142	and	_	
89-6	17143-17153	two-sample	_	
89-7	17154-17161	t-tests	_	
89-8	17162-17168	within	_	
89-9	17169-17173	each	_	
89-10	17174-17182	modality	_	
89-11	17182-17183	.	_	

#Text=Note: The p-values display results of ANOVA analysis.
90-1	17184-17188	Note	_	
90-2	17188-17189	:	_	
90-3	17190-17193	The	_	
90-4	17194-17202	p-values	_	
90-5	17203-17210	display	_	
90-6	17211-17218	results	_	
90-7	17219-17221	of	_	
90-8	17222-17227	ANOVA	_	
90-9	17228-17236	analysis	_	
90-10	17236-17237	.	_	

#Text=The red violin plot represents healthy controls (HC).
91-1	17238-17241	The	_	
91-2	17242-17245	red	_	
91-3	17246-17252	violin	_	
91-4	17253-17257	plot	_	
91-5	17258-17268	represents	_	
91-6	17269-17276	healthy	_	
91-7	17277-17285	controls	_	
91-8	17286-17287	(	_	
91-9	17287-17289	HC	_	
91-10	17289-17290	)	_	
91-11	17290-17291	.	_	

#Text=The green violin plot represents first-episode schizophrenia patients (FESZ).
92-1	17292-17295	The	_	
92-2	17296-17301	green	_	
92-3	17302-17308	violin	_	
92-4	17309-17313	plot	_	
92-5	17314-17324	represents	_	
92-6	17325-17338	first-episode	_	
92-7	17339-17352	schizophrenia	_	
92-8	17353-17361	patients	_	
92-9	17362-17363	(	_	
92-10	17363-17367	FESZ	_	
92-11	17367-17368	)	_	
92-12	17368-17369	.	_	

#Text=The blue violin plot represents the chronic schizophrenia patients (CSZ).
93-1	17370-17373	The	_	
93-2	17374-17378	blue	_	
93-3	17379-17385	violin	_	
93-4	17386-17390	plot	_	
93-5	17391-17401	represents	_	
93-6	17402-17405	the	_	
93-7	17406-17413	chronic	_	
93-8	17414-17427	schizophrenia	_	
93-9	17428-17436	patients	_	
93-10	17437-17438	(	_	
93-11	17438-17441	CSZ	_	
93-12	17441-17442	)	_	
93-13	17442-17443	.	_	

#Text=*represent 0.00001 < p < 0.05, ** represents 1e-5 < p < 1e-10, **represents p < 1e-10.
94-1	17444-17445	*	_	
94-2	17445-17454	represent	_	
94-3	17455-17462	0.00001	_	
94-4	17462-17463	 	_	
94-5	17463-17464	<	_	
94-6	17464-17465	 	_	
94-7	17465-17466	p	_	
94-8	17466-17467	 	_	
94-9	17467-17468	<	_	
94-10	17468-17469	 	_	
94-11	17469-17473	0.05	_	
94-12	17473-17474	,	_	
94-13	17475-17476	*	_	
94-14	17476-17477	*	_	
94-15	17478-17488	represents	_	
94-16	17489-17491	1e	_	
94-17	17491-17492	-	_	
94-18	17492-17493	5	_	
94-19	17493-17494	 	_	
94-20	17494-17495	<	_	
94-21	17495-17496	 	_	
94-22	17496-17497	p	_	
94-23	17497-17498	 	_	
94-24	17498-17499	<	_	
94-25	17499-17500	 	_	
94-26	17500-17502	1e	_	
94-27	17502-17503	-	_	
94-28	17503-17505	10	_	
94-29	17505-17506	,	_	
94-30	17507-17508	*	_	
94-31	17508-17509	*	_	
94-32	17509-17519	represents	_	
94-33	17520-17521	p	_	
94-34	17521-17522	 	_	
94-35	17522-17523	<	_	
94-36	17523-17524	 	_	
94-37	17524-17526	1e	_	
94-38	17526-17527	-	_	
94-39	17527-17529	10	_	
94-40	17529-17530	.	_	

#Text=(B)Different sensitivity comparison between the GM and FC modality to DOI.
95-1	17531-17532	(	_	
95-2	17532-17533	B	_	
95-3	17533-17534	)	_	
95-4	17534-17543	Different	_	
95-5	17544-17555	sensitivity	_	
95-6	17556-17566	comparison	_	
95-7	17567-17574	between	_	
95-8	17575-17578	the	_	
95-9	17579-17581	GM	_	
95-10	17582-17585	and	_	
95-11	17586-17588	FC	_	
95-12	17589-17597	modality	_	
95-13	17598-17600	to	_	
95-14	17601-17604	DOI	_	
95-15	17604-17605	.	_	

#Text=Note: the gray and black dots represent correlation between GM, FC loadings and DOI respectively.
96-1	17606-17610	Note	_	
96-2	17610-17611	:	_	
96-3	17612-17615	the	_	
96-4	17616-17620	gray	_	
96-5	17621-17624	and	_	
96-6	17625-17630	black	_	
96-7	17631-17635	dots	_	
96-8	17636-17645	represent	_	
96-9	17646-17657	correlation	_	
96-10	17658-17665	between	_	
96-11	17666-17668	GM	_	
96-12	17668-17669	,	_	
96-13	17670-17672	FC	_	
96-14	17673-17681	loadings	_	
96-15	17682-17685	and	_	
96-16	17686-17689	DOI	_	
96-17	17690-17702	respectively	_	
96-18	17702-17703	.	_	

#Text=The gray and black regression lines represent the slope of the correlation.
97-1	17704-17707	The	_	
97-2	17708-17712	gray	_	
97-3	17713-17716	and	_	
97-4	17717-17722	black	_	
97-5	17723-17733	regression	_	
97-6	17734-17739	lines	_	
97-7	17740-17749	represent	_	
97-8	17750-17753	the	_	
97-9	17754-17759	slope	_	
97-10	17760-17762	of	_	
97-11	17763-17766	the	_	
97-12	17767-17778	correlation	_	
97-13	17778-17779	.	_	

#Text=The two-tailed p-value of the z values between two slopes is significant (p = 0.00063).
98-1	17780-17783	The	_	
98-2	17784-17794	two-tailed	_	
98-3	17795-17802	p-value	_	
98-4	17803-17805	of	_	
98-5	17806-17809	the	_	
98-6	17810-17811	z	_	
98-7	17812-17818	values	_	
98-8	17819-17826	between	_	
98-9	17827-17830	two	_	
98-10	17831-17837	slopes	_	
98-11	17838-17840	is	_	
98-12	17841-17852	significant	_	
98-13	17853-17854	(	_	
98-14	17854-17855	p	_	
98-15	17855-17856	 	_	
98-16	17856-17857	=	_	
98-17	17857-17858	 	_	
98-18	17858-17865	0.00063	_	
98-19	17865-17866	)	_	
98-20	17866-17867	.	_	

#Text=Fig. 3
#Text=Group differences across HC, FESZ and CSZ measured by ANOVA in FC (p = 6.09 × 10−49), GM(p = 2.82 × 10−15) and SNP(p = 0.0024) were significant.
99-1	17868-17871	Fig	_	
99-2	17871-17872	.	_	
99-3	17873-17874	3	_	
99-4	17875-17880	Group	_	
99-5	17881-17892	differences	_	
99-6	17893-17899	across	_	
99-7	17900-17902	HC	_	
99-8	17902-17903	,	_	
99-9	17904-17908	FESZ	_	
99-10	17909-17912	and	_	
99-11	17913-17916	CSZ	_	
99-12	17917-17925	measured	_	
99-13	17926-17928	by	_	
99-14	17929-17934	ANOVA	_	
99-15	17935-17937	in	_	
99-16	17938-17940	FC	_	
99-17	17941-17942	(	_	
99-18	17942-17943	p	_	
99-19	17943-17944	 	_	
99-20	17944-17945	=	_	
99-21	17945-17946	 	_	
99-22	17946-17950	6.09	_	
99-23	17950-17951	 	_	
99-24	17951-17952	×	_	
99-25	17952-17953	 	_	
99-26	17953-17955	10	_	
99-27	17955-17956	−	_	
99-28	17956-17958	49	_	
99-29	17958-17959	)	_	
99-30	17959-17960	,	_	
99-31	17961-17963	GM	_	
99-32	17963-17964	(	_	
99-33	17964-17965	p	_	
99-34	17965-17966	 	_	
99-35	17966-17967	=	_	
99-36	17967-17968	 	_	
99-37	17968-17972	2.82	_	
99-38	17972-17973	 	_	
99-39	17973-17974	×	_	
99-40	17974-17975	 	_	
99-41	17975-17977	10	_	
99-42	17977-17978	−	_	
99-43	17978-17980	15	_	
99-44	17980-17981	)	_	
99-45	17982-17985	and	_	
99-46	17986-17989	SNP	_	
99-47	17989-17990	(	_	
99-48	17990-17991	p	_	
99-49	17991-17992	 	_	
99-50	17992-17993	=	_	
99-51	17993-17994	 	_	
99-52	17994-18000	0.0024	_	
99-53	18000-18001	)	_	
99-54	18002-18006	were	_	
99-55	18007-18018	significant	_	
99-56	18018-18019	.	_	

#Text=Fig. 3A further despicts the results of two sample t-test comparison between groups within each modality.
100-1	18020-18023	Fig	_	
100-2	18023-18024	.	_	
100-3	18025-18027	3A	_	
100-4	18028-18035	further	_	
100-5	18036-18044	despicts	_	
100-6	18045-18048	the	_	
100-7	18049-18056	results	_	
100-8	18057-18059	of	_	
100-9	18060-18063	two	_	
100-10	18064-18070	sample	_	
100-11	18071-18077	t-test	_	
100-12	18078-18088	comparison	_	
100-13	18089-18096	between	_	
100-14	18097-18103	groups	_	
100-15	18104-18110	within	_	
100-16	18111-18115	each	_	
100-17	18116-18124	modality	_	
100-18	18124-18125	.	_	

#Text=Both FC and GM displayed evidence of greater deficits at late disease stage compare to healthy controls and early stage (HC > FESZ>CSZ).
101-1	18126-18130	Both	_	
101-2	18131-18133	FC	_	
101-3	18134-18137	and	_	
101-4	18138-18140	GM	_	
101-5	18141-18150	displayed	_	
101-6	18151-18159	evidence	_	
101-7	18160-18162	of	_	
101-8	18163-18170	greater	_	
101-9	18171-18179	deficits	_	
101-10	18180-18182	at	_	
101-11	18183-18187	late	_	
101-12	18188-18195	disease	_	
101-13	18196-18201	stage	_	
101-14	18202-18209	compare	_	
101-15	18210-18212	to	_	
101-16	18213-18220	healthy	_	
101-17	18221-18229	controls	_	
101-18	18230-18233	and	_	
101-19	18234-18239	early	_	
101-20	18240-18245	stage	_	
101-21	18246-18247	(	_	
101-22	18247-18249	HC	_	
101-23	18249-18250	 	_	
101-24	18250-18251	>	_	
101-25	18251-18252	 	_	
101-26	18252-18256	FESZ	_	
101-27	18256-18257	>	_	
101-28	18257-18260	CSZ	_	
101-29	18260-18261	)	_	
101-30	18261-18262	.	_	

#Text=Notably, significant group differences were observed in all pairs for the FC component (HC-FESZ: p = 2.26 × 10−6, HC-CSZ: p < 1 × 10–10, FESZ-CSZ: p = 2.05 × 10−8), while the GM component only presented obvious significance in HC-CSZ (p < 1 × 10−10) and FESZ-CSZ (p = 5.34 × 10−7).
102-1	18263-18270	Notably	_	
102-2	18270-18271	,	_	
102-3	18272-18283	significant	_	
102-4	18284-18289	group	_	
102-5	18290-18301	differences	_	
102-6	18302-18306	were	_	
102-7	18307-18315	observed	_	
102-8	18316-18318	in	_	
102-9	18319-18322	all	_	
102-10	18323-18328	pairs	_	
102-11	18329-18332	for	_	
102-12	18333-18336	the	_	
102-13	18337-18339	FC	_	
102-14	18340-18349	component	_	
102-15	18350-18351	(	_	
102-16	18351-18358	HC-FESZ	_	
102-17	18358-18359	:	_	
102-18	18360-18361	p	_	
102-19	18361-18362	 	_	
102-20	18362-18363	=	_	
102-21	18363-18364	 	_	
102-22	18364-18368	2.26	_	
102-23	18368-18369	 	_	
102-24	18369-18370	×	_	
102-25	18370-18371	 	_	
102-26	18371-18373	10	_	
102-27	18373-18374	−	_	
102-28	18374-18375	6	_	
102-29	18375-18376	,	_	
102-30	18377-18383	HC-CSZ	_	
102-31	18383-18384	:	_	
102-32	18385-18386	p	_	
102-33	18386-18387	 	_	
102-34	18387-18388	<	_	
102-35	18388-18389	 	_	
102-36	18389-18390	1	_	
102-37	18390-18391	 	_	
102-38	18391-18392	×	_	
102-39	18392-18393	 	_	
102-40	18393-18395	10	_	
102-41	18395-18396	–	_	
102-42	18396-18398	10	_	
102-43	18398-18399	,	_	
102-44	18400-18408	FESZ-CSZ	_	
102-45	18408-18409	:	_	
102-46	18410-18411	p	_	
102-47	18411-18412	 	_	
102-48	18412-18413	=	_	
102-49	18413-18414	 	_	
102-50	18414-18418	2.05	_	
102-51	18418-18419	 	_	
102-52	18419-18420	×	_	
102-53	18420-18421	 	_	
102-54	18421-18423	10	_	
102-55	18423-18424	−	_	
102-56	18424-18425	8	_	
102-57	18425-18426	)	_	
102-58	18426-18427	,	_	
102-59	18428-18433	while	_	
102-60	18434-18437	the	_	
102-61	18438-18440	GM	_	
102-62	18441-18450	component	_	
102-63	18451-18455	only	_	
102-64	18456-18465	presented	_	
102-65	18466-18473	obvious	_	
102-66	18474-18486	significance	_	
102-67	18487-18489	in	_	
102-68	18490-18496	HC-CSZ	_	
102-69	18497-18498	(	_	
102-70	18498-18499	p	_	
102-71	18499-18500	 	_	
102-72	18500-18501	<	_	
102-73	18501-18502	 	_	
102-74	18502-18503	1	_	
102-75	18503-18504	 	_	
102-76	18504-18505	×	_	
102-77	18505-18506	 	_	
102-78	18506-18508	10	_	
102-79	18508-18509	−	_	
102-80	18509-18511	10	_	
102-81	18511-18512	)	_	
102-82	18513-18516	and	_	
102-83	18517-18525	FESZ-CSZ	_	
102-84	18526-18527	(	_	
102-85	18527-18528	p	_	
102-86	18528-18529	 	_	
102-87	18529-18530	=	_	
102-88	18530-18531	 	_	
102-89	18531-18535	5.34	_	
102-90	18535-18536	 	_	
102-91	18536-18537	×	_	
102-92	18537-18538	 	_	
102-93	18538-18540	10	_	
102-94	18540-18541	−	_	
102-95	18541-18542	7	_	
102-96	18542-18543	)	_	
102-97	18543-18544	.	_	

#Text=Compared to the imaging modalities, no significant group difference between FESZ and CSZ in the SNP component was revealed, but group difference between HC and FESZ (p = 0.0023), or HC and CSZ (p = 0.0083) was significant.
103-1	18545-18553	Compared	_	
103-2	18554-18556	to	_	
103-3	18557-18560	the	_	
103-4	18561-18568	imaging	_	
103-5	18569-18579	modalities	_	
103-6	18579-18580	,	_	
103-7	18581-18583	no	_	
103-8	18584-18595	significant	_	
103-9	18596-18601	group	_	
103-10	18602-18612	difference	_	
103-11	18613-18620	between	_	
103-12	18621-18625	FESZ	_	
103-13	18626-18629	and	_	
103-14	18630-18633	CSZ	_	
103-15	18634-18636	in	_	
103-16	18637-18640	the	_	
103-17	18641-18644	SNP	_	
103-18	18645-18654	component	_	
103-19	18655-18658	was	_	
103-20	18659-18667	revealed	_	
103-21	18667-18668	,	_	
103-22	18669-18672	but	_	
103-23	18673-18678	group	_	
103-24	18679-18689	difference	_	
103-25	18690-18697	between	_	
103-26	18698-18700	HC	_	
103-27	18701-18704	and	_	
103-28	18705-18709	FESZ	_	
103-29	18710-18711	(	_	
103-30	18711-18712	p	_	
103-31	18712-18713	 	_	
103-32	18713-18714	=	_	
103-33	18714-18715	 	_	
103-34	18715-18721	0.0023	_	
103-35	18721-18722	)	_	
103-36	18722-18723	,	_	
103-37	18724-18726	or	_	
103-38	18727-18729	HC	_	
103-39	18730-18733	and	_	
103-40	18734-18737	CSZ	_	
103-41	18738-18739	(	_	
103-42	18739-18740	p	_	
103-43	18740-18741	 	_	
103-44	18741-18742	=	_	
103-45	18742-18743	 	_	
103-46	18743-18749	0.0083	_	
103-47	18749-18750	)	_	
103-48	18751-18754	was	_	
103-49	18755-18766	significant	_	
103-50	18766-18767	.	_	

#Text=Moreover, Fig. 3B displays the relationship between imaging loadings and DOI.
104-1	18768-18776	Moreover	_	
104-2	18776-18777	,	_	
104-3	18778-18781	Fig	_	
104-4	18781-18782	.	_	
104-5	18783-18785	3B	_	
104-6	18786-18794	displays	_	
104-7	18795-18798	the	_	
104-8	18799-18811	relationship	_	
104-9	18812-18819	between	_	
104-10	18820-18827	imaging	_	
104-11	18828-18836	loadings	_	
104-12	18837-18840	and	_	
104-13	18841-18844	DOI	_	
104-14	18844-18845	.	_	

#Text=FC (k = −0.0036) presented a sharper slope than GM (k = −0.0006), which means FC deteriorates faster than GM with the same DOI.
105-1	18846-18848	FC	_	
105-2	18849-18850	(	_	
105-3	18850-18851	k	_	
105-4	18851-18852	 	_	
105-5	18852-18853	=	_	
105-6	18853-18854	 	_	
105-7	18854-18855	−	_	
105-8	18855-18861	0.0036	_	
105-9	18861-18862	)	_	
105-10	18863-18872	presented	_	
105-11	18873-18874	a	_	
105-12	18875-18882	sharper	_	
105-13	18883-18888	slope	_	
105-14	18889-18893	than	_	
105-15	18894-18896	GM	_	
105-16	18897-18898	(	_	
105-17	18898-18899	k	_	
105-18	18899-18900	 	_	
105-19	18900-18901	=	_	
105-20	18901-18902	 	_	
105-21	18902-18903	−	_	
105-22	18903-18909	0.0006	_	
105-23	18909-18910	)	_	
105-24	18910-18911	,	_	
105-25	18912-18917	which	_	
105-26	18918-18923	means	_	
105-27	18924-18926	FC	_	
105-28	18927-18939	deteriorates	_	
105-29	18940-18946	faster	_	
105-30	18947-18951	than	_	
105-31	18952-18954	GM	_	
105-32	18955-18959	with	_	
105-33	18960-18963	the	_	
105-34	18964-18968	same	_	
105-35	18969-18972	DOI	_	
105-36	18972-18973	.	_	

#Text=The z-value of the two slopes was −3.42 with a corresponding two-tailed p-value as 0.00063, which indicated that FC presented a stronger negative correlation with DOI than GM.
106-1	18974-18977	The	_	
106-2	18978-18985	z-value	_	
106-3	18986-18988	of	_	
106-4	18989-18992	the	_	
106-5	18993-18996	two	_	
106-6	18997-19003	slopes	_	
106-7	19004-19007	was	_	
106-8	19008-19009	−	_	
106-9	19009-19013	3.42	_	
106-10	19014-19018	with	_	
106-11	19019-19020	a	_	
106-12	19021-19034	corresponding	_	
106-13	19035-19045	two-tailed	_	
106-14	19046-19053	p-value	_	
106-15	19054-19056	as	_	
106-16	19057-19064	0.00063	_	
106-17	19064-19065	,	_	
106-18	19066-19071	which	_	
106-19	19072-19081	indicated	_	
106-20	19082-19086	that	_	
106-21	19087-19089	FC	_	
106-22	19090-19099	presented	_	
106-23	19100-19101	a	_	
106-24	19102-19110	stronger	_	
106-25	19111-19119	negative	_	
106-26	19120-19131	correlation	_	
106-27	19132-19136	with	_	
106-28	19137-19140	DOI	_	
106-29	19141-19145	than	_	
106-30	19146-19148	GM	_	
106-31	19148-19149	.	_	

#Text=The linked imaging modalities
#Text=The abnormal brain regions and functional connectivity revealed by three-way para-ICA.
107-1	19150-19153	The	_	
107-2	19154-19160	linked	_	
107-3	19161-19168	imaging	_	
107-4	19169-19179	modalities	_	
107-5	19180-19183	The	_	
107-6	19184-19192	abnormal	_	
107-7	19193-19198	brain	_	
107-8	19199-19206	regions	_	
107-9	19207-19210	and	_	
107-10	19211-19221	functional	_	
107-11	19222-19234	connectivity	_	
107-12	19235-19243	revealed	_	
107-13	19244-19246	by	_	
107-14	19247-19256	three-way	_	
107-15	19257-19265	para-ICA	_	
107-16	19265-19266	.	_	

#Text=(A) Brain regions showing gray matter abnormalities in the SNP-FC-GM pattern.
108-1	19267-19268	(	_	
108-2	19268-19269	A	_	
108-3	19269-19270	)	_	
108-4	19271-19276	Brain	_	
108-5	19277-19284	regions	_	
108-6	19285-19292	showing	_	
108-7	19293-19297	gray	_	
108-8	19298-19304	matter	_	
108-9	19305-19318	abnormalities	_	
108-10	19319-19321	in	_	
108-11	19322-19325	the	_	
108-12	19326-19335	SNP-FC-GM	_	
108-13	19336-19343	pattern	_	
108-14	19343-19344	.	_	

#Text=The red regions represent gray matter decrease in SZ while the blue regions represent gray matter increase in SZ.
109-1	19345-19348	The	_	
109-2	19349-19352	red	_	
109-3	19353-19360	regions	_	
109-4	19361-19370	represent	_	
109-5	19371-19375	gray	_	
109-6	19376-19382	matter	_	
109-7	19383-19391	decrease	_	
109-8	19392-19394	in	_	
109-9	19395-19397	SZ	_	
109-10	19398-19403	while	_	
109-11	19404-19407	the	_	
109-12	19408-19412	blue	_	
109-13	19413-19420	regions	_	
109-14	19421-19430	represent	_	
109-15	19431-19435	gray	_	
109-16	19436-19442	matter	_	
109-17	19443-19451	increase	_	
109-18	19452-19454	in	_	
109-19	19455-19457	SZ	_	
109-20	19457-19458	.	_	

#Text=(B) Imparied FC identified from the SNP-FC-GM pattern.
110-1	19459-19460	(	_	
110-2	19460-19461	B	_	
110-3	19461-19462	)	_	
110-4	19463-19471	Imparied	_	
110-5	19472-19474	FC	_	
110-6	19475-19485	identified	_	
110-7	19486-19490	from	_	
110-8	19491-19494	the	_	
110-9	19495-19504	SNP-FC-GM	_	
110-10	19505-19512	pattern	_	
110-11	19512-19513	.	_	

#Text=The red connecting lines represent FC decrease in SZ, while the blue connecting lines represent FC increase in SZ.
111-1	19514-19517	The	_	
111-2	19518-19521	red	_	
111-3	19522-19532	connecting	_	
111-4	19533-19538	lines	_	
111-5	19539-19548	represent	_	
111-6	19549-19551	FC	_	
111-7	19552-19560	decrease	_	
111-8	19561-19563	in	_	
111-9	19564-19566	SZ	_	
111-10	19566-19567	,	_	
111-11	19568-19573	while	_	
111-12	19574-19577	the	_	
111-13	19578-19582	blue	_	
111-14	19583-19593	connecting	_	
111-15	19594-19599	lines	_	
111-16	19600-19609	represent	_	
111-17	19610-19612	FC	_	
111-18	19613-19621	increase	_	
111-19	19622-19624	in	_	
111-20	19625-19627	SZ	_	
111-21	19627-19628	.	_	

#Text=Fig. 4
#Text=As shown in Fig. 4, the GM component and FC component were converted into Z scores and displayed at |Z| > 2.5.
112-1	19629-19632	Fig	_	
112-2	19632-19633	.	_	
112-3	19634-19635	4	_	
112-4	19636-19638	As	_	
112-5	19639-19644	shown	_	
112-6	19645-19647	in	_	
112-7	19648-19651	Fig	_	
112-8	19651-19652	.	_	
112-9	19653-19654	4	_	
112-10	19654-19655	,	_	
112-11	19656-19659	the	_	
112-12	19660-19662	GM	_	
112-13	19663-19672	component	_	
112-14	19673-19676	and	_	
112-15	19677-19679	FC	_	
112-16	19680-19689	component	_	
112-17	19690-19694	were	_	
112-18	19695-19704	converted	_	
112-19	19705-19709	into	_	
112-20	19710-19711	Z	_	
112-21	19712-19718	scores	_	
112-22	19719-19722	and	_	
112-23	19723-19732	displayed	_	
112-24	19733-19735	at	_	
112-25	19736-19737	|	_	
112-26	19737-19738	Z	_	
112-27	19738-19739	|	_	
112-28	19739-19740	 	_	
112-29	19740-19741	>	_	
112-30	19741-19742	 	_	
112-31	19742-19745	2.5	_	
112-32	19745-19746	.	_	

#Text=Since the components have been adjusted as HC > SZ on the mean of loading parameters as shown in Fig. 3, the red regions/connections in Fig. 4 indicated higher contribution in HC than SZ, and the blue regions/connections indicated higher contribution in SZ than HC.
113-1	19747-19752	Since	_	
113-2	19753-19756	the	_	
113-3	19757-19767	components	_	
113-4	19768-19772	have	_	
113-5	19773-19777	been	_	
113-6	19778-19786	adjusted	_	
113-7	19787-19789	as	_	
113-8	19790-19792	HC	_	
113-9	19792-19793	 	_	
113-10	19793-19794	>	_	
113-11	19794-19795	 	_	
113-12	19795-19797	SZ	_	
113-13	19798-19800	on	_	
113-14	19801-19804	the	_	
113-15	19805-19809	mean	_	
113-16	19810-19812	of	_	
113-17	19813-19820	loading	_	
113-18	19821-19831	parameters	_	
113-19	19832-19834	as	_	
113-20	19835-19840	shown	_	
113-21	19841-19843	in	_	
113-22	19844-19847	Fig	_	
113-23	19847-19848	.	_	
113-24	19849-19850	3	_	
113-25	19850-19851	,	_	
113-26	19852-19855	the	_	
113-27	19856-19859	red	_	
113-28	19860-19867	regions	_	
113-29	19867-19868	/	_	
113-30	19868-19879	connections	_	
113-31	19880-19882	in	_	
113-32	19883-19886	Fig	_	
113-33	19886-19887	.	_	
113-34	19888-19889	4	_	
113-35	19890-19899	indicated	_	
113-36	19900-19906	higher	_	
113-37	19907-19919	contribution	_	
113-38	19920-19922	in	_	
113-39	19923-19925	HC	_	
113-40	19926-19930	than	_	
113-41	19931-19933	SZ	_	
113-42	19933-19934	,	_	
113-43	19935-19938	and	_	
113-44	19939-19942	the	_	
113-45	19943-19947	blue	_	
113-46	19948-19955	regions	_	
113-47	19955-19956	/	_	
113-48	19956-19967	connections	_	
113-49	19968-19977	indicated	_	
113-50	19978-19984	higher	_	
113-51	19985-19997	contribution	_	
113-52	19998-20000	in	_	
113-53	20001-20003	SZ	_	
113-54	20004-20008	than	_	
113-55	20009-20011	HC	_	
113-56	20011-20012	.	_	

#Text=Accordingly, GM decrease in patients centered on amygdala, temporal gyrus, parahippocampal gyrus, postcentral gyrus, and increase in inferior parietal gyrus and cerebellum as shown in Fig. 4A.
114-1	20013-20024	Accordingly	_	
114-2	20024-20025	,	_	
114-3	20026-20028	GM	_	
114-4	20029-20037	decrease	_	
114-5	20038-20040	in	_	
114-6	20041-20049	patients	_	
114-7	20050-20058	centered	_	
114-8	20059-20061	on	_	
114-9	20062-20070	amygdala	_	
114-10	20070-20071	,	_	
114-11	20072-20080	temporal	_	
114-12	20081-20086	gyrus	_	
114-13	20086-20087	,	_	
114-14	20088-20103	parahippocampal	_	
114-15	20104-20109	gyrus	_	
114-16	20109-20110	,	_	
114-17	20111-20122	postcentral	_	
114-18	20123-20128	gyrus	_	
114-19	20128-20129	,	_	
114-20	20130-20133	and	_	
114-21	20134-20142	increase	_	
114-22	20143-20145	in	_	
114-23	20146-20154	inferior	_	
114-24	20155-20163	parietal	_	
114-25	20164-20169	gyrus	_	
114-26	20170-20173	and	_	
114-27	20174-20184	cerebellum	_	
114-28	20185-20187	as	_	
114-29	20188-20193	shown	_	
114-30	20194-20196	in	_	
114-31	20197-20200	Fig	_	
114-32	20200-20201	.	_	
114-33	20202-20204	4A	_	
114-34	20204-20205	.	_	

#Text=The detailed anatomical information of the abnormal brain regions are listed in Table S2.
115-1	20206-20209	The	_	
115-2	20210-20218	detailed	_	
115-3	20219-20229	anatomical	_	
115-4	20230-20241	information	_	
115-5	20242-20244	of	_	
115-6	20245-20248	the	_	
115-7	20249-20257	abnormal	_	
115-8	20258-20263	brain	_	
115-9	20264-20271	regions	_	
115-10	20272-20275	are	_	
115-11	20276-20282	listed	_	
115-12	20283-20285	in	_	
115-13	20286-20291	Table	_	
115-14	20292-20294	S2	_	
115-15	20294-20295	.	_	

#Text=As shown in Fig. 4B, SZ patients present lower FC primarily in amygdala, postcentral, hippocampus/parahippocampus, temporal gyrus, and higher FC primarily in cerebellare and inferior parietal related connectivity.
116-1	20296-20298	As	_	
116-2	20299-20304	shown	_	
116-3	20305-20307	in	_	
116-4	20308-20311	Fig	_	
116-5	20311-20312	.	_	
116-6	20313-20315	4B	_	
116-7	20315-20316	,	_	
116-8	20317-20319	SZ	_	
116-9	20320-20328	patients	_	
116-10	20329-20336	present	_	
116-11	20337-20342	lower	_	
116-12	20343-20345	FC	_	
116-13	20346-20355	primarily	_	
116-14	20356-20358	in	_	
116-15	20359-20367	amygdala	_	
116-16	20367-20368	,	_	
116-17	20369-20380	postcentral	_	
116-18	20380-20381	,	_	
116-19	20382-20393	hippocampus	_	
116-20	20393-20394	/	_	
116-21	20394-20409	parahippocampus	_	
116-22	20409-20410	,	_	
116-23	20411-20419	temporal	_	
116-24	20420-20425	gyrus	_	
116-25	20425-20426	,	_	
116-26	20427-20430	and	_	
116-27	20431-20437	higher	_	
116-28	20438-20440	FC	_	
116-29	20441-20450	primarily	_	
116-30	20451-20453	in	_	
116-31	20454-20465	cerebellare	_	
116-32	20466-20469	and	_	
116-33	20470-20478	inferior	_	
116-34	20479-20487	parietal	_	
116-35	20488-20495	related	_	
116-36	20496-20508	connectivity	_	
116-37	20508-20509	.	_	

#Text=The joint SNP component and pathway analysis
#Text=Mahattan plot and GO analysis of the joint SNP component.
117-1	20510-20513	The	_	
117-2	20514-20519	joint	_	
117-3	20520-20523	SNP	_	
117-4	20524-20533	component	_	
117-5	20534-20537	and	_	
117-6	20538-20545	pathway	_	
117-7	20546-20554	analysis	_	
117-8	20555-20563	Mahattan	_	
117-9	20564-20568	plot	_	
117-10	20569-20572	and	_	
117-11	20573-20575	GO	_	
117-12	20576-20584	analysis	_	
117-13	20585-20587	of	_	
117-14	20588-20591	the	_	
117-15	20592-20597	joint	_	
117-16	20598-20601	SNP	_	
117-17	20602-20611	component	_	
117-18	20611-20612	.	_	

#Text=(A) Manhattan plot of the identified SNP component.
118-1	20613-20614	(	_	
118-2	20614-20615	A	_	
118-3	20615-20616	)	_	
118-4	20617-20626	Manhattan	_	
118-5	20627-20631	plot	_	
118-6	20632-20634	of	_	
118-7	20635-20638	the	_	
118-8	20639-20649	identified	_	
118-9	20650-20653	SNP	_	
118-10	20654-20663	component	_	
118-11	20663-20664	.	_	

#Text=(B) GO analysis results of the high-ranking SNP with |Z-scores| > 2; P-values are all FDR corrected.
119-1	20665-20666	(	_	
119-2	20666-20667	B	_	
119-3	20667-20668	)	_	
119-4	20669-20671	GO	_	
119-5	20672-20680	analysis	_	
119-6	20681-20688	results	_	
119-7	20689-20691	of	_	
119-8	20692-20695	the	_	
119-9	20696-20708	high-ranking	_	
119-10	20709-20712	SNP	_	
119-11	20713-20717	with	_	
119-12	20718-20719	|	_	
119-13	20719-20727	Z-scores	_	
119-14	20727-20728	|	_	
119-15	20728-20729	 	_	
119-16	20729-20730	>	_	
119-17	20730-20731	 	_	
119-18	20731-20732	2	_	
119-19	20732-20733	;	_	
119-20	20734-20742	P-values	_	
119-21	20743-20746	are	_	
119-22	20747-20750	all	_	
119-23	20751-20754	FDR	_	
119-24	20755-20764	corrected	_	
119-25	20764-20765	.	_	

#Text=Fig. 5
#Text=Similarly, the SNP component was also transformed to Z scores and visualized at |Z| > 2, which highlighted 258 risk SNPs as listed in Table S2.
120-1	20766-20769	Fig	_	
120-2	20769-20770	.	_	
120-3	20771-20772	5	_	
120-4	20773-20782	Similarly	_	
120-5	20782-20783	,	_	
120-6	20784-20787	the	_	
120-7	20788-20791	SNP	_	
120-8	20792-20801	component	_	
120-9	20802-20805	was	_	
120-10	20806-20810	also	_	
120-11	20811-20822	transformed	_	
120-12	20823-20825	to	_	
120-13	20826-20827	Z	_	
120-14	20828-20834	scores	_	
120-15	20835-20838	and	_	
120-16	20839-20849	visualized	_	
120-17	20850-20852	at	_	
120-18	20853-20854	|	_	
120-19	20854-20855	Z	_	
120-20	20855-20856	|	_	
120-21	20856-20857	 	_	
120-22	20857-20858	>	_	
120-23	20858-20859	 	_	
120-24	20859-20860	2	_	
120-25	20860-20861	,	_	
120-26	20862-20867	which	_	
120-27	20868-20879	highlighted	_	
120-28	20880-20883	258	_	
120-29	20884-20888	risk	_	
120-30	20889-20893	SNPs	_	
120-31	20894-20896	as	_	
120-32	20897-20903	listed	_	
120-33	20904-20906	in	_	
120-34	20907-20912	Table	_	
120-35	20913-20915	S2	_	
120-36	20915-20916	.	_	

#Text=Fig. 5A displays a Manhattan plot for the SNP component.
121-1	20917-20920	Fig	_	
121-2	20920-20921	.	_	
121-3	20922-20924	5A	_	
121-4	20925-20933	displays	_	
121-5	20934-20935	a	_	
121-6	20936-20945	Manhattan	_	
121-7	20946-20950	plot	_	
121-8	20951-20954	for	_	
121-9	20955-20958	the	_	
121-10	20959-20962	SNP	_	
121-11	20963-20972	component	_	
121-12	20972-20973	.	_	

#Text=After annotating the 258 high-ranking SNPs, 101 genes were revealed, including SATB2, GABBR2, PDE4B and CACNA1C et al.
122-1	20974-20979	After	_	
122-2	20980-20990	annotating	_	
122-3	20991-20994	the	_	
122-4	20995-20998	258	_	
122-5	20999-21011	high-ranking	_	
122-6	21012-21016	SNPs	_	
122-7	21016-21017	,	_	
122-8	21018-21021	101	_	
122-9	21022-21027	genes	_	
122-10	21028-21032	were	_	
122-11	21033-21041	revealed	_	
122-12	21041-21042	,	_	
122-13	21043-21052	including	_	
122-14	21053-21058	SATB2	_	
122-15	21058-21059	,	_	
122-16	21060-21066	GABBR2	_	
122-17	21066-21067	,	_	
122-18	21068-21073	PDE4B	_	
122-19	21074-21077	and	_	
122-20	21078-21085	CACNA1C	_	
122-21	21086-21088	et	_	
122-22	21089-21091	al	_	
122-23	21091-21092	.	_	

#Text=Fig. 5B depicts the significant GO results, including cell junction, perinuclear region of cytoplasm, neuron part, synapse, postsynapse, neuron projection, plasma membrane receptor complex, postsynaptic density and postsynaptic specialization.
123-1	21093-21096	Fig	_	
123-2	21096-21097	.	_	
123-3	21098-21100	5B	_	
123-4	21101-21108	depicts	_	
123-5	21109-21112	the	_	
123-6	21113-21124	significant	_	
123-7	21125-21127	GO	_	
123-8	21128-21135	results	_	
123-9	21135-21136	,	_	
123-10	21137-21146	including	_	
123-11	21147-21151	cell	_	
123-12	21152-21160	junction	_	
123-13	21160-21161	,	_	
123-14	21162-21173	perinuclear	_	
123-15	21174-21180	region	_	
123-16	21181-21183	of	_	
123-17	21184-21193	cytoplasm	_	
123-18	21193-21194	,	_	
123-19	21195-21201	neuron	_	
123-20	21202-21206	part	_	
123-21	21206-21207	,	_	
123-22	21208-21215	synapse	_	
123-23	21215-21216	,	_	
123-24	21217-21228	postsynapse	_	
123-25	21228-21229	,	_	
123-26	21230-21236	neuron	_	
123-27	21237-21247	projection	_	
123-28	21247-21248	,	_	
123-29	21249-21255	plasma	_	
123-30	21256-21264	membrane	_	
123-31	21265-21273	receptor	_	
123-32	21274-21281	complex	_	
123-33	21281-21282	,	_	
123-34	21283-21295	postsynaptic	_	
123-35	21296-21303	density	_	
123-36	21304-21307	and	_	
123-37	21308-21320	postsynaptic	_	
123-38	21321-21335	specialization	_	
123-39	21335-21336	.	_	

#Text=Note that the p-vlaues shown in Fig. 5B were all FDR corrected.
124-1	21337-21341	Note	_	
124-2	21342-21346	that	_	
124-3	21347-21350	the	_	
124-4	21351-21359	p-vlaues	_	
124-5	21360-21365	shown	_	
124-6	21366-21368	in	_	
124-7	21369-21372	Fig	_	
124-8	21372-21373	.	_	
124-9	21374-21376	5B	_	
124-10	21377-21381	were	_	
124-11	21382-21385	all	_	
124-12	21386-21389	FDR	_	
124-13	21390-21399	corrected	_	
124-14	21399-21400	.	_	

#Text=The included genes for each GO function are listed in Table S3.
125-1	21401-21404	The	_	
125-2	21405-21413	included	_	
125-3	21414-21419	genes	_	
125-4	21420-21423	for	_	
125-5	21424-21428	each	_	
125-6	21429-21431	GO	_	
125-7	21432-21440	function	_	
125-8	21441-21444	are	_	
125-9	21445-21451	listed	_	
125-10	21452-21454	in	_	
125-11	21455-21460	Table	_	
125-12	21461-21463	S3	_	
125-13	21463-21464	.	_	

#Text=Discussion
#Text=This study first jointly analyzed correlation between FC, GM volume and SNP in schizophrenia and further evaluated the different sensitivity to DOI and disease stages for imaging modalities.
126-1	21465-21475	Discussion	_	
126-2	21476-21480	This	_	
126-3	21481-21486	study	_	
126-4	21487-21492	first	_	
126-5	21493-21500	jointly	_	
126-6	21501-21509	analyzed	_	
126-7	21510-21521	correlation	_	
126-8	21522-21529	between	_	
126-9	21530-21532	FC	_	
126-10	21532-21533	,	_	
126-11	21534-21536	GM	_	
126-12	21537-21543	volume	_	
126-13	21544-21547	and	_	
126-14	21548-21551	SNP	_	
126-15	21552-21554	in	_	
126-16	21555-21568	schizophrenia	_	
126-17	21569-21572	and	_	
126-18	21573-21580	further	_	
126-19	21581-21590	evaluated	_	
126-20	21591-21594	the	_	
126-21	21595-21604	different	_	
126-22	21605-21616	sensitivity	_	
126-23	21617-21619	to	_	
126-24	21620-21623	DOI	_	
126-25	21624-21627	and	_	
126-26	21628-21635	disease	_	
126-27	21636-21642	stages	_	
126-28	21643-21646	for	_	
126-29	21647-21654	imaging	_	
126-30	21655-21665	modalities	_	
126-31	21665-21666	.	_	

#Text=Results revealed a linked SNP-FC-GM pattern, with significant group differences among HC, FESZ and CSZ of each modality.
127-1	21667-21674	Results	_	
127-2	21675-21683	revealed	_	
127-3	21684-21685	a	_	
127-4	21686-21692	linked	_	
127-5	21693-21702	SNP-FC-GM	_	
127-6	21703-21710	pattern	_	
127-7	21710-21711	,	_	
127-8	21712-21716	with	_	
127-9	21717-21728	significant	_	
127-10	21729-21734	group	_	
127-11	21735-21746	differences	_	
127-12	21747-21752	among	_	
127-13	21753-21755	HC	_	
127-14	21755-21756	,	_	
127-15	21757-21761	FESZ	_	
127-16	21762-21765	and	_	
127-17	21766-21769	CSZ	_	
127-18	21770-21772	of	_	
127-19	21773-21777	each	_	
127-20	21778-21786	modality	_	
127-21	21786-21787	.	_	

#Text=Impairments of GM and FC were centered on hippocampal, temporal gyrus and cerebellum in schizophrenia.
128-1	21788-21799	Impairments	_	
128-2	21800-21802	of	_	
128-3	21803-21805	GM	_	
128-4	21806-21809	and	_	
128-5	21810-21812	FC	_	
128-6	21813-21817	were	_	
128-7	21818-21826	centered	_	
128-8	21827-21829	on	_	
128-9	21830-21841	hippocampal	_	
128-10	21841-21842	,	_	
128-11	21843-21851	temporal	_	
128-12	21852-21857	gyrus	_	
128-13	21858-21861	and	_	
128-14	21862-21872	cerebellum	_	
128-15	21873-21875	in	_	
128-16	21876-21889	schizophrenia	_	
128-17	21889-21890	.	_	

#Text=These changes were further significantly associated with SNPs residing in genes like SATB2, GABBR2, PDE4B and CACNA1C et al., involved in pathways of cell junction formation, and synapse and neuron projection.
129-1	21891-21896	These	_	
129-2	21897-21904	changes	_	
129-3	21905-21909	were	_	
129-4	21910-21917	further	_	
129-5	21918-21931	significantly	_	
129-6	21932-21942	associated	_	
129-7	21943-21947	with	_	
129-8	21948-21952	SNPs	_	
129-9	21953-21961	residing	_	
129-10	21962-21964	in	_	
129-11	21965-21970	genes	_	
129-12	21971-21975	like	_	
129-13	21976-21981	SATB2	_	
129-14	21981-21982	,	_	
129-15	21983-21989	GABBR2	_	
129-16	21989-21990	,	_	
129-17	21991-21996	PDE4B	_	
129-18	21997-22000	and	_	
129-19	22001-22008	CACNA1C	_	
129-20	22009-22011	et	_	
129-21	22012-22014	al	_	
129-22	22014-22015	.	_	
129-23	22015-22016	,	_	
129-24	22017-22025	involved	_	
129-25	22026-22028	in	_	
129-26	22029-22037	pathways	_	
129-27	22038-22040	of	_	
129-28	22041-22045	cell	_	
129-29	22046-22054	junction	_	
129-30	22055-22064	formation	_	
129-31	22064-22065	,	_	
129-32	22066-22069	and	_	
129-33	22070-22077	synapse	_	
129-34	22078-22081	and	_	
129-35	22082-22088	neuron	_	
129-36	22089-22099	projection	_	
129-37	22099-22100	.	_	

#Text=Moreover, post-hoc analysis revealed that both GM and FC presented greater deficits at later disease stages (HC > FESZ>CSZ), and FC presented a stronger negative correlation with DOI than GM.
130-1	22101-22109	Moreover	_	
130-2	22109-22110	,	_	
130-3	22111-22119	post-hoc	_	
130-4	22120-22128	analysis	_	
130-5	22129-22137	revealed	_	
130-6	22138-22142	that	_	
130-7	22143-22147	both	_	
130-8	22148-22150	GM	_	
130-9	22151-22154	and	_	
130-10	22155-22157	FC	_	
130-11	22158-22167	presented	_	
130-12	22168-22175	greater	_	
130-13	22176-22184	deficits	_	
130-14	22185-22187	at	_	
130-15	22188-22193	later	_	
130-16	22194-22201	disease	_	
130-17	22202-22208	stages	_	
130-18	22209-22210	(	_	
130-19	22210-22212	HC	_	
130-20	22212-22213	 	_	
130-21	22213-22214	>	_	
130-22	22214-22215	 	_	
130-23	22215-22219	FESZ	_	
130-24	22219-22220	>	_	
130-25	22220-22223	CSZ	_	
130-26	22223-22224	)	_	
130-27	22224-22225	,	_	
130-28	22226-22229	and	_	
130-29	22230-22232	FC	_	
130-30	22233-22242	presented	_	
130-31	22243-22244	a	_	
130-32	22245-22253	stronger	_	
130-33	22254-22262	negative	_	
130-34	22263-22274	correlation	_	
130-35	22275-22279	with	_	
130-36	22280-22283	DOI	_	
130-37	22284-22288	than	_	
130-38	22289-22291	GM	_	
130-39	22291-22292	.	_	

#Text=Linked SNP-FC-GM pattern
#Text=We first identified the most significantly correlated SNP-FC-GM pattern using three-way para-ICA, which passed the significant levels after Bonferroni correction for multiple comparisons.
131-1	22293-22299	Linked	_	
131-2	22300-22309	SNP-FC-GM	_	
131-3	22310-22317	pattern	_	
131-4	22318-22320	We	_	
131-5	22321-22326	first	_	
131-6	22327-22337	identified	_	
131-7	22338-22341	the	_	
131-8	22342-22346	most	_	
131-9	22347-22360	significantly	_	
131-10	22361-22371	correlated	_	
131-11	22372-22381	SNP-FC-GM	_	
131-12	22382-22389	pattern	_	
131-13	22390-22395	using	_	
131-14	22396-22405	three-way	_	
131-15	22406-22414	para-ICA	_	
131-16	22414-22415	,	_	
131-17	22416-22421	which	_	
131-18	22422-22428	passed	_	
131-19	22429-22432	the	_	
131-20	22433-22444	significant	_	
131-21	22445-22451	levels	_	
131-22	22452-22457	after	_	
131-23	22458-22468	Bonferroni	_	
131-24	22469-22479	correction	_	
131-25	22480-22483	for	_	
131-26	22484-22492	multiple	_	
131-27	22493-22504	comparisons	_	
131-28	22504-22505	.	_	

#Text=Then partial correlation on the identified SNP-FC-GM pattern (using diagnosis, age, education and gender as covariates) revealed a weak but still significant correlation among the three modalities.
132-1	22506-22510	Then	_	
132-2	22511-22518	partial	_	
132-3	22519-22530	correlation	_	
132-4	22531-22533	on	_	
132-5	22534-22537	the	_	
132-6	22538-22548	identified	_	
132-7	22549-22558	SNP-FC-GM	_	
132-8	22559-22566	pattern	_	
132-9	22567-22568	(	_	
132-10	22568-22573	using	_	
132-11	22574-22583	diagnosis	_	
132-12	22583-22584	,	_	
132-13	22585-22588	age	_	
132-14	22588-22589	,	_	
132-15	22590-22599	education	_	
132-16	22600-22603	and	_	
132-17	22604-22610	gender	_	
132-18	22611-22613	as	_	
132-19	22614-22624	covariates	_	
132-20	22624-22625	)	_	
132-21	22626-22634	revealed	_	
132-22	22635-22636	a	_	
132-23	22637-22641	weak	_	
132-24	22642-22645	but	_	
132-25	22646-22651	still	_	
132-26	22652-22663	significant	_	
132-27	22664-22675	correlation	_	
132-28	22676-22681	among	_	
132-29	22682-22685	the	_	
132-30	22686-22691	three	_	
132-31	22692-22702	modalities	_	
132-32	22702-22703	.	_	

#Text=We found decreased GM volume in the temporal gyrus, parahippocampal gyrus, postcentral gyrus and amygdala-hippocampus complex, consistent with the previous studies in, coaltered with the low FC strength in prefrontal, temporal, hippocampus/parahippocampus and amygdala.
133-1	22704-22706	We	_	
133-2	22707-22712	found	_	
133-3	22713-22722	decreased	_	
133-4	22723-22725	GM	_	
133-5	22726-22732	volume	_	
133-6	22733-22735	in	_	
133-7	22736-22739	the	_	
133-8	22740-22748	temporal	_	
133-9	22749-22754	gyrus	_	
133-10	22754-22755	,	_	
133-11	22756-22771	parahippocampal	_	
133-12	22772-22777	gyrus	_	
133-13	22777-22778	,	_	
133-14	22779-22790	postcentral	_	
133-15	22791-22796	gyrus	_	
133-16	22797-22800	and	_	
133-17	22801-22821	amygdala-hippocampus	_	
133-18	22822-22829	complex	_	
133-19	22829-22830	,	_	
133-20	22831-22841	consistent	_	
133-21	22842-22846	with	_	
133-22	22847-22850	the	_	
133-23	22851-22859	previous	_	
133-24	22860-22867	studies	_	
133-25	22868-22870	in	_	
133-26	22870-22871	,	_	
133-27	22872-22881	coaltered	_	
133-28	22882-22886	with	_	
133-29	22887-22890	the	_	
133-30	22891-22894	low	_	
133-31	22895-22897	FC	_	
133-32	22898-22906	strength	_	
133-33	22907-22909	in	_	
133-34	22910-22920	prefrontal	_	
133-35	22920-22921	,	_	
133-36	22922-22930	temporal	_	
133-37	22930-22931	,	_	
133-38	22932-22943	hippocampus	_	
133-39	22943-22944	/	_	
133-40	22944-22959	parahippocampus	_	
133-41	22960-22963	and	_	
133-42	22964-22972	amygdala	_	
133-43	22972-22973	.	_	

#Text=Increased GM were revealed mainly in cerebellum and inferior parietal lobule in patients, as well as increased FC in these two brain regions.
134-1	22974-22983	Increased	_	
134-2	22984-22986	GM	_	
134-3	22987-22991	were	_	
134-4	22992-23000	revealed	_	
134-5	23001-23007	mainly	_	
134-6	23008-23010	in	_	
134-7	23011-23021	cerebellum	_	
134-8	23022-23025	and	_	
134-9	23026-23034	inferior	_	
134-10	23035-23043	parietal	_	
134-11	23044-23050	lobule	_	
134-12	23051-23053	in	_	
134-13	23054-23062	patients	_	
134-14	23062-23063	,	_	
134-15	23064-23066	as	_	
134-16	23067-23071	well	_	
134-17	23072-23074	as	_	
134-18	23075-23084	increased	_	
134-19	23085-23087	FC	_	
134-20	23088-23090	in	_	
134-21	23091-23096	these	_	
134-22	23097-23100	two	_	
134-23	23101-23106	brain	_	
134-24	23107-23114	regions	_	
134-25	23114-23115	.	_	

#Text=Shared impaired brain regions between GM and FC modalities focused on hippocampus, temporal gyrus, cerebellum and parietal gyrus.
135-1	23116-23122	Shared	_	
135-2	23123-23131	impaired	_	
135-3	23132-23137	brain	_	
135-4	23138-23145	regions	_	
135-5	23146-23153	between	_	
135-6	23154-23156	GM	_	
135-7	23157-23160	and	_	
135-8	23161-23163	FC	_	
135-9	23164-23174	modalities	_	
135-10	23175-23182	focused	_	
135-11	23183-23185	on	_	
135-12	23186-23197	hippocampus	_	
135-13	23197-23198	,	_	
135-14	23199-23207	temporal	_	
135-15	23208-23213	gyrus	_	
135-16	23213-23214	,	_	
135-17	23215-23225	cerebellum	_	
135-18	23226-23229	and	_	
135-19	23230-23238	parietal	_	
135-20	23239-23244	gyrus	_	
135-21	23244-23245	.	_	

#Text=The decreased GM volumes of temporal gyrus are implicated for the impairment in sensory integration, storage of language and voice information, and higher-order cognitive functions.
136-1	23246-23249	The	_	
136-2	23250-23259	decreased	_	
136-3	23260-23262	GM	_	
136-4	23263-23270	volumes	_	
136-5	23271-23273	of	_	
136-6	23274-23282	temporal	_	
136-7	23283-23288	gyrus	_	
136-8	23289-23292	are	_	
136-9	23293-23303	implicated	_	
136-10	23304-23307	for	_	
136-11	23308-23311	the	_	
136-12	23312-23322	impairment	_	
136-13	23323-23325	in	_	
136-14	23326-23333	sensory	_	
136-15	23334-23345	integration	_	
136-16	23345-23346	,	_	
136-17	23347-23354	storage	_	
136-18	23355-23357	of	_	
136-19	23358-23366	language	_	
136-20	23367-23370	and	_	
136-21	23371-23376	voice	_	
136-22	23377-23388	information	_	
136-23	23388-23389	,	_	
136-24	23390-23393	and	_	
136-25	23394-23406	higher-order	_	
136-26	23407-23416	cognitive	_	
136-27	23417-23426	functions	_	
136-28	23426-23427	.	_	

#Text=Amygdala and hippocampus are critical for memory functions and affect perception.
137-1	23428-23436	Amygdala	_	
137-2	23437-23440	and	_	
137-3	23441-23452	hippocampus	_	
137-4	23453-23456	are	_	
137-5	23457-23465	critical	_	
137-6	23466-23469	for	_	
137-7	23470-23476	memory	_	
137-8	23477-23486	functions	_	
137-9	23487-23490	and	_	
137-10	23491-23497	affect	_	
137-11	23498-23508	perception	_	
137-12	23508-23509	.	_	

#Text=The parahippocampal gyrus is part of the medial temporal lobe, which receives input from heteromodal association areas of the cortex and projects into the limbic circuit for information transmission.
138-1	23510-23513	The	_	
138-2	23514-23529	parahippocampal	_	
138-3	23530-23535	gyrus	_	
138-4	23536-23538	is	_	
138-5	23539-23543	part	_	
138-6	23544-23546	of	_	
138-7	23547-23550	the	_	
138-8	23551-23557	medial	_	
138-9	23558-23566	temporal	_	
138-10	23567-23571	lobe	_	
138-11	23571-23572	,	_	
138-12	23573-23578	which	_	
138-13	23579-23587	receives	_	
138-14	23588-23593	input	_	
138-15	23594-23598	from	_	
138-16	23599-23610	heteromodal	_	
138-17	23611-23622	association	_	
138-18	23623-23628	areas	_	
138-19	23629-23631	of	_	
138-20	23632-23635	the	_	
138-21	23636-23642	cortex	_	
138-22	23643-23646	and	_	
138-23	23647-23655	projects	_	
138-24	23656-23660	into	_	
138-25	23661-23664	the	_	
138-26	23665-23671	limbic	_	
138-27	23672-23679	circuit	_	
138-28	23680-23683	for	_	
138-29	23684-23695	information	_	
138-30	23696-23708	transmission	_	
138-31	23708-23709	.	_	

#Text=The cerebellum has been revealed to primarily coordinate motor activity for years and viewed as a key cognitive region in the brain which is impaired in schizophrenia by the previous study.
139-1	23710-23713	The	_	
139-2	23714-23724	cerebellum	_	
139-3	23725-23728	has	_	
139-4	23729-23733	been	_	
139-5	23734-23742	revealed	_	
139-6	23743-23745	to	_	
139-7	23746-23755	primarily	_	
139-8	23756-23766	coordinate	_	
139-9	23767-23772	motor	_	
139-10	23773-23781	activity	_	
139-11	23782-23785	for	_	
139-12	23786-23791	years	_	
139-13	23792-23795	and	_	
139-14	23796-23802	viewed	_	
139-15	23803-23805	as	_	
139-16	23806-23807	a	_	
139-17	23808-23811	key	_	
139-18	23812-23821	cognitive	_	
139-19	23822-23828	region	_	
139-20	23829-23831	in	_	
139-21	23832-23835	the	_	
139-22	23836-23841	brain	_	
139-23	23842-23847	which	_	
139-24	23848-23850	is	_	
139-25	23851-23859	impaired	_	
139-26	23860-23862	in	_	
139-27	23863-23876	schizophrenia	_	
139-28	23877-23879	by	_	
139-29	23880-23883	the	_	
139-30	23884-23892	previous	_	
139-31	23893-23898	study	_	
139-32	23898-23899	.	_	

#Text=The parietal lobe is important in processes of language, attention and spatial working memory, which are likely to be disturbed in schizophrenia.
140-1	23900-23903	The	_	
140-2	23904-23912	parietal	_	
140-3	23913-23917	lobe	_	
140-4	23918-23920	is	_	
140-5	23921-23930	important	_	
140-6	23931-23933	in	_	
140-7	23934-23943	processes	_	
140-8	23944-23946	of	_	
140-9	23947-23955	language	_	
140-10	23955-23956	,	_	
140-11	23957-23966	attention	_	
140-12	23967-23970	and	_	
140-13	23971-23978	spatial	_	
140-14	23979-23986	working	_	
140-15	23987-23993	memory	_	
140-16	23993-23994	,	_	
140-17	23995-24000	which	_	
140-18	24001-24004	are	_	
140-19	24005-24011	likely	_	
140-20	24012-24014	to	_	
140-21	24015-24017	be	_	
140-22	24018-24027	disturbed	_	
140-23	24028-24030	in	_	
140-24	24031-24044	schizophrenia	_	
140-25	24044-24045	.	_	

#Text=The joint SNP component primarily highlighted SZ-susceptible genes including PDE4B, EGF, SATB2, PPP1R16B, GABBR2 and CACNA1C etc., which have been reported to be significantly associated with schizophrenia in previous studies.
141-1	24046-24049	The	_	
141-2	24050-24055	joint	_	
141-3	24056-24059	SNP	_	
141-4	24060-24069	component	_	
141-5	24070-24079	primarily	_	
141-6	24080-24091	highlighted	_	
141-7	24092-24106	SZ-susceptible	_	
141-8	24107-24112	genes	_	
141-9	24113-24122	including	_	
141-10	24123-24128	PDE4B	_	
141-11	24128-24129	,	_	
141-12	24130-24133	EGF	_	
141-13	24133-24134	,	_	
141-14	24135-24140	SATB2	_	
141-15	24140-24141	,	_	
141-16	24142-24150	PPP1R16B	_	
141-17	24150-24151	,	_	
141-18	24152-24158	GABBR2	_	
141-19	24159-24162	and	_	
141-20	24163-24170	CACNA1C	_	
141-21	24171-24174	etc	_	
141-22	24174-24175	.	_	
141-23	24175-24176	,	_	
141-24	24177-24182	which	_	
141-25	24183-24187	have	_	
141-26	24188-24192	been	_	
141-27	24193-24201	reported	_	
141-28	24202-24204	to	_	
141-29	24205-24207	be	_	
141-30	24208-24221	significantly	_	
141-31	24222-24232	associated	_	
141-32	24233-24237	with	_	
141-33	24238-24251	schizophrenia	_	
141-34	24252-24254	in	_	
141-35	24255-24263	previous	_	
141-36	24264-24271	studies	_	
141-37	24271-24272	.	_	

#Text=For example, PDE4B interacts with DISC1 to regulate cAMP signaling, which is impared in schizophrenia.
142-1	24273-24276	For	_	
142-2	24277-24284	example	_	
142-3	24284-24285	,	_	
142-4	24286-24291	PDE4B	_	
142-5	24292-24301	interacts	_	
142-6	24302-24306	with	_	
142-7	24307-24312	DISC1	_	
142-8	24313-24315	to	_	
142-9	24316-24324	regulate	_	
142-10	24325-24329	cAMP	_	
142-11	24330-24339	signaling	_	
142-12	24339-24340	,	_	
142-13	24341-24346	which	_	
142-14	24347-24349	is	_	
142-15	24350-24357	impared	_	
142-16	24358-24360	in	_	
142-17	24361-24374	schizophrenia	_	
142-18	24374-24375	.	_	

#Text=Patients with mutations or deletions within the SATB2 locus exhibit severe learning difficulties and profound mental retardation.
143-1	24376-24384	Patients	_	
143-2	24385-24389	with	_	
143-3	24390-24399	mutations	_	
143-4	24400-24402	or	_	
143-5	24403-24412	deletions	_	
143-6	24413-24419	within	_	
143-7	24420-24423	the	_	
143-8	24424-24429	SATB2	_	
143-9	24430-24435	locus	_	
143-10	24436-24443	exhibit	_	
143-11	24444-24450	severe	_	
143-12	24451-24459	learning	_	
143-13	24460-24472	difficulties	_	
143-14	24473-24476	and	_	
143-15	24477-24485	profound	_	
143-16	24486-24492	mental	_	
143-17	24493-24504	retardation	_	
143-18	24504-24505	.	_	

#Text=Devor et al. has found PP1 subunits including PPP1R16B plays a central role in the integration of fast and slow neurotransmission.
144-1	24506-24511	Devor	_	
144-2	24512-24514	et	_	
144-3	24515-24517	al	_	
144-4	24517-24518	.	_	
144-5	24519-24522	has	_	
144-6	24523-24528	found	_	
144-7	24529-24532	PP1	_	
144-8	24533-24541	subunits	_	
144-9	24542-24551	including	_	
144-10	24552-24560	PPP1R16B	_	
144-11	24561-24566	plays	_	
144-12	24567-24568	a	_	
144-13	24569-24576	central	_	
144-14	24577-24581	role	_	
144-15	24582-24584	in	_	
144-16	24585-24588	the	_	
144-17	24589-24600	integration	_	
144-18	24601-24603	of	_	
144-19	24604-24608	fast	_	
144-20	24609-24612	and	_	
144-21	24613-24617	slow	_	
144-22	24618-24635	neurotransmission	_	
144-23	24635-24636	.	_	

#Text=The CACNA1C is also revealed as a SZ-susceptible gene in.
145-1	24637-24640	The	_	
145-2	24641-24648	CACNA1C	_	
145-3	24649-24651	is	_	
145-4	24652-24656	also	_	
145-5	24657-24665	revealed	_	
145-6	24666-24668	as	_	
145-7	24669-24670	a	_	
145-8	24671-24685	SZ-susceptible	_	
145-9	24686-24690	gene	_	
145-10	24691-24693	in	_	
145-11	24693-24694	.	_	

#Text=Further GO analysis of the annotated top contributing genes revealed a significant enrichment of cell junction, synapse and neuron projection.
146-1	24695-24702	Further	_	
146-2	24703-24705	GO	_	
146-3	24706-24714	analysis	_	
146-4	24715-24717	of	_	
146-5	24718-24721	the	_	
146-6	24722-24731	annotated	_	
146-7	24732-24735	top	_	
146-8	24736-24748	contributing	_	
146-9	24749-24754	genes	_	
146-10	24755-24763	revealed	_	
146-11	24764-24765	a	_	
146-12	24766-24777	significant	_	
146-13	24778-24788	enrichment	_	
146-14	24789-24791	of	_	
146-15	24792-24796	cell	_	
146-16	24797-24805	junction	_	
146-17	24805-24806	,	_	
146-18	24807-24814	synapse	_	
146-19	24815-24818	and	_	
146-20	24819-24825	neuron	_	
146-21	24826-24836	projection	_	
146-22	24836-24837	.	_	

#Text=Consistently, reduced neuron projection of schizophrenia patients in the hippocampus and thalamocortex has also been revealed in previous studies.
147-1	24838-24850	Consistently	_	
147-2	24850-24851	,	_	
147-3	24852-24859	reduced	_	
147-4	24860-24866	neuron	_	
147-5	24867-24877	projection	_	
147-6	24878-24880	of	_	
147-7	24881-24894	schizophrenia	_	
147-8	24895-24903	patients	_	
147-9	24904-24906	in	_	
147-10	24907-24910	the	_	
147-11	24911-24922	hippocampus	_	
147-12	24923-24926	and	_	
147-13	24927-24940	thalamocortex	_	
147-14	24941-24944	has	_	
147-15	24945-24949	also	_	
147-16	24950-24954	been	_	
147-17	24955-24963	revealed	_	
147-18	24964-24966	in	_	
147-19	24967-24975	previous	_	
147-20	24976-24983	studies	_	
147-21	24983-24984	.	_	

#Text=Synapse primarily participates in the information transmission process.
148-1	24985-24992	Synapse	_	
148-2	24993-25002	primarily	_	
148-3	25003-25015	participates	_	
148-4	25016-25018	in	_	
148-5	25019-25022	the	_	
148-6	25023-25034	information	_	
148-7	25035-25047	transmission	_	
148-8	25048-25055	process	_	
148-9	25055-25056	.	_	

#Text=Impairment of synaptic transmission during childhood and adolescence would lead to altered synapse formation or pruning.
149-1	25057-25067	Impairment	_	
149-2	25068-25070	of	_	
149-3	25071-25079	synaptic	_	
149-4	25080-25092	transmission	_	
149-5	25093-25099	during	_	
149-6	25100-25109	childhood	_	
149-7	25110-25113	and	_	
149-8	25114-25125	adolescence	_	
149-9	25126-25131	would	_	
149-10	25132-25136	lead	_	
149-11	25137-25139	to	_	
149-12	25140-25147	altered	_	
149-13	25148-25155	synapse	_	
149-14	25156-25165	formation	_	
149-15	25166-25168	or	_	
149-16	25169-25176	pruning	_	
149-17	25176-25177	.	_	

#Text=Moreover, the SNP component was significantly correlated with the imaging impairments, supported by previous studies.
150-1	25178-25186	Moreover	_	
150-2	25186-25187	,	_	
150-3	25188-25191	the	_	
150-4	25192-25195	SNP	_	
150-5	25196-25205	component	_	
150-6	25206-25209	was	_	
150-7	25210-25223	significantly	_	
150-8	25224-25234	correlated	_	
150-9	25235-25239	with	_	
150-10	25240-25243	the	_	
150-11	25244-25251	imaging	_	
150-12	25252-25263	impairments	_	
150-13	25263-25264	,	_	
150-14	25265-25274	supported	_	
150-15	25275-25277	by	_	
150-16	25278-25286	previous	_	
150-17	25287-25294	studies	_	
150-18	25294-25295	.	_	

#Text=For example, GABBR1 and GABBR2 were revealed to be altered significantly in the lateral cerebellum of SZ patients.
151-1	25296-25299	For	_	
151-2	25300-25307	example	_	
151-3	25307-25308	,	_	
151-4	25309-25315	GABBR1	_	
151-5	25316-25319	and	_	
151-6	25320-25326	GABBR2	_	
151-7	25327-25331	were	_	
151-8	25332-25340	revealed	_	
151-9	25341-25343	to	_	
151-10	25344-25346	be	_	
151-11	25347-25354	altered	_	
151-12	25355-25368	significantly	_	
151-13	25369-25371	in	_	
151-14	25372-25375	the	_	
151-15	25376-25383	lateral	_	
151-16	25384-25394	cerebellum	_	
151-17	25395-25397	of	_	
151-18	25398-25400	SZ	_	
151-19	25401-25409	patients	_	
151-20	25409-25410	.	_	

#Text=SATB2 has been reported to control the hippocampal levels of a large cohort of miRNAs, many of which are implicated in synaptic plastic and memory formation.
152-1	25411-25416	SATB2	_	
152-2	25417-25420	has	_	
152-3	25421-25425	been	_	
152-4	25426-25434	reported	_	
152-5	25435-25437	to	_	
152-6	25438-25445	control	_	
152-7	25446-25449	the	_	
152-8	25450-25461	hippocampal	_	
152-9	25462-25468	levels	_	
152-10	25469-25471	of	_	
152-11	25472-25473	a	_	
152-12	25474-25479	large	_	
152-13	25480-25486	cohort	_	
152-14	25487-25489	of	_	
152-15	25490-25496	miRNAs	_	
152-16	25496-25497	,	_	
152-17	25498-25502	many	_	
152-18	25503-25505	of	_	
152-19	25506-25511	which	_	
152-20	25512-25515	are	_	
152-21	25516-25526	implicated	_	
152-22	25527-25529	in	_	
152-23	25530-25538	synaptic	_	
152-24	25539-25546	plastic	_	
152-25	25547-25550	and	_	
152-26	25551-25557	memory	_	
152-27	25558-25567	formation	_	
152-28	25567-25568	.	_	

#Text=The CACNA1C gene is widely expressed in the entire nervous system, especially the thalamus and hippocampus areas.
153-1	25569-25572	The	_	
153-2	25573-25580	CACNA1C	_	
153-3	25581-25585	gene	_	
153-4	25586-25588	is	_	
153-5	25589-25595	widely	_	
153-6	25596-25605	expressed	_	
153-7	25606-25608	in	_	
153-8	25609-25612	the	_	
153-9	25613-25619	entire	_	
153-10	25620-25627	nervous	_	
153-11	25628-25634	system	_	
153-12	25634-25635	,	_	
153-13	25636-25646	especially	_	
153-14	25647-25650	the	_	
153-15	25651-25659	thalamus	_	
153-16	25660-25663	and	_	
153-17	25664-25675	hippocampus	_	
153-18	25676-25681	areas	_	
153-19	25681-25682	.	_	

#Text=Decreased expression of PDE4B has been observed in the tissues of Brodmann's area 6 of frontal cortex and cerebellum.
154-1	25683-25692	Decreased	_	
154-2	25693-25703	expression	_	
154-3	25704-25706	of	_	
154-4	25707-25712	PDE4B	_	
154-5	25713-25716	has	_	
154-6	25717-25721	been	_	
154-7	25722-25730	observed	_	
154-8	25731-25733	in	_	
154-9	25734-25737	the	_	
154-10	25738-25745	tissues	_	
154-11	25746-25748	of	_	
154-12	25749-25759	Brodmann's	_	
154-13	25760-25764	area	_	
154-14	25765-25766	6	_	
154-15	25767-25769	of	_	
154-16	25770-25777	frontal	_	
154-17	25778-25784	cortex	_	
154-18	25785-25788	and	_	
154-19	25789-25799	cerebellum	_	
154-20	25799-25800	.	_	

#Text=Different sensitivity to disease stage and DOI
#Text=Post-hoc 2-sample t-test revealed that GM impairments in FESZ were not significant compared to HC, while CSZ exhibited significant group difference compared to both FESZ and HC.
155-1	25801-25810	Different	_	
155-2	25811-25822	sensitivity	_	
155-3	25823-25825	to	_	
155-4	25826-25833	disease	_	
155-5	25834-25839	stage	_	
155-6	25840-25843	and	_	
155-7	25844-25847	DOI	_	
155-8	25848-25856	Post-hoc	_	
155-9	25857-25858	2	_	
155-10	25858-25859	-	_	
155-11	25859-25865	sample	_	
155-12	25866-25872	t-test	_	
155-13	25873-25881	revealed	_	
155-14	25882-25886	that	_	
155-15	25887-25889	GM	_	
155-16	25890-25901	impairments	_	
155-17	25902-25904	in	_	
155-18	25905-25909	FESZ	_	
155-19	25910-25914	were	_	
155-20	25915-25918	not	_	
155-21	25919-25930	significant	_	
155-22	25931-25939	compared	_	
155-23	25940-25942	to	_	
155-24	25943-25945	HC	_	
155-25	25945-25946	,	_	
155-26	25947-25952	while	_	
155-27	25953-25956	CSZ	_	
155-28	25957-25966	exhibited	_	
155-29	25967-25978	significant	_	
155-30	25979-25984	group	_	
155-31	25985-25995	difference	_	
155-32	25996-26004	compared	_	
155-33	26005-26007	to	_	
155-34	26008-26012	both	_	
155-35	26013-26017	FESZ	_	
155-36	26018-26021	and	_	
155-37	26022-26024	HC	_	
155-38	26024-26025	.	_	

#Text=Unlike GM, FC presented significant group difference between FESZ and HC, and a larger impairment in CSZ.
156-1	26026-26032	Unlike	_	
156-2	26033-26035	GM	_	
156-3	26035-26036	,	_	
156-4	26037-26039	FC	_	
156-5	26040-26049	presented	_	
156-6	26050-26061	significant	_	
156-7	26062-26067	group	_	
156-8	26068-26078	difference	_	
156-9	26079-26086	between	_	
156-10	26087-26091	FESZ	_	
156-11	26092-26095	and	_	
156-12	26096-26098	HC	_	
156-13	26098-26099	,	_	
156-14	26100-26103	and	_	
156-15	26104-26105	a	_	
156-16	26106-26112	larger	_	
156-17	26113-26123	impairment	_	
156-18	26124-26126	in	_	
156-19	26127-26130	CSZ	_	
156-20	26130-26131	.	_	

#Text=We have noticed that there were some literatures in schizophrenia stating that notable GM and FC deficits were revealed in the early stage of the disease.
157-1	26132-26134	We	_	
157-2	26135-26139	have	_	
157-3	26140-26147	noticed	_	
157-4	26148-26152	that	_	
157-5	26153-26158	there	_	
157-6	26159-26163	were	_	
157-7	26164-26168	some	_	
157-8	26169-26180	literatures	_	
157-9	26181-26183	in	_	
157-10	26184-26197	schizophrenia	_	
157-11	26198-26205	stating	_	
157-12	26206-26210	that	_	
157-13	26211-26218	notable	_	
157-14	26219-26221	GM	_	
157-15	26222-26225	and	_	
157-16	26226-26228	FC	_	
157-17	26229-26237	deficits	_	
157-18	26238-26242	were	_	
157-19	26243-26251	revealed	_	
157-20	26252-26254	in	_	
157-21	26255-26258	the	_	
157-22	26259-26264	early	_	
157-23	26265-26270	stage	_	
157-24	26271-26273	of	_	
157-25	26274-26277	the	_	
157-26	26278-26285	disease	_	
157-27	26285-26286	.	_	

#Text=However, in current work, we only observed moderately decreased GM in FESZ, due to the following potential reasons.1) The first-episode patients collected in current study have a relatively short duration of illness (≤ 2 years), less than those FESZ reported with DOI≤5 years, and previous studies also reported un-significant GMV reduction in the high-risking patients and progressive GMV reductions in schizophrenia patients, supporting our findings. 2) Earlier age of onset of schizophrenia has been reported to be associated with larger regional GM deficits and worse outcome.
158-1	26287-26294	However	_	
158-2	26294-26295	,	_	
158-3	26296-26298	in	_	
158-4	26299-26306	current	_	
158-5	26307-26311	work	_	
158-6	26311-26312	,	_	
158-7	26313-26315	we	_	
158-8	26316-26320	only	_	
158-9	26321-26329	observed	_	
158-10	26330-26340	moderately	_	
158-11	26341-26350	decreased	_	
158-12	26351-26353	GM	_	
158-13	26354-26356	in	_	
158-14	26357-26361	FESZ	_	
158-15	26361-26362	,	_	
158-16	26363-26366	due	_	
158-17	26367-26369	to	_	
158-18	26370-26373	the	_	
158-19	26374-26383	following	_	
158-20	26384-26393	potential	_	
158-21	26394-26401	reasons	_	
158-22	26401-26403	.1	_	
158-23	26403-26404	)	_	
158-24	26405-26408	The	_	
158-25	26409-26422	first-episode	_	
158-26	26423-26431	patients	_	
158-27	26432-26441	collected	_	
158-28	26442-26444	in	_	
158-29	26445-26452	current	_	
158-30	26453-26458	study	_	
158-31	26459-26463	have	_	
158-32	26464-26465	a	_	
158-33	26466-26476	relatively	_	
158-34	26477-26482	short	_	
158-35	26483-26491	duration	_	
158-36	26492-26494	of	_	
158-37	26495-26502	illness	_	
158-38	26503-26504	(	_	
158-39	26504-26505	≤	_	
158-40	26506-26507	2	_	
158-41	26507-26508	 	_	
158-42	26508-26513	years	_	
158-43	26513-26514	)	_	
158-44	26514-26515	,	_	
158-45	26516-26520	less	_	
158-46	26521-26525	than	_	
158-47	26526-26531	those	_	
158-48	26532-26536	FESZ	_	
158-49	26537-26545	reported	_	
158-50	26546-26550	with	_	
158-51	26551-26554	DOI	_	
158-52	26554-26555	≤	_	
158-53	26555-26556	5	_	
158-54	26556-26557	 	_	
158-55	26557-26562	years	_	
158-56	26562-26563	,	_	
158-57	26564-26567	and	_	
158-58	26568-26576	previous	_	
158-59	26577-26584	studies	_	
158-60	26585-26589	also	_	
158-61	26590-26598	reported	_	
158-62	26599-26613	un-significant	_	
158-63	26614-26617	GMV	_	
158-64	26618-26627	reduction	_	
158-65	26628-26630	in	_	
158-66	26631-26634	the	_	
158-67	26635-26647	high-risking	_	
158-68	26648-26656	patients	_	
158-69	26657-26660	and	_	
158-70	26661-26672	progressive	_	
158-71	26673-26676	GMV	_	
158-72	26677-26687	reductions	_	
158-73	26688-26690	in	_	
158-74	26691-26704	schizophrenia	_	
158-75	26705-26713	patients	_	
158-76	26713-26714	,	_	
158-77	26715-26725	supporting	_	
158-78	26726-26729	our	_	
158-79	26730-26738	findings	_	
158-80	26738-26739	.	_	
158-81	26740-26741	2	_	
158-82	26741-26742	)	_	
158-83	26743-26750	Earlier	_	
158-84	26751-26754	age	_	
158-85	26755-26757	of	_	
158-86	26758-26763	onset	_	
158-87	26764-26766	of	_	
158-88	26767-26780	schizophrenia	_	
158-89	26781-26784	has	_	
158-90	26785-26789	been	_	
158-91	26790-26798	reported	_	
158-92	26799-26801	to	_	
158-93	26802-26804	be	_	
158-94	26805-26815	associated	_	
158-95	26816-26820	with	_	
158-96	26821-26827	larger	_	
158-97	26828-26836	regional	_	
158-98	26837-26839	GM	_	
158-99	26840-26848	deficits	_	
158-100	26849-26852	and	_	
158-101	26853-26858	worse	_	
158-102	26859-26866	outcome	_	
158-103	26866-26867	.	_	

#Text=In this study, the FESZ patients are primarily middle-aged adults (33.60 ± 10.80 years old) rather than adolescents, which may infer less GM impairments in the patients compared to other studies. 3) We only focused on the subgroups of the GM and FC data which were simultaneously related with the SNP cluster.
159-1	26868-26870	In	_	
159-2	26871-26875	this	_	
159-3	26876-26881	study	_	
159-4	26881-26882	,	_	
159-5	26883-26886	the	_	
159-6	26887-26891	FESZ	_	
159-7	26892-26900	patients	_	
159-8	26901-26904	are	_	
159-9	26905-26914	primarily	_	
159-10	26915-26926	middle-aged	_	
159-11	26927-26933	adults	_	
159-12	26934-26935	(	_	
159-13	26935-26940	33.60	_	
159-14	26940-26941	 	_	
159-15	26941-26942	±	_	
159-16	26942-26943	 	_	
159-17	26943-26948	10.80	_	
159-18	26948-26949	 	_	
159-19	26949-26954	years	_	
159-20	26955-26958	old	_	
159-21	26958-26959	)	_	
159-22	26960-26966	rather	_	
159-23	26967-26971	than	_	
159-24	26972-26983	adolescents	_	
159-25	26983-26984	,	_	
159-26	26985-26990	which	_	
159-27	26991-26994	may	_	
159-28	26995-27000	infer	_	
159-29	27001-27005	less	_	
159-30	27006-27008	GM	_	
159-31	27009-27020	impairments	_	
159-32	27021-27023	in	_	
159-33	27024-27027	the	_	
159-34	27028-27036	patients	_	
159-35	27037-27045	compared	_	
159-36	27046-27048	to	_	
159-37	27049-27054	other	_	
159-38	27055-27062	studies	_	
159-39	27062-27063	.	_	
159-40	27064-27065	3	_	
159-41	27065-27066	)	_	
159-42	27067-27069	We	_	
159-43	27070-27074	only	_	
159-44	27075-27082	focused	_	
159-45	27083-27085	on	_	
159-46	27086-27089	the	_	
159-47	27090-27099	subgroups	_	
159-48	27100-27102	of	_	
159-49	27103-27106	the	_	
159-50	27107-27109	GM	_	
159-51	27110-27113	and	_	
159-52	27114-27116	FC	_	
159-53	27117-27121	data	_	
159-54	27122-27127	which	_	
159-55	27128-27132	were	_	
159-56	27133-27147	simultaneously	_	
159-57	27148-27155	related	_	
159-58	27156-27160	with	_	
159-59	27161-27164	the	_	
159-60	27165-27168	SNP	_	
159-61	27169-27176	cluster	_	
159-62	27176-27177	.	_	

#Text=For example, lower gray matter volumes in FESZ reported in previous studies were mostly found in the anterior cingulate, insula, caudate and putamen.
160-1	27178-27181	For	_	
160-2	27182-27189	example	_	
160-3	27189-27190	,	_	
160-4	27191-27196	lower	_	
160-5	27197-27201	gray	_	
160-6	27202-27208	matter	_	
160-7	27209-27216	volumes	_	
160-8	27217-27219	in	_	
160-9	27220-27224	FESZ	_	
160-10	27225-27233	reported	_	
160-11	27234-27236	in	_	
160-12	27237-27245	previous	_	
160-13	27246-27253	studies	_	
160-14	27254-27258	were	_	
160-15	27259-27265	mostly	_	
160-16	27266-27271	found	_	
160-17	27272-27274	in	_	
160-18	27275-27278	the	_	
160-19	27279-27287	anterior	_	
160-20	27288-27297	cingulate	_	
160-21	27297-27298	,	_	
160-22	27299-27305	insula	_	
160-23	27305-27306	,	_	
160-24	27307-27314	caudate	_	
160-25	27315-27318	and	_	
160-26	27319-27326	putamen	_	
160-27	27326-27327	.	_	

#Text=While in this study, the peak regions were observed in the amygdala, temporal pole, parahippocampal gyrus, postcentral gyrus, primarily reported in chronic patients, which may lead to the un-significant group difference in FESZ.
161-1	27328-27333	While	_	
161-2	27334-27336	in	_	
161-3	27337-27341	this	_	
161-4	27342-27347	study	_	
161-5	27347-27348	,	_	
161-6	27349-27352	the	_	
161-7	27353-27357	peak	_	
161-8	27358-27365	regions	_	
161-9	27366-27370	were	_	
161-10	27371-27379	observed	_	
161-11	27380-27382	in	_	
161-12	27383-27386	the	_	
161-13	27387-27395	amygdala	_	
161-14	27395-27396	,	_	
161-15	27397-27405	temporal	_	
161-16	27406-27410	pole	_	
161-17	27410-27411	,	_	
161-18	27412-27427	parahippocampal	_	
161-19	27428-27433	gyrus	_	
161-20	27433-27434	,	_	
161-21	27435-27446	postcentral	_	
161-22	27447-27452	gyrus	_	
161-23	27452-27453	,	_	
161-24	27454-27463	primarily	_	
161-25	27464-27472	reported	_	
161-26	27473-27475	in	_	
161-27	27476-27483	chronic	_	
161-28	27484-27492	patients	_	
161-29	27492-27493	,	_	
161-30	27494-27499	which	_	
161-31	27500-27503	may	_	
161-32	27504-27508	lead	_	
161-33	27509-27511	to	_	
161-34	27512-27515	the	_	
161-35	27516-27530	un-significant	_	
161-36	27531-27536	group	_	
161-37	27537-27547	difference	_	
161-38	27548-27550	in	_	
161-39	27551-27555	FESZ	_	
161-40	27555-27556	.	_	

#Text=Notably, these impaired regions were also identified in the FC component, which presented significant group difference between FESZ and HC.
162-1	27557-27564	Notably	_	
162-2	27564-27565	,	_	
162-3	27566-27571	these	_	
162-4	27572-27580	impaired	_	
162-5	27581-27588	regions	_	
162-6	27589-27593	were	_	
162-7	27594-27598	also	_	
162-8	27599-27609	identified	_	
162-9	27610-27612	in	_	
162-10	27613-27616	the	_	
162-11	27617-27619	FC	_	
162-12	27620-27629	component	_	
162-13	27629-27630	,	_	
162-14	27631-27636	which	_	
162-15	27637-27646	presented	_	
162-16	27647-27658	significant	_	
162-17	27659-27664	group	_	
162-18	27665-27675	difference	_	
162-19	27676-27683	between	_	
162-20	27684-27688	FESZ	_	
162-21	27689-27692	and	_	
162-22	27693-27695	HC	_	
162-23	27695-27696	.	_	

#Text=Previous studies supported this by reporting abnormalities in these regions at first-episode stages, for example the middle temporal gyrus and parahippocampus areas.
163-1	27697-27705	Previous	_	
163-2	27706-27713	studies	_	
163-3	27714-27723	supported	_	
163-4	27724-27728	this	_	
163-5	27729-27731	by	_	
163-6	27732-27741	reporting	_	
163-7	27742-27755	abnormalities	_	
163-8	27756-27758	in	_	
163-9	27759-27764	these	_	
163-10	27765-27772	regions	_	
163-11	27773-27775	at	_	
163-12	27776-27789	first-episode	_	
163-13	27790-27796	stages	_	
163-14	27796-27797	,	_	
163-15	27798-27801	for	_	
163-16	27802-27809	example	_	
163-17	27810-27813	the	_	
163-18	27814-27820	middle	_	
163-19	27821-27829	temporal	_	
163-20	27830-27835	gyrus	_	
163-21	27836-27839	and	_	
163-22	27840-27855	parahippocampus	_	
163-23	27856-27861	areas	_	
163-24	27861-27862	.	_	

#Text=Accordingly, we suggested that functional connectivity presented a greater gradient of decline to duration of illness than GMV in specific brain regions at the early stage of the disease, including the parahippocampus, inferior temporal gyrus and postcentral gyrus.
164-1	27863-27874	Accordingly	_	
164-2	27874-27875	,	_	
164-3	27876-27878	we	_	
164-4	27879-27888	suggested	_	
164-5	27889-27893	that	_	
164-6	27894-27904	functional	_	
164-7	27905-27917	connectivity	_	
164-8	27918-27927	presented	_	
164-9	27928-27929	a	_	
164-10	27930-27937	greater	_	
164-11	27938-27946	gradient	_	
164-12	27947-27949	of	_	
164-13	27950-27957	decline	_	
164-14	27958-27960	to	_	
164-15	27961-27969	duration	_	
164-16	27970-27972	of	_	
164-17	27973-27980	illness	_	
164-18	27981-27985	than	_	
164-19	27986-27989	GMV	_	
164-20	27990-27992	in	_	
164-21	27993-28001	specific	_	
164-22	28002-28007	brain	_	
164-23	28008-28015	regions	_	
164-24	28016-28018	at	_	
164-25	28019-28022	the	_	
164-26	28023-28028	early	_	
164-27	28029-28034	stage	_	
164-28	28035-28037	of	_	
164-29	28038-28041	the	_	
164-30	28042-28049	disease	_	
164-31	28049-28050	,	_	
164-32	28051-28060	including	_	
164-33	28061-28064	the	_	
164-34	28065-28080	parahippocampus	_	
164-35	28080-28081	,	_	
164-36	28082-28090	inferior	_	
164-37	28091-28099	temporal	_	
164-38	28100-28105	gyrus	_	
164-39	28106-28109	and	_	
164-40	28110-28121	postcentral	_	
164-41	28122-28127	gyrus	_	
164-42	28127-28128	.	_	

#Text=More importantly, even though these results are statistically significant, further validation based on longitude subjects and larger dataset were also awaited.
165-1	28129-28133	More	_	
165-2	28134-28145	importantly	_	
165-3	28145-28146	,	_	
165-4	28147-28151	even	_	
165-5	28152-28158	though	_	
165-6	28159-28164	these	_	
165-7	28165-28172	results	_	
165-8	28173-28176	are	_	
165-9	28177-28190	statistically	_	
165-10	28191-28202	significant	_	
165-11	28202-28203	,	_	
165-12	28204-28211	further	_	
165-13	28212-28222	validation	_	
165-14	28223-28228	based	_	
165-15	28229-28231	on	_	
165-16	28232-28241	longitude	_	
165-17	28242-28250	subjects	_	
165-18	28251-28254	and	_	
165-19	28255-28261	larger	_	
165-20	28262-28269	dataset	_	
165-21	28270-28274	were	_	
165-22	28275-28279	also	_	
165-23	28280-28287	awaited	_	
165-24	28287-28288	.	_	

#Text=A limitation in this study is that all the chronic patients received medication, and even though we have regressed out the medication effect before conducting analysis, the differences between FESZ and chronic patients could still be influenced by the antipsychotic medication and/or symptom severity.
166-1	28289-28290	A	_	
166-2	28291-28301	limitation	_	
166-3	28302-28304	in	_	
166-4	28305-28309	this	_	
166-5	28310-28315	study	_	
166-6	28316-28318	is	_	
166-7	28319-28323	that	_	
166-8	28324-28327	all	_	
166-9	28328-28331	the	_	
166-10	28332-28339	chronic	_	
166-11	28340-28348	patients	_	
166-12	28349-28357	received	_	
166-13	28358-28368	medication	_	
166-14	28368-28369	,	_	
166-15	28370-28373	and	_	
166-16	28374-28378	even	_	
166-17	28379-28385	though	_	
166-18	28386-28388	we	_	
166-19	28389-28393	have	_	
166-20	28394-28403	regressed	_	
166-21	28404-28407	out	_	
166-22	28408-28411	the	_	
166-23	28412-28422	medication	_	
166-24	28423-28429	effect	_	
166-25	28430-28436	before	_	
166-26	28437-28447	conducting	_	
166-27	28448-28456	analysis	_	
166-28	28456-28457	,	_	
166-29	28458-28461	the	_	
166-30	28462-28473	differences	_	
166-31	28474-28481	between	_	
166-32	28482-28486	FESZ	_	
166-33	28487-28490	and	_	
166-34	28491-28498	chronic	_	
166-35	28499-28507	patients	_	
166-36	28508-28513	could	_	
166-37	28514-28519	still	_	
166-38	28520-28522	be	_	
166-39	28523-28533	influenced	_	
166-40	28534-28536	by	_	
166-41	28537-28540	the	_	
166-42	28541-28554	antipsychotic	_	
166-43	28555-28565	medication	_	
166-44	28566-28569	and	_	
166-45	28569-28570	/	_	
166-46	28570-28572	or	_	
166-47	28573-28580	symptom	_	
166-48	28581-28589	severity	_	
166-49	28589-28590	.	_	

#Text=A second limitation is that our sample size, especially FESZ, is relatively small and the absence of a replication dataset with all 3 modalities; however, these findings still provide important clues for the study of schizophrenia progression.
167-1	28591-28592	A	_	
167-2	28593-28599	second	_	
167-3	28600-28610	limitation	_	
167-4	28611-28613	is	_	
167-5	28614-28618	that	_	
167-6	28619-28622	our	_	
167-7	28623-28629	sample	_	
167-8	28630-28634	size	_	
167-9	28634-28635	,	_	
167-10	28636-28646	especially	_	
167-11	28647-28651	FESZ	_	
167-12	28651-28652	,	_	
167-13	28653-28655	is	_	
167-14	28656-28666	relatively	_	
167-15	28667-28672	small	_	
167-16	28673-28676	and	_	
167-17	28677-28680	the	_	
167-18	28681-28688	absence	_	
167-19	28689-28691	of	_	
167-20	28692-28693	a	_	
167-21	28694-28705	replication	_	
167-22	28706-28713	dataset	_	
167-23	28714-28718	with	_	
167-24	28719-28722	all	_	
167-25	28723-28724	3	_	
167-26	28725-28735	modalities	_	
167-27	28735-28736	;	_	
167-28	28737-28744	however	_	
167-29	28744-28745	,	_	
167-30	28746-28751	these	_	
167-31	28752-28760	findings	_	
167-32	28761-28766	still	_	
167-33	28767-28774	provide	_	
167-34	28775-28784	important	_	
167-35	28785-28790	clues	_	
167-36	28791-28794	for	_	
167-37	28795-28798	the	_	
167-38	28799-28804	study	_	
167-39	28805-28807	of	_	
167-40	28808-28821	schizophrenia	_	
167-41	28822-28833	progression	_	
167-42	28833-28834	.	_	

#Text=Another limitation is that we preselected the risk SNPs based on the PGC's GWAS results rather than Chinese Han GWAS study.
168-1	28835-28842	Another	_	
168-2	28843-28853	limitation	_	
168-3	28854-28856	is	_	
168-4	28857-28861	that	_	
168-5	28862-28864	we	_	
168-6	28865-28876	preselected	_	
168-7	28877-28880	the	_	
168-8	28881-28885	risk	_	
168-9	28886-28890	SNPs	_	
168-10	28891-28896	based	_	
168-11	28897-28899	on	_	
168-12	28900-28903	the	_	
168-13	28904-28909	PGC's	_	
168-14	28910-28914	GWAS	_	
168-15	28915-28922	results	_	
168-16	28923-28929	rather	_	
168-17	28930-28934	than	_	
168-18	28935-28942	Chinese	_	
168-19	28943-28946	Han	_	
168-20	28947-28951	GWAS	_	
168-21	28952-28957	study	_	
168-22	28957-28958	.	_	

#Text=However, Li et al. has recently demonstrated that the top risk loci from PGC's GWAS are largely consistent between the two populations, which provide support for our preselecting SNPs from PGC and analyzing them on the Chinese Han dataset.
169-1	28959-28966	However	_	
169-2	28966-28967	,	_	
169-3	28968-28970	Li	_	
169-4	28971-28973	et	_	
169-5	28974-28976	al	_	
169-6	28976-28977	.	_	
169-7	28978-28981	has	_	
169-8	28982-28990	recently	_	
169-9	28991-29003	demonstrated	_	
169-10	29004-29008	that	_	
169-11	29009-29012	the	_	
169-12	29013-29016	top	_	
169-13	29017-29021	risk	_	
169-14	29022-29026	loci	_	
169-15	29027-29031	from	_	
169-16	29032-29037	PGC's	_	
169-17	29038-29042	GWAS	_	
169-18	29043-29046	are	_	
169-19	29047-29054	largely	_	
169-20	29055-29065	consistent	_	
169-21	29066-29073	between	_	
169-22	29074-29077	the	_	
169-23	29078-29081	two	_	
169-24	29082-29093	populations	_	
169-25	29093-29094	,	_	
169-26	29095-29100	which	_	
169-27	29101-29108	provide	_	
169-28	29109-29116	support	_	
169-29	29117-29120	for	_	
169-30	29121-29124	our	_	
169-31	29125-29137	preselecting	_	
169-32	29138-29142	SNPs	_	
169-33	29143-29147	from	_	
169-34	29148-29151	PGC	_	
169-35	29152-29155	and	_	
169-36	29156-29165	analyzing	_	
169-37	29166-29170	them	_	
169-38	29171-29173	on	_	
169-39	29174-29177	the	_	
169-40	29178-29185	Chinese	_	
169-41	29186-29189	Han	_	
169-42	29190-29197	dataset	_	
169-43	29197-29198	.	_	

#Text=Future work should validate the results using Chinese GWAS results when the summary data of the Chinese GWAS study is available to the public.
170-1	29199-29205	Future	_	
170-2	29206-29210	work	_	
170-3	29211-29217	should	_	
170-4	29218-29226	validate	_	
170-5	29227-29230	the	_	
170-6	29231-29238	results	_	
170-7	29239-29244	using	_	
170-8	29245-29252	Chinese	_	
170-9	29253-29257	GWAS	_	
170-10	29258-29265	results	_	
170-11	29266-29270	when	_	
170-12	29271-29274	the	_	
170-13	29275-29282	summary	_	
170-14	29283-29287	data	_	
170-15	29288-29290	of	_	
170-16	29291-29294	the	_	
170-17	29295-29302	Chinese	_	
170-18	29303-29307	GWAS	_	
170-19	29308-29313	study	_	
170-20	29314-29316	is	_	
170-21	29317-29326	available	_	
170-22	29327-29329	to	_	
170-23	29330-29333	the	_	
170-24	29334-29340	public	_	
170-25	29340-29341	.	_	

#Text=Conclusions
#Text=To the best of our knowledge, this study is the first attempt to evaluate the associations between the SNP-FC-GM patterns in schizophrenia and compare the sensitivity to DOI and disease stages for imaging modalities.
171-1	29342-29353	Conclusions	_	
171-2	29354-29356	To	_	
171-3	29357-29360	the	_	
171-4	29361-29365	best	_	
171-5	29366-29368	of	_	
171-6	29369-29372	our	_	
171-7	29373-29382	knowledge	_	
171-8	29382-29383	,	_	
171-9	29384-29388	this	_	
171-10	29389-29394	study	_	
171-11	29395-29397	is	_	
171-12	29398-29401	the	_	
171-13	29402-29407	first	_	
171-14	29408-29415	attempt	_	
171-15	29416-29418	to	_	
171-16	29419-29427	evaluate	_	
171-17	29428-29431	the	_	
171-18	29432-29444	associations	_	
171-19	29445-29452	between	_	
171-20	29453-29456	the	_	
171-21	29457-29466	SNP-FC-GM	_	
171-22	29467-29475	patterns	_	
171-23	29476-29478	in	_	
171-24	29479-29492	schizophrenia	_	
171-25	29493-29496	and	_	
171-26	29497-29504	compare	_	
171-27	29505-29508	the	_	
171-28	29509-29520	sensitivity	_	
171-29	29521-29523	to	_	
171-30	29524-29527	DOI	_	
171-31	29528-29531	and	_	
171-32	29532-29539	disease	_	
171-33	29540-29546	stages	_	
171-34	29547-29550	for	_	
171-35	29551-29558	imaging	_	
171-36	29559-29569	modalities	_	
171-37	29569-29570	.	_	

#Text=Results suggested that: 1) GM volume impairments and FC abnormalities in hippocampus, temporal gyrus, parietal and cerebellum are revealed in schizophrenia, which were associated with genetic factors e.g., SATB2, GABBR2, PDE4B, CACNA1C etc. 2) GM and FC showed evidence of greater deficits at later disease stages (HC > FESZ>CSZ), while SNP indicated a non-gradual variation trend with un-significant group difference observed between FESZ and CSZ; 3) Group difference between HC and FESZ of FC was more obvious than GM, and FC presented a stronger negative correlation with DOI than GM.
172-1	29571-29578	Results	_	
172-2	29579-29588	suggested	_	
172-3	29589-29593	that	_	
172-4	29593-29594	:	_	
172-5	29595-29596	1	_	
172-6	29596-29597	)	_	
172-7	29598-29600	GM	_	
172-8	29601-29607	volume	_	
172-9	29608-29619	impairments	_	
172-10	29620-29623	and	_	
172-11	29624-29626	FC	_	
172-12	29627-29640	abnormalities	_	
172-13	29641-29643	in	_	
172-14	29644-29655	hippocampus	_	
172-15	29655-29656	,	_	
172-16	29657-29665	temporal	_	
172-17	29666-29671	gyrus	_	
172-18	29671-29672	,	_	
172-19	29673-29681	parietal	_	
172-20	29682-29685	and	_	
172-21	29686-29696	cerebellum	_	
172-22	29697-29700	are	_	
172-23	29701-29709	revealed	_	
172-24	29710-29712	in	_	
172-25	29713-29726	schizophrenia	_	
172-26	29726-29727	,	_	
172-27	29728-29733	which	_	
172-28	29734-29738	were	_	
172-29	29739-29749	associated	_	
172-30	29750-29754	with	_	
172-31	29755-29762	genetic	_	
172-32	29763-29770	factors	_	
172-33	29771-29774	e.g	_	
172-34	29774-29775	.	_	
172-35	29775-29776	,	_	
172-36	29777-29782	SATB2	_	
172-37	29782-29783	,	_	
172-38	29784-29790	GABBR2	_	
172-39	29790-29791	,	_	
172-40	29792-29797	PDE4B	_	
172-41	29797-29798	,	_	
172-42	29799-29806	CACNA1C	_	
172-43	29807-29810	etc	_	
172-44	29810-29811	.	_	
172-45	29812-29813	2	_	
172-46	29813-29814	)	_	
172-47	29815-29817	GM	_	
172-48	29818-29821	and	_	
172-49	29822-29824	FC	_	
172-50	29825-29831	showed	_	
172-51	29832-29840	evidence	_	
172-52	29841-29843	of	_	
172-53	29844-29851	greater	_	
172-54	29852-29860	deficits	_	
172-55	29861-29863	at	_	
172-56	29864-29869	later	_	
172-57	29870-29877	disease	_	
172-58	29878-29884	stages	_	
172-59	29885-29886	(	_	
172-60	29886-29888	HC	_	
172-61	29888-29889	 	_	
172-62	29889-29890	>	_	
172-63	29890-29891	 	_	
172-64	29891-29895	FESZ	_	
172-65	29895-29896	>	_	
172-66	29896-29899	CSZ	_	
172-67	29899-29900	)	_	
172-68	29900-29901	,	_	
172-69	29902-29907	while	_	
172-70	29908-29911	SNP	_	
172-71	29912-29921	indicated	_	
172-72	29922-29923	a	_	
172-73	29924-29935	non-gradual	_	
172-74	29936-29945	variation	_	
172-75	29946-29951	trend	_	
172-76	29952-29956	with	_	
172-77	29957-29971	un-significant	_	
172-78	29972-29977	group	_	
172-79	29978-29988	difference	_	
172-80	29989-29997	observed	_	
172-81	29998-30005	between	_	
172-82	30006-30010	FESZ	_	
172-83	30011-30014	and	_	
172-84	30015-30018	CSZ	_	
172-85	30018-30019	;	_	
172-86	30020-30021	3	_	
172-87	30021-30022	)	_	
172-88	30023-30028	Group	_	
172-89	30029-30039	difference	_	
172-90	30040-30047	between	_	
172-91	30048-30050	HC	_	
172-92	30051-30054	and	_	
172-93	30055-30059	FESZ	_	
172-94	30060-30062	of	_	
172-95	30063-30065	FC	_	
172-96	30066-30069	was	_	
172-97	30070-30074	more	_	
172-98	30075-30082	obvious	_	
172-99	30083-30087	than	_	
172-100	30088-30090	GM	_	
172-101	30090-30091	,	_	
172-102	30092-30095	and	_	
172-103	30096-30098	FC	_	
172-104	30099-30108	presented	_	
172-105	30109-30110	a	_	
172-106	30111-30119	stronger	_	
172-107	30120-30128	negative	_	
172-108	30129-30140	correlation	_	
172-109	30141-30145	with	_	
172-110	30146-30149	DOI	_	
172-111	30150-30154	than	_	
172-112	30155-30157	GM	_	
172-113	30157-30158	.	_	

#Text=Collectively, these results deep our understandings of impaired SNP-FC-GM correlation towards schizophrenia and provide important clues regarding the impact of mental illness at various disease stages.
173-1	30159-30171	Collectively	_	
173-2	30171-30172	,	_	
173-3	30173-30178	these	_	
173-4	30179-30186	results	_	
173-5	30187-30191	deep	_	
173-6	30192-30195	our	_	
173-7	30196-30210	understandings	_	
173-8	30211-30213	of	_	
173-9	30214-30222	impaired	_	
173-10	30223-30232	SNP-FC-GM	_	
173-11	30233-30244	correlation	_	
173-12	30245-30252	towards	_	
173-13	30253-30266	schizophrenia	_	
173-14	30267-30270	and	_	
173-15	30271-30278	provide	_	
173-16	30279-30288	important	_	
173-17	30289-30294	clues	_	
173-18	30295-30304	regarding	_	
173-19	30305-30308	the	_	
173-20	30309-30315	impact	_	
173-21	30316-30318	of	_	
173-22	30319-30325	mental	_	
173-23	30326-30333	illness	_	
173-24	30334-30336	at	_	
173-25	30337-30344	various	_	
173-26	30345-30352	disease	_	
173-27	30353-30359	stages	_	
173-28	30359-30360	.	_	

#Text=Fundings
#Text=This work was supported by the  (No. 61773380, 81871081), the  (No.
174-1	30361-30369	Fundings	_	
174-2	30370-30374	This	_	
174-3	30375-30379	work	_	
174-4	30380-30383	was	_	
174-5	30384-30393	supported	_	
174-6	30394-30396	by	_	
174-7	30397-30400	the	_	
174-8	30402-30403	(	_	
174-9	30403-30405	No	_	
174-10	30405-30406	.	_	
174-11	30407-30415	61773380	_	
174-12	30415-30416	,	_	
174-13	30417-30425	81871081	_	
174-14	30425-30426	)	_	
174-15	30426-30427	,	_	
174-16	30428-30431	the	_	
174-17	30433-30434	(	_	
174-18	30434-30436	No	_	
174-19	30436-30437	.	_	

#Text=XDB32040100), and  (No.
175-1	30438-30449	XDB32040100	_	
175-2	30449-30450	)	_	
175-3	30450-30451	,	_	
175-4	30452-30455	and	_	
175-5	30457-30458	(	_	
175-6	30458-30460	No	_	
175-7	30460-30461	.	_	

#Text=Z181100001518005), the  (BE2016630),  (2017YFC0112000), and  grants (R56MH117107, R01EB005846, P20GM103472, R01REB020407).
176-1	30462-30478	Z181100001518005	_	
176-2	30478-30479	)	_	
176-3	30479-30480	,	_	
176-4	30481-30484	the	_	
176-5	30486-30487	(	_	
176-6	30487-30496	BE2016630	_	
176-7	30496-30497	)	_	
176-8	30497-30498	,	_	
176-9	30500-30501	(	_	
176-10	30501-30515	2017YFC0112000	_	
176-11	30515-30516	)	_	
176-12	30516-30517	,	_	
176-13	30518-30521	and	_	
176-14	30523-30529	grants	_	
176-15	30530-30531	(	_	
176-16	30531-30542	R56MH117107	_	
176-17	30542-30543	,	_	
176-18	30544-30555	R01EB005846	_	
176-19	30555-30556	,	_	
176-20	30557-30568	P20GM103472	_	
176-21	30568-30569	,	_	
176-22	30570-30582	R01REB020407	_	
176-23	30582-30583	)	_	
176-24	30583-30584	.	_	

#Text=Author contribution
#Text=JS and NL designed the research; NL conducted the analyses; NL and JS wrote the paper.
177-1	30585-30591	Author	_	
177-2	30592-30604	contribution	_	
177-3	30605-30607	JS	_	
177-4	30608-30611	and	_	
177-5	30612-30614	NL	_	
177-6	30615-30623	designed	_	
177-7	30624-30627	the	_	
177-8	30628-30636	research	_	
177-9	30636-30637	;	_	
177-10	30638-30640	NL	_	
177-11	30641-30650	conducted	_	
177-12	30651-30654	the	_	
177-13	30655-30663	analyses	_	
177-14	30663-30664	;	_	
177-15	30665-30667	NL	_	
177-16	30668-30671	and	_	
177-17	30672-30674	JS	_	
177-18	30675-30680	wrote	_	
177-19	30681-30684	the	_	
177-20	30685-30690	paper	_	
177-21	30690-30691	.	_	

#Text=LT and FZ recruited and collected the data.
178-1	30692-30694	LT	_	
178-2	30695-30698	and	_	
178-3	30699-30701	FZ	_	
178-4	30702-30711	recruited	_	
178-5	30712-30715	and	_	
178-6	30716-30725	collected	_	
178-7	30726-30729	the	_	
178-8	30730-30734	data	_	
178-9	30734-30735	.	_	

#Text=The remaining authors contributed to paper revision and discussion.
179-1	30736-30739	The	_	
179-2	30740-30749	remaining	_	
179-3	30750-30757	authors	_	
179-4	30758-30769	contributed	_	
179-5	30770-30772	to	_	
179-6	30773-30778	paper	_	
179-7	30779-30787	revision	_	
179-8	30788-30791	and	_	
179-9	30792-30802	discussion	_	
179-10	30802-30803	.	_	

#Text=Declarations of interests
#Text=The authors report no biomedical financial interests or potential conflicts of interest.
180-1	30804-30816	Declarations	_	
180-2	30817-30819	of	_	
180-3	30820-30829	interests	_	
180-4	30830-30833	The	_	
180-5	30834-30841	authors	_	
180-6	30842-30848	report	_	
180-7	30849-30851	no	_	
180-8	30852-30862	biomedical	_	
180-9	30863-30872	financial	_	
180-10	30873-30882	interests	_	
180-11	30883-30885	or	_	
180-12	30886-30895	potential	_	
180-13	30896-30905	conflicts	_	
180-14	30906-30908	of	_	
180-15	30909-30917	interest	_	
180-16	30917-30918	.	_	

#Text=Compliance with ethical standards
#Text=All subjects provided written informed consent under institutional board approval.
181-1	30919-30929	Compliance	_	
181-2	30930-30934	with	_	
181-3	30935-30942	ethical	_	
181-4	30943-30952	standards	_	
181-5	30953-30956	All	_	
181-6	30957-30965	subjects	_	
181-7	30966-30974	provided	_	
181-8	30975-30982	written	_	
181-9	30983-30991	informed	_	
181-10	30992-30999	consent	_	
181-11	31000-31005	under	_	
181-12	31006-31019	institutional	_	
181-13	31020-31025	board	_	
181-14	31026-31034	approval	_	
181-15	31034-31035	.	_	

#Text=All procedures involving human participants performed in this study were in accordance with the ethical standards of the institutional or national research committee and Helsinki declaration.
182-1	31036-31039	All	_	
182-2	31040-31050	procedures	_	
182-3	31051-31060	involving	_	
182-4	31061-31066	human	_	
182-5	31067-31079	participants	_	
182-6	31080-31089	performed	_	
182-7	31090-31092	in	_	
182-8	31093-31097	this	_	
182-9	31098-31103	study	_	
182-10	31104-31108	were	_	
182-11	31109-31111	in	_	
182-12	31112-31122	accordance	_	
182-13	31123-31127	with	_	
182-14	31128-31131	the	_	
182-15	31132-31139	ethical	_	
182-16	31140-31149	standards	_	
182-17	31150-31152	of	_	
182-18	31153-31156	the	_	
182-19	31157-31170	institutional	_	
182-20	31171-31173	or	_	
182-21	31174-31182	national	_	
182-22	31183-31191	research	_	
182-23	31192-31201	committee	_	
182-24	31202-31205	and	_	
182-25	31206-31214	Helsinki	_	
182-26	31215-31226	declaration	_	
182-27	31226-31227	.	_	

#Text=References
#Text=Altered cerebellar-cerebral functional connectivity in geriatric depression
#Text=Data quality control in genetic case-control association studies
#Text=The role of the cerebellum in schizophrenia
#Text=Longitudinal loss of gray matter volume in patients with first-episode schizophrenia: DARTEL automated analysis and ROI validation
#Text=Multimodal fusion of brain imaging data: a key to finding the missing link(s) in complex mental illness
#Text=A method for making group inferences from functional MRI data using independent component analysis
#Text=Brain anatomical abnormalities in high-risk individuals, first-episode, and chronic schizophrenia: an activation likelihood estimation meta-analysis of illness progression
#Text=Multifaceted genomic risk for brain function in schizophrenia
#Text=Shared genetic risk of schizophrenia and gray matter reduction in 6p22.1
#Text=A systematic review of the long-term outcome of early onset schizophrenia
#Text=Schizophrenia and anteroventral thalamic nucleus: selective decrease of parvalbumin-immunoreactive thalamocortical projection neurons
#Text=Genetic evidence for role of integration of fast and slow neurotransmission in schizophrenia
#Text=Artifact removal in the context of group ICA: A comparison of single-subject and group approaches
#Text=Dynamic functional connectivity impairments in early schizophrenia and clinical high-risk for psychosis
#Text=Subcortical structures and cognitive dysfunction in first episode schizophrenia
#Text=PDE4B polymorphisms and decreased PDE4B expression are associated with schizophrenia
#Text=Protein palmitoylation in neuronal development and synaptic plasticity
#Text=Meta-analysis of gray matter anomalies in schizophrenia: application of anatomic likelihood estimation and network analysis
#Text=The bipolar disorder risk allele at CACNA1C also confers risk of recurrent major depression and of schizophrenia
#Text=Hippocampal neurons in schizophrenia
#Text=What happens after the first episode?
183-1	31228-31238	References	_	
183-2	31239-31246	Altered	_	
183-3	31247-31266	cerebellar-cerebral	_	
183-4	31267-31277	functional	_	
183-5	31278-31290	connectivity	_	
183-6	31291-31293	in	_	
183-7	31294-31303	geriatric	_	
183-8	31304-31314	depression	_	
183-9	31315-31319	Data	_	
183-10	31320-31327	quality	_	
183-11	31328-31335	control	_	
183-12	31336-31338	in	_	
183-13	31339-31346	genetic	_	
183-14	31347-31359	case-control	_	
183-15	31360-31371	association	_	
183-16	31372-31379	studies	_	
183-17	31380-31383	The	_	
183-18	31384-31388	role	_	
183-19	31389-31391	of	_	
183-20	31392-31395	the	_	
183-21	31396-31406	cerebellum	_	
183-22	31407-31409	in	_	
183-23	31410-31423	schizophrenia	_	
183-24	31424-31436	Longitudinal	_	
183-25	31437-31441	loss	_	
183-26	31442-31444	of	_	
183-27	31445-31449	gray	_	
183-28	31450-31456	matter	_	
183-29	31457-31463	volume	_	
183-30	31464-31466	in	_	
183-31	31467-31475	patients	_	
183-32	31476-31480	with	_	
183-33	31481-31494	first-episode	_	
183-34	31495-31508	schizophrenia	_	
183-35	31508-31509	:	_	
183-36	31510-31516	DARTEL	_	
183-37	31517-31526	automated	_	
183-38	31527-31535	analysis	_	
183-39	31536-31539	and	_	
183-40	31540-31543	ROI	_	
183-41	31544-31554	validation	_	
183-42	31555-31565	Multimodal	_	
183-43	31566-31572	fusion	_	
183-44	31573-31575	of	_	
183-45	31576-31581	brain	_	
183-46	31582-31589	imaging	_	
183-47	31590-31594	data	_	
183-48	31594-31595	:	_	
183-49	31596-31597	a	_	
183-50	31598-31601	key	_	
183-51	31602-31604	to	_	
183-52	31605-31612	finding	_	
183-53	31613-31616	the	_	
183-54	31617-31624	missing	_	
183-55	31625-31629	link	_	
183-56	31629-31630	(	_	
183-57	31630-31631	s	_	
183-58	31631-31632	)	_	
183-59	31633-31635	in	_	
183-60	31636-31643	complex	_	
183-61	31644-31650	mental	_	
183-62	31651-31658	illness	_	
183-63	31659-31660	A	_	
183-64	31661-31667	method	_	
183-65	31668-31671	for	_	
183-66	31672-31678	making	_	
183-67	31679-31684	group	_	
183-68	31685-31695	inferences	_	
183-69	31696-31700	from	_	
183-70	31701-31711	functional	_	
183-71	31712-31715	MRI	_	
183-72	31716-31720	data	_	
183-73	31721-31726	using	_	
183-74	31727-31738	independent	_	
183-75	31739-31748	component	_	
183-76	31749-31757	analysis	_	
183-77	31758-31763	Brain	_	
183-78	31764-31774	anatomical	_	
183-79	31775-31788	abnormalities	_	
183-80	31789-31791	in	_	
183-81	31792-31801	high-risk	_	
183-82	31802-31813	individuals	_	
183-83	31813-31814	,	_	
183-84	31815-31828	first-episode	_	
183-85	31828-31829	,	_	
183-86	31830-31833	and	_	
183-87	31834-31841	chronic	_	
183-88	31842-31855	schizophrenia	_	
183-89	31855-31856	:	_	
183-90	31857-31859	an	_	
183-91	31860-31870	activation	_	
183-92	31871-31881	likelihood	_	
183-93	31882-31892	estimation	_	
183-94	31893-31906	meta-analysis	_	
183-95	31907-31909	of	_	
183-96	31910-31917	illness	_	
183-97	31918-31929	progression	_	
183-98	31930-31942	Multifaceted	_	
183-99	31943-31950	genomic	_	
183-100	31951-31955	risk	_	
183-101	31956-31959	for	_	
183-102	31960-31965	brain	_	
183-103	31966-31974	function	_	
183-104	31975-31977	in	_	
183-105	31978-31991	schizophrenia	_	
183-106	31992-31998	Shared	_	
183-107	31999-32006	genetic	_	
183-108	32007-32011	risk	_	
183-109	32012-32014	of	_	
183-110	32015-32028	schizophrenia	_	
183-111	32029-32032	and	_	
183-112	32033-32037	gray	_	
183-113	32038-32044	matter	_	
183-114	32045-32054	reduction	_	
183-115	32055-32057	in	_	
183-116	32058-32064	6p22.1	_	
183-117	32065-32066	A	_	
183-118	32067-32077	systematic	_	
183-119	32078-32084	review	_	
183-120	32085-32087	of	_	
183-121	32088-32091	the	_	
183-122	32092-32101	long-term	_	
183-123	32102-32109	outcome	_	
183-124	32110-32112	of	_	
183-125	32113-32118	early	_	
183-126	32119-32124	onset	_	
183-127	32125-32138	schizophrenia	_	
183-128	32139-32152	Schizophrenia	_	
183-129	32153-32156	and	_	
183-130	32157-32170	anteroventral	_	
183-131	32171-32179	thalamic	_	
183-132	32180-32187	nucleus	_	
183-133	32187-32188	:	_	
183-134	32189-32198	selective	_	
183-135	32199-32207	decrease	_	
183-136	32208-32210	of	_	
183-137	32211-32237	parvalbumin-immunoreactive	_	
183-138	32238-32253	thalamocortical	_	
183-139	32254-32264	projection	_	
183-140	32265-32272	neurons	_	
183-141	32273-32280	Genetic	_	
183-142	32281-32289	evidence	_	
183-143	32290-32293	for	_	
183-144	32294-32298	role	_	
183-145	32299-32301	of	_	
183-146	32302-32313	integration	_	
183-147	32314-32316	of	_	
183-148	32317-32321	fast	_	
183-149	32322-32325	and	_	
183-150	32326-32330	slow	_	
183-151	32331-32348	neurotransmission	_	
183-152	32349-32351	in	_	
183-153	32352-32365	schizophrenia	_	
183-154	32366-32374	Artifact	_	
183-155	32375-32382	removal	_	
183-156	32383-32385	in	_	
183-157	32386-32389	the	_	
183-158	32390-32397	context	_	
183-159	32398-32400	of	_	
183-160	32401-32406	group	_	
183-161	32407-32410	ICA	_	
183-162	32410-32411	:	_	
183-163	32412-32413	A	_	
183-164	32414-32424	comparison	_	
183-165	32425-32427	of	_	
183-166	32428-32442	single-subject	_	
183-167	32443-32446	and	_	
183-168	32447-32452	group	_	
183-169	32453-32463	approaches	_	
183-170	32464-32471	Dynamic	_	
183-171	32472-32482	functional	_	
183-172	32483-32495	connectivity	_	
183-173	32496-32507	impairments	_	
183-174	32508-32510	in	_	
183-175	32511-32516	early	_	
183-176	32517-32530	schizophrenia	_	
183-177	32531-32534	and	_	
183-178	32535-32543	clinical	_	
183-179	32544-32553	high-risk	_	
183-180	32554-32557	for	_	
183-181	32558-32567	psychosis	_	
183-182	32568-32579	Subcortical	_	
183-183	32580-32590	structures	_	
183-184	32591-32594	and	_	
183-185	32595-32604	cognitive	_	
183-186	32605-32616	dysfunction	_	
183-187	32617-32619	in	_	
183-188	32620-32625	first	_	
183-189	32626-32633	episode	_	
183-190	32634-32647	schizophrenia	_	
183-191	32648-32653	PDE4B	_	
183-192	32654-32667	polymorphisms	_	
183-193	32668-32671	and	_	
183-194	32672-32681	decreased	_	
183-195	32682-32687	PDE4B	_	
183-196	32688-32698	expression	_	
183-197	32699-32702	are	_	
183-198	32703-32713	associated	_	
183-199	32714-32718	with	_	
183-200	32719-32732	schizophrenia	_	
183-201	32733-32740	Protein	_	
183-202	32741-32755	palmitoylation	_	
183-203	32756-32758	in	_	
183-204	32759-32767	neuronal	_	
183-205	32768-32779	development	_	
183-206	32780-32783	and	_	
183-207	32784-32792	synaptic	_	
183-208	32793-32803	plasticity	_	
183-209	32804-32817	Meta-analysis	_	
183-210	32818-32820	of	_	
183-211	32821-32825	gray	_	
183-212	32826-32832	matter	_	
183-213	32833-32842	anomalies	_	
183-214	32843-32845	in	_	
183-215	32846-32859	schizophrenia	_	
183-216	32859-32860	:	_	
183-217	32861-32872	application	_	
183-218	32873-32875	of	_	
183-219	32876-32884	anatomic	_	
183-220	32885-32895	likelihood	_	
183-221	32896-32906	estimation	_	
183-222	32907-32910	and	_	
183-223	32911-32918	network	_	
183-224	32919-32927	analysis	_	
183-225	32928-32931	The	_	
183-226	32932-32939	bipolar	_	
183-227	32940-32948	disorder	_	
183-228	32949-32953	risk	_	
183-229	32954-32960	allele	_	
183-230	32961-32963	at	_	
183-231	32964-32971	CACNA1C	_	
183-232	32972-32976	also	_	
183-233	32977-32984	confers	_	
183-234	32985-32989	risk	_	
183-235	32990-32992	of	_	
183-236	32993-33002	recurrent	_	
183-237	33003-33008	major	_	
183-238	33009-33019	depression	_	
183-239	33020-33023	and	_	
183-240	33024-33026	of	_	
183-241	33027-33040	schizophrenia	_	
183-242	33041-33052	Hippocampal	_	
183-243	33053-33060	neurons	_	
183-244	33061-33063	in	_	
183-245	33064-33077	schizophrenia	_	
183-246	33078-33082	What	_	
183-247	33083-33090	happens	_	
183-248	33091-33096	after	_	
183-249	33097-33100	the	_	
183-250	33101-33106	first	_	
183-251	33107-33114	episode	_	
183-252	33114-33115	?	_	

#Text=a review of progressive brain changes in chronically ill patients with schizophrenia
#Text=Satb2 determines miRNA expression and long-term memory in the adult central nervous system
#Text=Progressive reduction in gray matter in patients with schizophrenia assessed with MR imaging by using causal network analysis
#Text=Disintegration of sensorimotor brain networks in schizophrenia
#Text=Lack of evidence for regional brain volume or cortical thickness abnormalities in youths at clinical high risk for psychosis: findings from the longitudinal youth at risk study
#Text=Reduced frontotemporal functional connectivity in schizophrenia associated with auditory hallucinations
#Text=Estimating the number of independent components for functional magnetic resonance imaging data
#Text=Brain-wide analysis of functional connectivity in first-episode and chronic stages of schizophrenia
#Text=Genome-wide association analysis identifies 30 new susceptibility loci for schizophrenia
#Text=Intragenic duplication-a novel causative mechanism for SATB2-associated syndrome
#Text=A review of multivariate analyses in imaging genetics
#Text=Differentiating patterns of amygdala-frontal functional connectivity in schizophrenia and bipolar disorder
#Text=Linked 4-way multimodal brain differences in schizophrenia in a large chinese han population
#Text=A schizophrenia-related genetic-brain-cognition pathway revealed in a large Chinese population
#Text=
#Text=Anomalous asymmetry of fusiform and parahippocampal gyrus gray matter in schizophrenia: A postmortem study
#Text=Functional integration between the posterior hippocampus and prefrontal cortex is impaired in both first episode schizophrenia and the at risk mental state
#Text=Dysregulated maturation of the functional connectome in antipsychotic-naïve, first-episode patients with adolescent-onset schizophrenia
#Text=Predicting individualized clinical measures by a generalized prediction framework and multimodal fusion of MRI data
#Text=Regionally specific disturbance of dorsolateral prefrontal-hippocampal functional connectivity in schizophrenia
#Text=DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling
#Text=Analysis of complex brain disorders with gene expression microarrays: schizophrenia as a disease of the synapse
#Text=Mitochondria control functional CaV1.2 expression in smooth muscle cells of cerebral arteries
#Text=Anterior temporal lobes mediate semantic representation: Mimicking semantic dementia by using rTMS in normal participants
#Text=PLINK: a tool set for whole-genome association and population-based linkage analyses
#Text=Multimodal meta-analysis of structural and functional brain changes in first episode psychosis and the effects of antipsychotic medication
#Text=Sustained attention impairment correlates to gray matter decreases in first episode neuroleptic-naive schizophrenic patients
#Text=Biological insights from 108 schizophrenia-associated genetic loci
#Text=Systematic meta-review and quality assessment of the structural brain alterations in schizophrenia
#Text=A review of multivariate methods for multimodal fusion of brain imaging data
#Text=Combination of Resting State fMRI, DTI, and sMRI Data to Discriminate Schizophrenia by N-way MCCA + jICA
#Text=In search of multimodal neuroimaging biomarkers of cognitive deficits in schizophrenia
#Text=Multimodal neuromarkers in schizophrenia via cognition-guided MRI fusion
#Text=Regional changes in brain gray and white matter in patients with schizophrenia demonstrated with voxel-based analysis of MRI
#Text=Visual perceptual and working memory impairments in schizophrenia
#Text=Expression of GABA A α2-, β1-and ɛ-receptors are altered significantly in the lateral cerebellum of subjects with schizophrenia, major depression and bipolar disorder
#Text=Abnormal functional connectivity of brain network hubs associated with symptom severity in treatment-naive patients with obsessive–compulsive disorder: a resting-state functional MRI study
#Text=Patterns of regional gray matter loss at different stages of schizophrenia: a multisite, cross-sectional VBM study in first-episode and chronic illness
#Text=Whole brain resting state functional connectivity abnormalities in schizophrenia
#Text=A three-way parallel ICA approach to analyze links among genetics, brain structure and brain function
#Text=WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013
#Text=Meta-analysis of regional brain volumes in schizophrenia
#Text=Structural and functional brain abnormalities in drug-naive, first-episode, and chronic patients with schizophrenia: a multimodal MRI study
#Text=BRANT: A Versatile and Extendable Resting-State fMRI Toolkit
#Text=A prospective longitudinal volumetric MRI study of superior temporal gyrus gray matter and amygdala-hippocampal complex in chronic schizophrenia
#Text=Evidence for progressive brain abnormalities in early schizophrenia: a cross-sectional structural and functional connectivity study
#Text=Altered resting-state functional connectivity and anatomical connectivity of hippocampus in schizophrenia
#Text=Supplementary data
#Text=Supplementary data to this article can be found online at https://doi.org/10.1016/j.nicl.2019.101887.
184-1	33116-33117	a	_	
184-2	33118-33124	review	_	
184-3	33125-33127	of	_	
184-4	33128-33139	progressive	_	
184-5	33140-33145	brain	_	
184-6	33146-33153	changes	_	
184-7	33154-33156	in	_	
184-8	33157-33168	chronically	_	
184-9	33169-33172	ill	_	
184-10	33173-33181	patients	_	
184-11	33182-33186	with	_	
184-12	33187-33200	schizophrenia	_	
184-13	33201-33206	Satb2	_	
184-14	33207-33217	determines	_	
184-15	33218-33223	miRNA	_	
184-16	33224-33234	expression	_	
184-17	33235-33238	and	_	
184-18	33239-33248	long-term	_	
184-19	33249-33255	memory	_	
184-20	33256-33258	in	_	
184-21	33259-33262	the	_	
184-22	33263-33268	adult	_	
184-23	33269-33276	central	_	
184-24	33277-33284	nervous	_	
184-25	33285-33291	system	_	
184-26	33292-33303	Progressive	_	
184-27	33304-33313	reduction	_	
184-28	33314-33316	in	_	
184-29	33317-33321	gray	_	
184-30	33322-33328	matter	_	
184-31	33329-33331	in	_	
184-32	33332-33340	patients	_	
184-33	33341-33345	with	_	
184-34	33346-33359	schizophrenia	_	
184-35	33360-33368	assessed	_	
184-36	33369-33373	with	_	
184-37	33374-33376	MR	_	
184-38	33377-33384	imaging	_	
184-39	33385-33387	by	_	
184-40	33388-33393	using	_	
184-41	33394-33400	causal	_	
184-42	33401-33408	network	_	
184-43	33409-33417	analysis	_	
184-44	33418-33432	Disintegration	_	
184-45	33433-33435	of	_	
184-46	33436-33448	sensorimotor	_	
184-47	33449-33454	brain	_	
184-48	33455-33463	networks	_	
184-49	33464-33466	in	_	
184-50	33467-33480	schizophrenia	_	
184-51	33481-33485	Lack	_	
184-52	33486-33488	of	_	
184-53	33489-33497	evidence	_	
184-54	33498-33501	for	_	
184-55	33502-33510	regional	_	
184-56	33511-33516	brain	_	
184-57	33517-33523	volume	_	
184-58	33524-33526	or	_	
184-59	33527-33535	cortical	_	
184-60	33536-33545	thickness	_	
184-61	33546-33559	abnormalities	_	
184-62	33560-33562	in	_	
184-63	33563-33569	youths	_	
184-64	33570-33572	at	_	
184-65	33573-33581	clinical	_	
184-66	33582-33586	high	_	
184-67	33587-33591	risk	_	
184-68	33592-33595	for	_	
184-69	33596-33605	psychosis	_	
184-70	33605-33606	:	_	
184-71	33607-33615	findings	_	
184-72	33616-33620	from	_	
184-73	33621-33624	the	_	
184-74	33625-33637	longitudinal	_	
184-75	33638-33643	youth	_	
184-76	33644-33646	at	_	
184-77	33647-33651	risk	_	
184-78	33652-33657	study	_	
184-79	33658-33665	Reduced	_	
184-80	33666-33680	frontotemporal	_	
184-81	33681-33691	functional	_	
184-82	33692-33704	connectivity	_	
184-83	33705-33707	in	_	
184-84	33708-33721	schizophrenia	_	
184-85	33722-33732	associated	_	
184-86	33733-33737	with	_	
184-87	33738-33746	auditory	_	
184-88	33747-33761	hallucinations	_	
184-89	33762-33772	Estimating	_	
184-90	33773-33776	the	_	
184-91	33777-33783	number	_	
184-92	33784-33786	of	_	
184-93	33787-33798	independent	_	
184-94	33799-33809	components	_	
184-95	33810-33813	for	_	
184-96	33814-33824	functional	_	
184-97	33825-33833	magnetic	_	
184-98	33834-33843	resonance	_	
184-99	33844-33851	imaging	_	
184-100	33852-33856	data	_	
184-101	33857-33867	Brain-wide	_	
184-102	33868-33876	analysis	_	
184-103	33877-33879	of	_	
184-104	33880-33890	functional	_	
184-105	33891-33903	connectivity	_	
184-106	33904-33906	in	_	
184-107	33907-33920	first-episode	_	
184-108	33921-33924	and	_	
184-109	33925-33932	chronic	_	
184-110	33933-33939	stages	_	
184-111	33940-33942	of	_	
184-112	33943-33956	schizophrenia	_	
184-113	33957-33968	Genome-wide	_	
184-114	33969-33980	association	_	
184-115	33981-33989	analysis	_	
184-116	33990-34000	identifies	_	
184-117	34001-34003	30	_	
184-118	34004-34007	new	_	
184-119	34008-34022	susceptibility	_	
184-120	34023-34027	loci	_	
184-121	34028-34031	for	_	
184-122	34032-34045	schizophrenia	_	
184-123	34046-34056	Intragenic	_	
184-124	34057-34070	duplication-a	_	
184-125	34071-34076	novel	_	
184-126	34077-34086	causative	_	
184-127	34087-34096	mechanism	_	
184-128	34097-34100	for	_	
184-129	34101-34106	SATB2	_	
184-130	34106-34107	-	_	
184-131	34107-34117	associated	_	
184-132	34118-34126	syndrome	_	
184-133	34127-34128	A	_	
184-134	34129-34135	review	_	
184-135	34136-34138	of	_	
184-136	34139-34151	multivariate	_	
184-137	34152-34160	analyses	_	
184-138	34161-34163	in	_	
184-139	34164-34171	imaging	_	
184-140	34172-34180	genetics	_	
184-141	34181-34196	Differentiating	_	
184-142	34197-34205	patterns	_	
184-143	34206-34208	of	_	
184-144	34209-34225	amygdala-frontal	_	
184-145	34226-34236	functional	_	
184-146	34237-34249	connectivity	_	
184-147	34250-34252	in	_	
184-148	34253-34266	schizophrenia	_	
184-149	34267-34270	and	_	
184-150	34271-34278	bipolar	_	
184-151	34279-34287	disorder	_	
184-152	34288-34294	Linked	_	
184-153	34295-34296	4	_	
184-154	34296-34297	-	_	
184-155	34297-34300	way	_	
184-156	34301-34311	multimodal	_	
184-157	34312-34317	brain	_	
184-158	34318-34329	differences	_	
184-159	34330-34332	in	_	
184-160	34333-34346	schizophrenia	_	
184-161	34347-34349	in	_	
184-162	34350-34351	a	_	
184-163	34352-34357	large	_	
184-164	34358-34365	chinese	_	
184-165	34366-34369	han	_	
184-166	34370-34380	population	_	
184-167	34381-34382	A	_	
184-168	34383-34404	schizophrenia-related	_	
184-169	34405-34428	genetic-brain-cognition	_	
184-170	34429-34436	pathway	_	
184-171	34437-34445	revealed	_	
184-172	34446-34448	in	_	
184-173	34449-34450	a	_	
184-174	34451-34456	large	_	
184-175	34457-34464	Chinese	_	
184-176	34465-34475	population	_	
184-177	34477-34486	Anomalous	_	
184-178	34487-34496	asymmetry	_	
184-179	34497-34499	of	_	
184-180	34500-34508	fusiform	_	
184-181	34509-34512	and	_	
184-182	34513-34528	parahippocampal	_	
184-183	34529-34534	gyrus	_	
184-184	34535-34539	gray	_	
184-185	34540-34546	matter	_	
184-186	34547-34549	in	_	
184-187	34550-34563	schizophrenia	_	
184-188	34563-34564	:	_	
184-189	34565-34566	A	_	
184-190	34567-34577	postmortem	_	
184-191	34578-34583	study	_	
184-192	34584-34594	Functional	_	
184-193	34595-34606	integration	_	
184-194	34607-34614	between	_	
184-195	34615-34618	the	_	
184-196	34619-34628	posterior	_	
184-197	34629-34640	hippocampus	_	
184-198	34641-34644	and	_	
184-199	34645-34655	prefrontal	_	
184-200	34656-34662	cortex	_	
184-201	34663-34665	is	_	
184-202	34666-34674	impaired	_	
184-203	34675-34677	in	_	
184-204	34678-34682	both	_	
184-205	34683-34688	first	_	
184-206	34689-34696	episode	_	
184-207	34697-34710	schizophrenia	_	
184-208	34711-34714	and	_	
184-209	34715-34718	the	_	
184-210	34719-34721	at	_	
184-211	34722-34726	risk	_	
184-212	34727-34733	mental	_	
184-213	34734-34739	state	_	
184-214	34740-34752	Dysregulated	_	
184-215	34753-34763	maturation	_	
184-216	34764-34766	of	_	
184-217	34767-34770	the	_	
184-218	34771-34781	functional	_	
184-219	34782-34792	connectome	_	
184-220	34793-34795	in	_	
184-221	34796-34815	antipsychotic-naïve	_	
184-222	34815-34816	,	_	
184-223	34817-34830	first-episode	_	
184-224	34831-34839	patients	_	
184-225	34840-34844	with	_	
184-226	34845-34861	adolescent-onset	_	
184-227	34862-34875	schizophrenia	_	
184-228	34876-34886	Predicting	_	
184-229	34887-34901	individualized	_	
184-230	34902-34910	clinical	_	
184-231	34911-34919	measures	_	
184-232	34920-34922	by	_	
184-233	34923-34924	a	_	
184-234	34925-34936	generalized	_	
184-235	34937-34947	prediction	_	
184-236	34948-34957	framework	_	
184-237	34958-34961	and	_	
184-238	34962-34972	multimodal	_	
184-239	34973-34979	fusion	_	
184-240	34980-34982	of	_	
184-241	34983-34986	MRI	_	
184-242	34987-34991	data	_	
184-243	34992-35002	Regionally	_	
184-244	35003-35011	specific	_	
184-245	35012-35023	disturbance	_	
184-246	35024-35026	of	_	
184-247	35027-35039	dorsolateral	_	
184-248	35040-35062	prefrontal-hippocampal	_	
184-249	35063-35073	functional	_	
184-250	35074-35086	connectivity	_	
184-251	35087-35089	in	_	
184-252	35090-35103	schizophrenia	_	
184-253	35104-35109	DISC1	_	
184-254	35110-35113	and	_	
184-255	35114-35119	PDE4B	_	
184-256	35120-35123	are	_	
184-257	35124-35135	interacting	_	
184-258	35136-35143	genetic	_	
184-259	35144-35151	factors	_	
184-260	35152-35154	in	_	
184-261	35155-35168	schizophrenia	_	
184-262	35169-35173	that	_	
184-263	35174-35182	regulate	_	
184-264	35183-35187	cAMP	_	
184-265	35188-35197	signaling	_	
184-266	35198-35206	Analysis	_	
184-267	35207-35209	of	_	
184-268	35210-35217	complex	_	
184-269	35218-35223	brain	_	
184-270	35224-35233	disorders	_	
184-271	35234-35238	with	_	
184-272	35239-35243	gene	_	
184-273	35244-35254	expression	_	
184-274	35255-35266	microarrays	_	
184-275	35266-35267	:	_	
184-276	35268-35281	schizophrenia	_	
184-277	35282-35284	as	_	
184-278	35285-35286	a	_	
184-279	35287-35294	disease	_	
184-280	35295-35297	of	_	
184-281	35298-35301	the	_	
184-282	35302-35309	synapse	_	
184-283	35310-35322	Mitochondria	_	
184-284	35323-35330	control	_	
184-285	35331-35341	functional	_	
184-286	35342-35348	CaV1.2	_	
184-287	35349-35359	expression	_	
184-288	35360-35362	in	_	
184-289	35363-35369	smooth	_	
184-290	35370-35376	muscle	_	
184-291	35377-35382	cells	_	
184-292	35383-35385	of	_	
184-293	35386-35394	cerebral	_	
184-294	35395-35403	arteries	_	
184-295	35404-35412	Anterior	_	
184-296	35413-35421	temporal	_	
184-297	35422-35427	lobes	_	
184-298	35428-35435	mediate	_	
184-299	35436-35444	semantic	_	
184-300	35445-35459	representation	_	
184-301	35459-35460	:	_	
184-302	35461-35470	Mimicking	_	
184-303	35471-35479	semantic	_	
184-304	35480-35488	dementia	_	
184-305	35489-35491	by	_	
184-306	35492-35497	using	_	
184-307	35498-35502	rTMS	_	
184-308	35503-35505	in	_	
184-309	35506-35512	normal	_	
184-310	35513-35525	participants	_	
184-311	35526-35531	PLINK	_	
184-312	35531-35532	:	_	
184-313	35533-35534	a	_	
184-314	35535-35539	tool	_	
184-315	35540-35543	set	_	
184-316	35544-35547	for	_	
184-317	35548-35560	whole-genome	_	
184-318	35561-35572	association	_	
184-319	35573-35576	and	_	
184-320	35577-35593	population-based	_	
184-321	35594-35601	linkage	_	
184-322	35602-35610	analyses	_	
184-323	35611-35621	Multimodal	_	
184-324	35622-35635	meta-analysis	_	
184-325	35636-35638	of	_	
184-326	35639-35649	structural	_	
184-327	35650-35653	and	_	
184-328	35654-35664	functional	_	
184-329	35665-35670	brain	_	
184-330	35671-35678	changes	_	
184-331	35679-35681	in	_	
184-332	35682-35687	first	_	
184-333	35688-35695	episode	_	
184-334	35696-35705	psychosis	_	
184-335	35706-35709	and	_	
184-336	35710-35713	the	_	
184-337	35714-35721	effects	_	
184-338	35722-35724	of	_	
184-339	35725-35738	antipsychotic	_	
184-340	35739-35749	medication	_	
184-341	35750-35759	Sustained	_	
184-342	35760-35769	attention	_	
184-343	35770-35780	impairment	_	
184-344	35781-35791	correlates	_	
184-345	35792-35794	to	_	
184-346	35795-35799	gray	_	
184-347	35800-35806	matter	_	
184-348	35807-35816	decreases	_	
184-349	35817-35819	in	_	
184-350	35820-35825	first	_	
184-351	35826-35833	episode	_	
184-352	35834-35851	neuroleptic-naive	_	
184-353	35852-35865	schizophrenic	_	
184-354	35866-35874	patients	_	
184-355	35875-35885	Biological	_	
184-356	35886-35894	insights	_	
184-357	35895-35899	from	_	
184-358	35900-35903	108	_	
184-359	35904-35928	schizophrenia-associated	_	
184-360	35929-35936	genetic	_	
184-361	35937-35941	loci	_	
184-362	35942-35952	Systematic	_	
184-363	35953-35964	meta-review	_	
184-364	35965-35968	and	_	
184-365	35969-35976	quality	_	
184-366	35977-35987	assessment	_	
184-367	35988-35990	of	_	
184-368	35991-35994	the	_	
184-369	35995-36005	structural	_	
184-370	36006-36011	brain	_	
184-371	36012-36023	alterations	_	
184-372	36024-36026	in	_	
184-373	36027-36040	schizophrenia	_	
184-374	36041-36042	A	_	
184-375	36043-36049	review	_	
184-376	36050-36052	of	_	
184-377	36053-36065	multivariate	_	
184-378	36066-36073	methods	_	
184-379	36074-36077	for	_	
184-380	36078-36088	multimodal	_	
184-381	36089-36095	fusion	_	
184-382	36096-36098	of	_	
184-383	36099-36104	brain	_	
184-384	36105-36112	imaging	_	
184-385	36113-36117	data	_	
184-386	36118-36129	Combination	_	
184-387	36130-36132	of	_	
184-388	36133-36140	Resting	_	
184-389	36141-36146	State	_	
184-390	36147-36151	fMRI	_	
184-391	36151-36152	,	_	
184-392	36153-36156	DTI	_	
184-393	36156-36157	,	_	
184-394	36158-36161	and	_	
184-395	36162-36166	sMRI	_	
184-396	36167-36171	Data	_	
184-397	36172-36174	to	_	
184-398	36175-36187	Discriminate	_	
184-399	36188-36201	Schizophrenia	_	
184-400	36202-36204	by	_	
184-401	36205-36210	N-way	_	
184-402	36211-36215	MCCA	_	
184-403	36216-36217	+	_	
184-404	36218-36222	jICA	_	
184-405	36223-36225	In	_	
184-406	36226-36232	search	_	
184-407	36233-36235	of	_	
184-408	36236-36246	multimodal	_	
184-409	36247-36259	neuroimaging	_	
184-410	36260-36270	biomarkers	_	
184-411	36271-36273	of	_	
184-412	36274-36283	cognitive	_	
184-413	36284-36292	deficits	_	
184-414	36293-36295	in	_	
184-415	36296-36309	schizophrenia	_	
184-416	36310-36320	Multimodal	_	
184-417	36321-36333	neuromarkers	_	
184-418	36334-36336	in	_	
184-419	36337-36350	schizophrenia	_	
184-420	36351-36354	via	_	
184-421	36355-36371	cognition-guided	_	
184-422	36372-36375	MRI	_	
184-423	36376-36382	fusion	_	
184-424	36383-36391	Regional	_	
184-425	36392-36399	changes	_	
184-426	36400-36402	in	_	
184-427	36403-36408	brain	_	
184-428	36409-36413	gray	_	
184-429	36414-36417	and	_	
184-430	36418-36423	white	_	
184-431	36424-36430	matter	_	
184-432	36431-36433	in	_	
184-433	36434-36442	patients	_	
184-434	36443-36447	with	_	
184-435	36448-36461	schizophrenia	_	
184-436	36462-36474	demonstrated	_	
184-437	36475-36479	with	_	
184-438	36480-36491	voxel-based	_	
184-439	36492-36500	analysis	_	
184-440	36501-36503	of	_	
184-441	36504-36507	MRI	_	
184-442	36508-36514	Visual	_	
184-443	36515-36525	perceptual	_	
184-444	36526-36529	and	_	
184-445	36530-36537	working	_	
184-446	36538-36544	memory	_	
184-447	36545-36556	impairments	_	
184-448	36557-36559	in	_	
184-449	36560-36573	schizophrenia	_	
184-450	36574-36584	Expression	_	
184-451	36585-36587	of	_	
184-452	36588-36592	GABA	_	
184-453	36593-36594	A	_	
184-454	36595-36597	α2	_	
184-455	36597-36598	-	_	
184-456	36598-36599	,	_	
184-457	36600-36602	β1	_	
184-458	36602-36603	-	_	
184-459	36603-36606	and	_	
184-460	36607-36618	ɛ-receptors	_	
184-461	36619-36622	are	_	
184-462	36623-36630	altered	_	
184-463	36631-36644	significantly	_	
184-464	36645-36647	in	_	
184-465	36648-36651	the	_	
184-466	36652-36659	lateral	_	
184-467	36660-36670	cerebellum	_	
184-468	36671-36673	of	_	
184-469	36674-36682	subjects	_	
184-470	36683-36687	with	_	
184-471	36688-36701	schizophrenia	_	
184-472	36701-36702	,	_	
184-473	36703-36708	major	_	
184-474	36709-36719	depression	_	
184-475	36720-36723	and	_	
184-476	36724-36731	bipolar	_	
184-477	36732-36740	disorder	_	
184-478	36741-36749	Abnormal	_	
184-479	36750-36760	functional	_	
184-480	36761-36773	connectivity	_	
184-481	36774-36776	of	_	
184-482	36777-36782	brain	_	
184-483	36783-36790	network	_	
184-484	36791-36795	hubs	_	
184-485	36796-36806	associated	_	
184-486	36807-36811	with	_	
184-487	36812-36819	symptom	_	
184-488	36820-36828	severity	_	
184-489	36829-36831	in	_	
184-490	36832-36847	treatment-naive	_	
184-491	36848-36856	patients	_	
184-492	36857-36861	with	_	
184-493	36862-36882	obsessive–compulsive	_	
184-494	36883-36891	disorder	_	
184-495	36891-36892	:	_	
184-496	36893-36894	a	_	
184-497	36895-36908	resting-state	_	
184-498	36909-36919	functional	_	
184-499	36920-36923	MRI	_	
184-500	36924-36929	study	_	
184-501	36930-36938	Patterns	_	
184-502	36939-36941	of	_	
184-503	36942-36950	regional	_	
184-504	36951-36955	gray	_	
184-505	36956-36962	matter	_	
184-506	36963-36967	loss	_	
184-507	36968-36970	at	_	
184-508	36971-36980	different	_	
184-509	36981-36987	stages	_	
184-510	36988-36990	of	_	
184-511	36991-37004	schizophrenia	_	
184-512	37004-37005	:	_	
184-513	37006-37007	a	_	
184-514	37008-37017	multisite	_	
184-515	37017-37018	,	_	
184-516	37019-37034	cross-sectional	_	
184-517	37035-37038	VBM	_	
184-518	37039-37044	study	_	
184-519	37045-37047	in	_	
184-520	37048-37061	first-episode	_	
184-521	37062-37065	and	_	
184-522	37066-37073	chronic	_	
184-523	37074-37081	illness	_	
184-524	37082-37087	Whole	_	
184-525	37088-37093	brain	_	
184-526	37094-37101	resting	_	
184-527	37102-37107	state	_	
184-528	37108-37118	functional	_	
184-529	37119-37131	connectivity	_	
184-530	37132-37145	abnormalities	_	
184-531	37146-37148	in	_	
184-532	37149-37162	schizophrenia	_	
184-533	37163-37164	A	_	
184-534	37165-37174	three-way	_	
184-535	37175-37183	parallel	_	
184-536	37184-37187	ICA	_	
184-537	37188-37196	approach	_	
184-538	37197-37199	to	_	
184-539	37200-37207	analyze	_	
184-540	37208-37213	links	_	
184-541	37214-37219	among	_	
184-542	37220-37228	genetics	_	
184-543	37228-37229	,	_	
184-544	37230-37235	brain	_	
184-545	37236-37245	structure	_	
184-546	37246-37249	and	_	
184-547	37250-37255	brain	_	
184-548	37256-37264	function	_	
184-549	37265-37274	WEB-based	_	
184-550	37275-37279	GEne	_	
184-551	37280-37283	SeT	_	
184-552	37284-37292	AnaLysis	_	
184-553	37293-37300	Toolkit	_	
184-554	37301-37302	(	_	
184-555	37302-37312	WebGestalt	_	
184-556	37312-37313	)	_	
184-557	37313-37314	:	_	
184-558	37315-37321	update	_	
184-559	37322-37326	2013	_	
184-560	37327-37340	Meta-analysis	_	
184-561	37341-37343	of	_	
184-562	37344-37352	regional	_	
184-563	37353-37358	brain	_	
184-564	37359-37366	volumes	_	
184-565	37367-37369	in	_	
184-566	37370-37383	schizophrenia	_	
184-567	37384-37394	Structural	_	
184-568	37395-37398	and	_	
184-569	37399-37409	functional	_	
184-570	37410-37415	brain	_	
184-571	37416-37429	abnormalities	_	
184-572	37430-37432	in	_	
184-573	37433-37443	drug-naive	_	
184-574	37443-37444	,	_	
184-575	37445-37458	first-episode	_	
184-576	37458-37459	,	_	
184-577	37460-37463	and	_	
184-578	37464-37471	chronic	_	
184-579	37472-37480	patients	_	
184-580	37481-37485	with	_	
184-581	37486-37499	schizophrenia	_	
184-582	37499-37500	:	_	
184-583	37501-37502	a	_	
184-584	37503-37513	multimodal	_	
184-585	37514-37517	MRI	_	
184-586	37518-37523	study	_	
184-587	37524-37529	BRANT	_	
184-588	37529-37530	:	_	
184-589	37531-37532	A	_	
184-590	37533-37542	Versatile	_	
184-591	37543-37546	and	_	
184-592	37547-37557	Extendable	_	
184-593	37558-37571	Resting-State	_	
184-594	37572-37576	fMRI	_	
184-595	37577-37584	Toolkit	_	
184-596	37585-37586	A	_	
184-597	37587-37598	prospective	_	
184-598	37599-37611	longitudinal	_	
184-599	37612-37622	volumetric	_	
184-600	37623-37626	MRI	_	
184-601	37627-37632	study	_	
184-602	37633-37635	of	_	
184-603	37636-37644	superior	_	
184-604	37645-37653	temporal	_	
184-605	37654-37659	gyrus	_	
184-606	37660-37664	gray	_	
184-607	37665-37671	matter	_	
184-608	37672-37675	and	_	
184-609	37676-37696	amygdala-hippocampal	_	
184-610	37697-37704	complex	_	
184-611	37705-37707	in	_	
184-612	37708-37715	chronic	_	
184-613	37716-37729	schizophrenia	_	
184-614	37730-37738	Evidence	_	
184-615	37739-37742	for	_	
184-616	37743-37754	progressive	_	
184-617	37755-37760	brain	_	
184-618	37761-37774	abnormalities	_	
184-619	37775-37777	in	_	
184-620	37778-37783	early	_	
184-621	37784-37797	schizophrenia	_	
184-622	37797-37798	:	_	
184-623	37799-37800	a	_	
184-624	37801-37816	cross-sectional	_	
184-625	37817-37827	structural	_	
184-626	37828-37831	and	_	
184-627	37832-37842	functional	_	
184-628	37843-37855	connectivity	_	
184-629	37856-37861	study	_	
184-630	37862-37869	Altered	_	
184-631	37870-37883	resting-state	_	
184-632	37884-37894	functional	_	
184-633	37895-37907	connectivity	_	
184-634	37908-37911	and	_	
184-635	37912-37922	anatomical	_	
184-636	37923-37935	connectivity	_	
184-637	37936-37938	of	_	
184-638	37939-37950	hippocampus	_	
184-639	37951-37953	in	_	
184-640	37954-37967	schizophrenia	_	
184-641	37968-37981	Supplementary	_	
184-642	37982-37986	data	_	
184-643	37987-38000	Supplementary	_	
184-644	38001-38005	data	_	
184-645	38006-38008	to	_	
184-646	38009-38013	this	_	
184-647	38014-38021	article	_	
184-648	38022-38025	can	_	
184-649	38026-38028	be	_	
184-650	38029-38034	found	_	
184-651	38035-38041	online	_	
184-652	38042-38044	at	_	
184-653	38045-38050	https	_	
184-654	38050-38051	:	_	
184-655	38051-38052	/	_	
184-656	38052-38053	/	_	
184-657	38053-38060	doi.org	_	
184-658	38060-38061	/	_	
184-659	38061-38068	10.1016	_	
184-660	38068-38069	/	_	
184-661	38069-38075	j.nicl	_	
184-662	38075-38087	.2019.101887	_	
184-663	38087-38088	.	_	
